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Foreword
This thesis represents four years of research undertaken at the Animal Cell Technology Unit
of the Instituto de Tecnologia Química e Biológica from the Universidade Nova de Lisboa /
Instituto de Biologia Experimental e Tecnológica under the supervision of Dr. Paula Alves
and Professor Manuel Carrondo.
The work presented in this dissertation intended to create fundamental knowledge in
the downstream processing of complex biopharmaceuticals, in particular, of enveloped viral
vectors that constitute a relevant system for application in gene therapy and vaccination.
The use of rational, sound analytical tools combined with state-of-the-art unit operation
principles contributed to build a more solid and cost-effective strategy for the development
of the current purification processes for these complex biologicals.
Tiago Vicente
Oeiras, Portugal
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Summary
Viral vectors and virus-like particles hold a tremendous potential in various clinical appli-
cations in the areas of gene therapy and/or vaccination, drawing the attention of biotech-
nology and pharmaceutical companies. The majority of these products are manufactured
in animal cell cultures, inherently making the process costly. A great deal of effort is
taking place to generate optimized biological and engineering strategies to find scalable
and cost-effective processes, easily transferable to cGMP facilities. However, the imple-
mentation of robust downstream processes generating this type of biopharmaceuticals in
the amounts required for pre-clinical and clinical trials is still lacking and lagging. By in-
cluding a labile lipid membrane layer harboring glycoproteins (often critical for infection)
over the viral capsid, enveloped viruses bring extra challenges in terms of their bioprocess-
ing particularly downstream. The work developed during this thesis aimed at improving
the state-of-the-art purification processes for these types of viral particles. The rationale
was to integrate process understanding with product characterization, still scarce in such
biological systems.
An introduction in Chapter 1 reviews the current advances in the development of the
purification processes for these types of complex biopharmaceuticals. A focus is given to
the development of rational approaches in detriment of an empirical-based process devel-
opment. As starting points, the better known principles and solutions provided by more
mature systems as mAbs and recombinant proteins were utilized.
The first part of this thesis, Part I, deals with a somewhat simpler system – a virus-
like particle from Rotavirus (RLP). Chapter 2 describes on the integration of an anion-
exchange chromatographic step into the DSP of this RLP vaccine candidate. Ion-exchange
chromatography is a separation process of choice, if not the most used, for the recov-
ery/purification of biologicals. The objective of this study was to gain preliminary theo-
retical and predictive knowledge on this chromatographic process when employed for such
a VLP. Membrane chromatography has been studied for the adsorption of these RLPs.
Screening studies provided evidence on the sensitive effect of the ionic strength and the
pH of the equilibration buffer on final product recovery. We could implement a steric mass
action (SMA) model for the prediction of the elution profile of purified RLP pulses and
confirm that these VLPs can be purified to clinical grade at almost 50% global recovery
yield, with close to 100% removal of host bulk DNA and 98% of host cell protein using the
proposed DSP.
In Part II, we step further into complexity and take baculovirus as an enveloped
xxi
virus model. In Chapter 3, a scalable, cost-effective DSP is tested and proposed based
on membrane processes. These viruses have recently been recognized as promising for
human gene therapy or vaccination. A complete downstream process comprising three
steps—depth filtration, ultra/diafiltration and membrane sorption—was established as a
strong DSP backbone. Global recovery yields of clinical grade material reached 40% using
technologies easy to scale under cGMP guidelines, constituting a major breakthrough over
the yet much lower yield and non-scalable purification process based on ultracentrifugation
density gradients.
Chapter 4 and Chapter 5 report on the development of a scale-down approach based
on surface plasmon resonance (SPR); an analytical “pseudo”-chromatographic tool for ana-
lyzing binding and elution of the viruses over a surface mimicking the ion-exchange matrix
has been developed. Chapter 4 describes the necessary theory implementation and test-
ing of conditions using bovine serum albumin (BSA) as a model protein. A sorption rate
model capable of quantitatively describing BSA binding and elution for protein titers from
dilute to overloaded conditions and a broad range of salt concentrations was proposed.
Chapter 5 validates this tool for our baculovirus vector system. By separately study-
ing the key component cuts of the baculovirus bioreaction bulk—the product (infective
baculovirus), the main product-related impurities (damaged baculovirus particles), and
the main process-related impurities (host cell protein, host cell dsDNA and endotoxins)—
adsorption isotherms over a broad range of equilibrium conditions were obtained.
Chapter 6 describes a similar rationale as the one put forward in the previous two
chapters, but here using dynamic light scattering (DLS) for the determination of the
ζ(zeta)-potential (a measure of the electrostatic equilibria) of the different components
of this baculovirus system. For this purpose, the main species, product (infective virus
particle) and product-derived impurities (dsDNA-, glycoprotein-, and envelope-deprived
baculovirus particles), were isolated and correspondent ζ-potentials were measured through
DLS. A deterministic model based on the virus components, that are critical for their bio-
logical function, was fine-tuned accounting for the experimental data. The contribution of
these viral components to the overall particle electrostatic interaction energy profile (calcu-
lated between the particle and a putative ion-exchange surface) was evaluated allowing to
distinguish the electrostatic properties of the infective virus particle from the major virus-
related impurities. A prediction of the operating conditions promoting process selectivity
was achieved based on such an approach. Such knowledge has serious impact at the final
targeted clinical application as the quality/potency of the virus preparation is improved
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by decreasing the total to infective virus particle ratio (TP/IP) as intended.
Chapter 7 works out as a proof of concept study of the developed scaled-down, funda-
mental-based tools. From preliminary tests resorting to the insights gained in Chapters
5 and 6, a more straightforward testing of membrane prototypes for anion-exchange chro-
matography was performed. Such study allowed to draw important conclusions regarding
the effect of ligand density in overall process performance in terms of recovery yields and
purity. Lowering ligand density was shown to be beneficial for baculovirus particle pu-
rification, decreasing host cell protein, host cell dsDNA and non-infective baculoviruses,
increasing overall yields by over 20% as compared to the current process. The previously
implemented SMA model provided, for this enveloped virus system, a useful predicting
tool generating methodologies to help increase resolution/selectivity.
This thesis has contributed to the fields of gene therapy, vaccination and bioengineering
of complex biopharmaceuticals by developing innovative analytical tools combined with
in silico models grounded on fundamental knowledge. This was possible due to an in-depth
study of both the product physico-chemical properties and the unit operations principles
used, in particular ion-exchange chromatography. This work demonstrates how rational
design and optimization can streamline process development of such challenging biological
particles. We believe that the methodologies developed herein provide a new way of creating
knowledge allowing for a more rational process design of these and potentially other viruses
and VLPs.
xxiii

Resumo
A indústria farmacêutica e de biotecnologia está a focar a sua atenção numa nova classe
de produtos biológicos: biofármacos complexos. Vectores virais e partículas semelhantes a
vírus (VLPs) representam dois tipos destes produtos com enorme potencial para aplicações
clínicas nas áreas de terapia génica e vacinação. Estes biofármacos são na sua maioria
produzidos por células animais, o que torna o seu processo de produção inerentemente
complexo. Há actualmente um grande esforço na tentativa de obter as melhores estratégias,
tanto ao nível biológico como ao nível de engenharia de processos, capazes de encontrar
soluções que permitam aumento de escala economicamente viável, facilmente transferíveis
e implementáveis em instalações com boas práticas de fabrico (cGMP). No entanto, o
desenvolvimento de estratégias de purificação capazes de processar este tipo de material
biológico nas quantidades necessárias em testes pré-clínicos e clínicos está ainda bem aquém
do que seria desejável. Os vírus com envelope representam um dos tipos de biofármacos
mais complexos: incluem não apenas cápside e genoma viral mas também uma membrana
lipídica glicoproteica necessária para a sua função biológica, i.e. para a manutenção da sua
infecciosidade. De facto, a fragilidade destes envelopes levanta sérias preocupações no que
respeita ao design dos processos de purificação. O trabalho desenvolvido nesta dissertação
teve o objectivo de melhorar o estado actual da arte ao nível dos processos de purificação
deste tipo de partículas de elevada complexidade através do desenvolvimento de estratégias
inovadoras, contribuindo para o conhecimento mais fundamental. A abordagem consistiu
em alcançar um novo patamar de conhecimento, actualmente ainda muito escasso, ao nível
da purificação e da caracterização deste tipo de partículas biológicas.
A introdução, apresentada no Capítulo 1, revê os actuais avanços no desenvolvimento
dos processos de purificação destes biofármacos complexos. Dá-se especial ênfase ao desen-
volvimento de abordagens mais racionais em detrimento do desenvolvimento de processos
apenas baseado em conhecimento empírico. Existem já algumas abordagens relevantes na
literatura focadas neste tipo de biofármacos, além de ser possível ter como base o conhec-
imento adquirido de outros sistemas mais bem caracterizados como é o caso de anticorpos
monoclonais ou proteínas recombinantes.
O primeiro passo deste trabalho, aqui apresentado na Parte I, trata de um sistema
biológico ligeiramente mais simples – uma partícula semelhante a vírus do Rotavírus (RLP)
– como modelo biológico relevante. O Capítulo 2 reporta a integração de um passo
de cromatografia de troca aniónica no processo de purificação desta vacina de enorme
potencial. A cromatografia de troca iónica é um dos processos de separação mais usados na
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recolha/purificação de produtos biológicos. O objectivo deste estudo foi obter conhecimento
teórico e predictivo preliminar neste processo cromatográfico quando implementado neste
sistema. Para esse efeito, foi usada cromatografia de membranas para estudar a adsorção
de RLPs. Estudos sistemáticos permitiram determinar o impacto da força iónica e pH do
tampão na recolha final de produto. Foi possível implementar com sucesso um modelo
estérico de acção mássica (SMA) para a predição do perfil de eluição de pulsos purificados
de RLPs e confirmar que, usando este processo de purificação, este tipo de partículas
semelhantes a vírus podem ser processados até elevada pureza com rendimentos globais de
46%, ∼100% de remoção de DNA celular e 98% de proteína celular.
Na Parte II, entramos num nível de complexidade superior usando baculovírus como
modelo de vírus com envelope. No Capítulo 3, testa-se um processo de purificação es-
calável e económico baseado em processos de membranas. Estes vírus foram recentemente
reconhecidos como altamente promissores em terapia génica humana ou para vacinação.
Foi estabelecido um processo completo de purificação baseado em três passos: filtração por
filtro de profundidade, ultra/diafiltração e sorção por membranas. Os rendimentos globais
de purificação de virus a elevada pureza alcançaram os 40% usando tecnologias muito
simples de transferir para escalas de produção em instalações operando com boas práti-
cas de fabrico. Esta estratégia integrada de purificação representa um marco importante
face ao procedimento clássico baseado em gradientes de densidade por ultracentrifugação
tipicamente apresentando muito menores rendimentos e não passível de aumento de escala.
Os Capítulos 4 e 5 desenvolvem um modelo para redução de escala de ensaio baseado
em espectroscopia de surface plasmon resonance (SPR). Sendo a cromatografia de troca
iónica um passo crucial neste processo e susceptível de melhoramento, foi implementada
uma ferramenta “pseudo”-cromatográfica usando esta metodologia analítica com o fim de
analisar a adsorção e eluição dos vírus numa superfície mimetizando uma matriz cro-
matográfica de troca iónica. O Capítulo 4 descreve a teoria necessária para analisar
convenientemente as condições de adsorção usando um modelo de proteína, albumina de
soro bovino (BSA). Nesse sentido foi postulado um modelo de sorção capaz de descre-
ver quantitativamente a adsorção e eluição de BSA desde concentrações muito diluídas a
condições de saturação e numa larga janela de concentrações de sal. O Capítulo 5 valida
esta mesma ferramenta para o nosso sistema biológico relevante, baculovírus. Ao estudar
de forma isolada os componentes chave de um caldo de biorreacção de baculovírus—o pro-
duto (baculovírus infeccioso), as principais impurezas relativas ao produto (partículas de
baculovírus degradadas), e as principais impurezas relativas ao processo (proteína celu-
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lar, dsDNA e endotoxinas)—, foram obtidas isotérmicas de adsorção numa gama larga de
condições de equilíbrio. Não seria possível obter tal informação usando os mesmos recursos
implementando os típicos ensaios de cromatografia por membranas em pequena escala.
O Capítulo 6 descreve uma estratégia semelhante à utilizada nos dois capítulos an-
teriores, usando aqui a técnica de dispersão dinânima de luz (DLS) para a determinação
do potencial-ζ(zeta) (uma medida do equilíbrio electrostático) dos diferentes componentes
deste sistema de baculovírus. Neste sentido, as principais espécies, produto (baculovírus
infeccioso) e principais impurezas relativas ao produto (baculovírus sem, respectivamente,
genoma, glicoproteína, e envelope), foram isoladas e os seus potenciais-ζ foram avaliados.
De acordo com os dados experimentais, adaptou-se um modelo determinístico baseado nos
componentes virais críticos para a função biológica viral. Analisou-se a contribuição destes
componentes virais no perfil de energia de interacção electrostática global (experimentado
entre a partícula viral e uma superfície hipotética de troca iónica) permitindo distinguir
as propriedades electrostáticas dos vírus infecciosos e das impurezas analisadas. Baseado
nesta estratégia, conseguiu obter-se uma predição das condições operatórias óptimas para
melhorar a selectividade do processo cromatográfico em questão. Tal conhecimento tem
um forte impacto na desejada aplicação final dado que a qualidade/potência da preparação
viral é melhorada ao reduzir significativamente a razão entre partículas virais totais e
partículas virais infecciosas (TP/IP) como pretendido.
No Capítulo 7 faz-se uma prova de conceito da importância e utilidade das ferramen-
tas fundamentais aqui desenvolvidas. A partir de testes preliminares usando o conheci-
mento apreendido nos Capítulos 5 e 6 foi possível realizar uma análise de protótipos de
membranas cromatográficas muito mais rápida e eficiente. Este estudo permitiu tirar im-
portantes conclusões acerca do efeito da densidade de ligando nos rendimentos globais do
processo e performance em termos de remoção de impurezas. A utilização de densidades
relativamente baixas de ligando mostrou ser vantajosa para aumentar (em mais de 20%)
o rendimento de purificação de baculovírus, reduzindo a proteína celular, dsDNA celular
e baculovírus não infecciosos no produto final. O modelo SMA previamente estabelecido
serviu também neste sistema mais complexo como uma boa ferramenta para prever o com-
portamento do processo cromatográfico e gerar recomendações úteis para incrementar a
resolução/selectividade do processo.
Em suma, esta tese gerou importantes contribuições para os campos da terapia génica,
vacinologia, engenharia de biofármacos complexos e cromatografia. Criaram-se ferramentas
analíticas inovadoras combinadas com modelos matemáticos in silico solidamente alicerça-
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dos em conhecimento fundamental. Tal foi possível devido a um estudo em profundidade
das propriedades fisico-químicas do produto e dos princípios das operações unitárias us-
adas, em particular, cromatografia de troca iónica. Este trabalho de investigação demons-
tra como o design e optimização racionais podem acelerar o desenvolvimento de processos
para partículas biológicas complexas. Indubitavelmente, a tendência aqui desenvolvida e
demonstrada irá servir no progresso desta área científica, conseguindo gerar e integrar co-
nhecimento básico com potencial para aplicação a outro tipo de vectores virais com (ou
sem) envelope ou VLPs.
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INTRODUCTION
Adapted from:
Vicente T, Mota JPB, Peixoto C, Alves PM, Carrondo MJT. Rational design and op-
timization of downstream processes of viral particles for biopharmaceutical applications:
current advances. Biotechnology Advances ; submitted.

DOWNSTREAM PROCESSING DEVELOPMENT OF ENVELOPED VIRUSES FOR CLINICAL APPLICATIONS
Abstract
The advent of advanced therapies in the pharmaceutical industry has moved the spotlight
into virus-like particles and viral vectors produced in cell culture holding great promise
in a myriad of clinical targets, including cancer prophylaxis and treatment. Even though
a couple of cases have reached the clinic, these products have yet to overcome a number
of biological and technological challenges before broad utilization. Concerning the man-
ufacturing processes, there is significant research focusing on the optimization of current
cell culture systems and, more recently, on developing scalable downstream processes to
generate material for pre-clinical and clinical trials. We review the current options for down-
stream processing of these complex biopharmaceuticals and underline current advances on
knowledge-based toolboxes proposed for rational optimization of their processing. Ratio-
nal tools developed to increase the yet scarce knowledge on the purification processes of
complex biologicals are discussed as alternative to empirical, “black-boxed” based strate-
gies classically used for process development. Innovative methodologies based on surface
plasmon resonance, dynamic light scattering, scale-down high-throughput screening and
mathematical modeling for supporting ion-exchange chromatography show great potential
for a more efficient and cost-effective process design, optimization and equipment proto-
typing.
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1.1 Introduction
Over the last 25 years, the pharmaceutical industry has been shifting a great deal of interest
and resources into the development of novel pharmaceutical molecules based on biologicals:
biopharmaceuticals (Crommelin et al., 2003). Beyond the exponential market growth on
monoclonal antibodies (mAbs), there is today great promise for novel biopharmaceuticals
based on virus particles, either for vaccination (e.g., virus-like particles (VLPs) (Buck-
land, 2005)) or for gene or cell therapies (e.g., recombinant viral vectors (Ferguson et al.,
2010)). These products are not only far larger than mAbs—e.g., over 107 Da for an HPV-
VLP (Hanslip et al., 2006) when compared to the average 1.5 × 105 Da molecular weight
of an immunoglobulin G (IgG) (Shukla et al., 2007)—but are also required to contain a
well assembled three-dimensional geometry, properly characterized with the necessary sub-
units in the proper place and ratio and with the proper post-translational modifications
of the exposed proteins. The latter being critical for instance to elicit the desired immune
responses (for vaccination purposes) or to allow efficient cell target internalization and
ultimately transgene expression (for gene therapy purposes).
Moreover, viral vectors should remain infective, which in some systems, as retroviral
vectors, means the presence of specific viral enzymes biologically active for completion of
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the gene transfer process (Carmo et al., 2009). All this complexity raises both biological
and technological challenges (Rodrigues et al., 2007a).
As far as the manufacturing process is concerned, there have been great achievements
in the implementation of scalable systems using animal cells for improvement of product
titer and quality. However, much less effort has been put to the essential downstream
purification processes for the more complex biopharmaceutical particles thus constituting
currently a major bottleneck.
Due to the intricate nature of these biological particles, there are critical implications
on the downstream processing concerning purity, potency and quality of the final product.
The regulatory authorities—US Food and Drug Administration (FDA) and the European
Medicines Evaluation Agency (EMEA)—require the industry to define strict process and
product guidelines. According to the desired final target: i) the process-derived impurities
such as host cell protein (HCP) and host cell (HC) DNA contents must be below a certain
limit—purity—; ii) the concentration (or titer) must be as high as possible so that the
volume of the required dose is as reduced as possible—potency—; iii) the quantity of
product-derived impurities, damaged, non-functional virus particles should be as low as
possible compared to the functional virus particles—quality. The downstream processes
should thus be designed to accommodate these requirements. Often, a sensible compromise
must be made between cost, throughput, and purity to meet both the quality and potency
aimed at in a given pre-clinical or clinical trial. It is the goal of the integrated manufacturing
process to ideally deliver the product in large quantities (scalability), with high quality
(purity) and in high titer (potency), and doing so in a cost-effective manner.
This chapter discusses the state of the art of the everlasting quest for the design of
“the ideal” DSP for these complex biopharmaceuticals. The rising interest in the use of
knowledgeable tools for process design and optimization over heuristics-based process de-
velopment is discussed, addressing relevant case studies where process knowledge and/or
product characterization had an impact on improving current recovery yields and produc-
tivities.
1.2 Current choices in DSP of complex biopharmaceu-
ticals
The state of the art in the purification of complex biopharmaceuticals produced by animal
cell culture has its ground on membrane and chromatographic processes (Przybycien et al.,
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2004; Peixoto et al., 2007; Rodrigues et al., 2007a; Konz et al., 2008; Vicente et al., 2009a,b).
These unit operations are part of some of the commonly named platform technologies for
purification; prominent examples include monoclonal antibodies (mAbs) (Kelley et al.,
2009; Li et al., 2009) and adenoviral vectors (Konz et al., 2008), where there is already
considerable processing knowledge and maturity.
Hereby we overview the current choices for the three major steps of a general DSP
for virus particles—clarification, concentration/purification and polishing (Lightfoot and
Moscariello, 2004). For virus particles purification, the scientific community has long made
an enormous effort to move away from the single ultracentrifugation, density gradient-based
purification protocols that were and, in some cases, still are the standard purification step
(Konz et al., 2008). The relevance of understanding/studying in-depth the product of
interest—enveloped (or not) virus particle—product lability, the importance of working
out the specific biological issues and translate these into process requirements are dis-
cussed herein. The statement “the process defines the product” dictated by the regulatory
authorities, is, indeed, somewhat bidirectional in these systems.
Fig. 1.1 depicts the schematic of a general DSP flow diagram, encompassing the typical
requirements/fed materials, the desired removal targets, i.e., the waste products coming
out of each step, the typical unit operations employed, and the potential issues that can
be encountered. The schematic is meant to be an outlined strategy for virus particles, to
which process practitioners and developers can resort to.
Meanwhile, one should mention that, in the field of protein purification, unit operations
alternative to chromatography-based processes are generating unique interest (Przybycien
et al., 2004). For instance, in mAb manufacturing the overall downstream processing (DSP)
can become prohibitively expensive due to the large cost of Protein A (or G) based affinity
chromatography used as a capture step. Indeed, the increase in product titers has created
a bottleneck downstream as the capacities cannot physically accommodate the economies
of scale achieved upstream (Gottschalk, 2008). Aqueous-two or three phase partitioning,
precipitation and crystallization have been revisited over the last years so that alternative
production-scale DSP processes may become more cost-effective, whether removing totally
or still integrating less chromatographic processes (Przybycien et al., 2004). Certain viruses
withstand phase separations with polyethylene glycol (PEG) (Aboud et al., 1982; Lewis and
Metcalf, 1988; Tsoka et al., 2000; Smith et al., 2008), ammonium sulphate (Maranga et al.,
2002) or calcium phosphate (Morling and Russell, 1995). Nevertheless, the implementation
of these alternative unit operations has yet to receive wider emphasis for virus purification;
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this is likely due to the fact that these particles are generally more labile and prone to
irreversible aggregation through flocculation or precipitation procedures.
1.2.1 Clarification
A suitable clarification step should efficiently remove cell debris and large aggregates, while
maintaining and protecting the quality of the product in the flowthrough stream. Often,
even before the clarification process, due to the presence of a reasonable content in host
cell derived proteases (Gotoh et al., 2001), product preservatives may have to be added
during bioreaction or while initiating DSP: e.g., in the baculovirus expression vector sys-
tem (BEVS) using insect cell hosts, a protease inhibitor cocktail is routinely added for
preservation of the virus-like particle produced, avoiding the degradation of the external
glycoprotein layer essential for proper bioactivity upon final application (Vieira et al.,
2005).
On the other hand, if the product of interest is not secreted to the extracellular medium,
cell membrane disruption may be necessary to obtain significant productivities: examples
include non-enveloped viruses as adenoviruses (Konz et al., 2008), where detergent is added
to the bioreactor for cell membrane solubilization.
Clarification steps widely used in biopharmaceutical purification include the use of
centrifugation for cell sedimentation (either continuous or batch). More recently, however,
membrane processes appear as an attractive alternative: scalability is guaranteed as the
membrane area is easily up-scaled either by using cartridges of larger membrane sheet
area or stacking membrane units in parallel mounted in stainless steel holders. These
processes either work in dead-end mode, eg., using disposable depth-filtration modules
(Peixoto et al., 2007; Mellado et al., 2008; Vicente et al., 2009a,b) or in tangential flow
mode, using membrane cassettes or hollow fiber units (Saha et al., 1994) with cut-offs
within the micrometric order of magnitude. The use of depth filters makes the sieving
and particulate retention process much more efficient because of the depth-dependent size
separation factor; also, due to the charged nature of state-of-the-art depth-filter membranes
and their three-dimensional arrangement (Prashad and Tarrach, 2006), a higher degree of
coarser impurity accumulation is achieved, while still facilitating the passage of the finer
particles, which include virus particles from the tens to the hundreds of nanometers size.
In line with the increasing interest in the use of cleaning- and validation-free disposable
technologies, membrane processes represent a clear advantage over centrifugation as the
former are very easily adaptable to disposable formats. Indeed, major manufacturers of
7
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bioseparation equipment and consumables add every year to their portfolios innovative
materials of this kind.
Other alternative for clarification step is expanded-bed chromatography (Hjorth, 1997)
where process intensification is achieved by allowing clarification of the bioreaction bulk
and capturing of the virus particles simultaneously. Adenovirus type 5 (Ad5) has been
successfully processed by these means (Lusky, 2005; Peixoto et al., 2006). However, this
unit operation is typically labour-consuming with some technical issues in terms of clean-
ing and regeneration, and necessary fluidized bed heights compromising robustness. Such
drawbacks have failed expanded-bed chromatography when compared to what novel mem-
brane technologies can bring in terms of ease of operation.
Concerning more rational process developments, little has been reported besides the
implementation of fouling models to predict permeate flux decay over time (Shukla and
Kandula, 2009). Process development normally relies on heuristics of critical operating con-
ditions, such as fluxes through dead-end filters or recirculation flow rates, in order to find
the best options minimizing membrane fouling in tangential flow filtration (TFF) (Grzenia
et al., 2006). Important efforts are especially directed to controlling product stability at
a very early stage in the purification train. Process development teams therefore invest
in clarifying the product as quickly as possible (removing potential impairing agents in
the bulk), preventing the virus particles to precipitate or aggregate irreversibly (Fig. 1.1).
Nevertheless, important lessons should be learned from high-cell density process platforms
where extremely high turbidities are achieved through perfusion cell cultures; a combina-
tion of flocculant addition, selective precipitation of particulates or even sedimentation can
be rationally devised to improve the clarification step at reasonable throughputs and high
recoveries (Shukla and Kandula, 2009). For the typical cell density used for viral produc-
tions, membrane processes perform fairly well with recovery yields frequently surpassing
90% (Nayak et al., 2005; Peixoto et al., 2008; Vicente et al., 2009a).
1.2.2 Concentration/purification
As mentioned in the preceding section, concentration is a critical step, ubiquitous in DSP of
virus particles (Grzenia et al., 2008). The stream volume should be reduced as earlier in the
process as possible in order to reduce the upfront investment in downstream equipment and
materials. Moreover, it enhances processing safety as some of the virus preparations may
require BSL2 or BSL3 manufacturing laboratories and the handling of bulky volumes may
prove challenging. The goal, at this stage, is to remove effectively low molecular weight
9
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(MW) HCP, fragmented HC DNA, and possibly fragmented product-related impurities,
eg., viral proteins (Fig. 1.1). The concentration factor should be as high as achievable,
however, aggregation must be considered as for example in adenovirus (Konz et al., 2005)
or baculovirus (Barsoum, 1999) concentration. It is advisable under such situations to eval-
uate whether or not aggregation can be prevented by addition of certain additives (Wright
et al., 2005). This is also why ultracentrifugation-based purification processes present nor-
mally very low recovery yields as irreversible aggregation might be taking place during
virus banding or pelleting. It is then critical to have prompt analyticals to assess particle
aggregation; dynamic light scattering (DLS) can be used very straightforwardly to monitor
this issue during the concentration step (Trilisky and Lenhoff, 2007; Vicente et al., 2010d)
in alternative to capillary (zone) electrophoresis and/or analytical ultracentrifugation.
For some of the cell systems used, there is a large content of HC DNA constituting a
major threat to the required target purity (10 ng/dose with up to 200 bp fragment length
(FDA, 2010)). In order to reduce the amount of nuclease units necessary for efficient nucleic
acid digestion (typically BenzonaseTM), it is advisable in most of the cases to perform this
incubation immediately after concentration and prior to the diafiltration step for buffer
exchange.
Positive chromatography, i.e., operated in bind-elute mode, constitutes an alternative
for the concentration/purification step. When chromatography is operated as a capture
step at this stage, good concentration factors can be achieved upon elution if the prod-
uct is rather diluted in the bulk and if the capacity of the chosen matrix is significant;
this has been an option in purification of retroviral vectors (Rodrigues et al., 2007b) or
influenza virus vaccines (Kalbfuss et al., 2007). Membrane adsorbers and monolithic ma-
trices constitute relevant options for capture at this early stage, as these materials present
higher capacities and faster processing for large bioparticles making them suitable for non-
concentrated clarified feedstocks.
Nonetheless, other chromatographic chemistries have been efficiently used including
hydrophobic interaction (Chahal et al., 2007; Wolff et al., 2010), hydroxyapatite (O’Riordan
et al., 2000; Kuiper et al., 2002) and sulfated (Wolff et al., 2010) ligands, the latter two
considered as “pseudo”-affinity chromatography ligands.
High-performance TFF (HPTFF) has shown to be a very promising concentration/pu-
rification step for mAb refining (van Reis et al., 1997; Fontes and van Reis, 2009). HPTFF
employs charged ultrafiltration membranes that promote selectivity for protein-protein
separations. The rational framework implemented by van Reis and colleagues (van Reis
10
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et al., 1997) can be used as a guideline for HPTFF of viruses or VLPs. For systems that have
other challenges as, for example, a mixture of two virus particles differing slightly in their
physico-chemical properties, this kind of approach might be worthwhile pursuing. Adeno-
associated viruses (AAVs) produced in insect cells by baculovirus infection (Merten et al.,
2005) or lentivirus from baculovirus transduction (Lesch et al., 2008) are such examples
where this approach might outperform current concentration steps.
The scalability and cost-effectiveness of the described membrane processes (including
membrane chromatography) should be highlighted (van Reis and Zydney, 2007; Peixoto
et al., 2008). These unit operations are very amenable to any cGMP process scheme; they
often fill the serious gap of the labour- and time-consuming density-gradient procedures,
making them impracticable at larger scales for viral vector/VLP manufacturing.
1.2.3 Polishing
Polishing is a critical step for the purification of biopharmaceuticals; purity is mandatory
and product quality/potency must be as high as achievable so that its final clinical appli-
cation is effective and safe. Therefore, this step is typically quite challenging as it should
resolve impurities—either process- or product-related—very closely related to the product
of interest.
Chromatographic processes are the workhorses for this step as they allow high resolution
separations (Lyddiatt, 2002; Przybycien et al., 2004; Morenweiser, 2005). Ion-exchange
(IEX) chromatography constitutes a process of choice for resolving HCP-virus particle,
HC DNA-virus particle, or damaged virus particle-virus particle feedstreams. A significant
number of case studies can be found in the literature where this solution is implemented
(Barsoum, 1999; Debelak et al., 2000; Vellekamp et al., 2001; Kaludov et al., 2002; Yamada
et al., 2003; Davidoff et al., 2004; Specht et al., 2004; Rodrigues et al., 2006; Trilisky and
Lenhoff, 2007; Wu et al., 2007; Kalbfuss et al., 2007; Vicente et al., 2008; Peixoto et al.,
2008; Rodrigues et al., 2008; Kutner et al., 2009; Vicente et al., 2009a; Okada et al., 2009;
Dormond et al., 2010). It is often the case that IEX chromatography is used vertically
within the DSP strategy as it easily fits from early capture to final purification steps. IEX
is typically operated in positive (bind-elute) mode: most of the impurities are collected in
the flowthrough pool, while the virus particles and some of the impurities are retained in
the matrix. Due to the differences in charge of the different components, it is possible to
use this process with high resolution elution gradients, separating the adsorbed materials
into fractionated cuts, even though they are closely related.
11
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Negative (flowthrough) mode has also potential as it can be implemented for adsorption
of resilient impurities as HCP or product-related impurities. Case studies from the mAb
process scale purification (Zhou et al., 2006; Gottschalk, 2008) should serve as a basis for
implementation of such process also for large biopharmaceuticals.
Gel filtration or size-exclusion chromatography (SEC) and ultrafiltration/diafiltration
(usually by TFF) are two other widely used processes at the very latest stage for formulating
the product (Rodrigues et al., 2007b; Peixoto et al., 2007; Dormond et al., 2010). Both rely
on size making them suitable for buffer exchange, the former permitting milder conditions.
TFF scales more easily (adding membrane area) than SEC which is limited to a process
scale chromatography column (the load should not exceed 10% of column bed volume).
1.3 In pursuit of an ideal DSP platform
The fundamental desideratum in the large scale manufacturing process of any product is
that the technologies and resources involved must be cost-effective. Such “tenet” is also
applicable for complex biopharmaceuticals. However, as these products are designed to
clinical applications, the safety concerns require complex, thus not inexpensive, DSPs.
The ideal DSP platform for virus particles must decrease the impurity levels to accept-
able values while maintaining and concentrating the product in its functional state. Given
the complexity of such particles and their physico-chemical properties, variable for different
viruses, setting up a universal and high-yield DSP platform shall be extremely challenging
or even impossible. For example, non-enveloped viruses as AAVs or adenoviruses are prone
to aggregation with HC DNA (Konz et al., 2005) or other impurities whereas enveloped
viruses as lenti- or influenza-viruses are much more shear-sensitive, thus labile, due to the
extra lipid membrane harboring glycoproteins essential for viral infectivity. Similarly, the
requirements for enveloped viruses will be different depending on their use: gene therapy
applications will require smoother DSPs to preserve receptors than vaccines, where epitopes
are often enough to elicit an immunological reaction.
Nonetheless, more restrict DSP platforms can still be designed for the purification of,
at least, subset classes of virus particles. Indeed, if the physico-chemical properties do not
differ much, the products should behave similarly upon processing. As in any platform,
minor refinements can then be done in order to maximize throughput and recovery yield.
Furthermore, in what concerns the technologies used, new DSP matrices are being
regarded as common denominators to the purification of large biopharmaceuticals. Dis-
12
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posable membrane adsorbers and monoliths are being used as excellent alternatives to
packed-bed chromatography. A number of reports have shown these to be suitable choices
for purification of various virus particles (Branovic et al., 2003; Kramberger et al., 2004;
Charcosset, 2006; Etzel and Riordan, 2009; Whitfield et al., 2009; Gutiérrez-Aguirre et al.,
2009).
1.3.1 Classical versus rational process development
Process optimization still relies mainly on empirical-based strategies because there is much
to be known about the biophysico-chemical properties of such particles. However, more
rational strategies bringing together a variety of fundamentals, analytical and predictive
modeling tools shall provide deeper insights into a more efficient, thus cost-effective and
quicker process optimization. This section overviews efforts being taken by researchers and
developers towards this trend where product- and process-knowledge is obtained aiming at a
more rational design and improvement for the existing processes. These would contribute
to a faster process development at very early stages (or even later for fine-tuning) in
the product development lifecycle; furthermore, such rationale serves as solid ground for
the implementation of Quality by Design (QbD) rules meeting the Process Analytical
Technology (PAT) initiative (Mollerup et al., 2008).
Fig. 1.2 depicts the two main paths one can use for process optimization. Such schematic
should be interpreted widely: it can be equally grasped as a step-by-step diagram either
for one-step optimization (e.g., a chromatographic unit operation) or for integrated pro-
cess optimization, learning, for example, from lessons on other complex biopharmaceutical
systems (Cruz et al., 2002). On the left, the stacked boxes space representing a significant
experimental work and resources (costs of goods and time included) to obtain the optimal
operating conditions should be highlighted; in the rational process development strategy,
by implementing scaled-down tools and concomitant suitable mathematical modeling for
such unit operations, the amount of resources spent are substantially reduced to obtain an
increased amount of data/process insight. One should also emphasize the fundamentals of
the Quality by Design (QbD) approach being depicted here as key: a focused seeking of
process understanding and control via product characterization permits the definition of
improved design of experiments (DoE). The feedback of knowledge gathered brings clear
benefits in terms of what is known about the product at the different stages of the manu-
facturing process but also for more easily defining the design space where fine-tunings can
be done safely, predicting the expected gains in terms of productivity/yield or savings in
13
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Figure 1.2: Schematic representation of a process development task for viral vector/VLP bio-
pharmaceuticals: a perspective on rational versus black-box optimization. Elliptical, curved and
squared box shapes stand respectively for ’current knowledge/data analysis’, ’experimental work’
and ’implemented tool’. Notice that the ’scaled-down tools’ boxes are purposely curved as these tools
also encompass experimental work. Thicker arrows represent the authors’ standpoint on the most
sound strategy for process development; HTS, DoE, QbD stand for, respectively, high throughput
screening, design of experiments and quality by design.
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resources.
We agree with Nfor and colleagues (Nfor et al., 2009) in that rational purification pro-
cess development will become more entrenched in the biopharmaceutical industry. Overly
complex and computationally demanding mathematical models may render process opti-
mization untractable, which may lead to failure due to lack of basic experimental data, if
the tools are chosen based on a sensible rationale, the chances to success make it worth
trying. Basic understanding adds value by allowing to identify earlier the critical issues
and devising ways to overcome them.
Analyticals and their critical role in process development
Analyticals play a pivotal role for whatever approach used (Kelner and Bhalgat, 2007).
When dealing with complex biological particles, a number of assays must be in place
to properly assess product identity, quality, titer, purity and consistency throughout the
manufacturing process. It is clear that one should determine what is effect of any changes
in an operating condition; this applies equally to trial-and-error experimentation or during
in silico design of a certain unit operation. For the case of virus particles the list may
include: infective virus titer determination (via cell based assays using immunocyto- or
histo-chemistry assays or FACS), real-time quantitative PCR (for viral genome titration),
transmission or scanning electron microscopy (for particle visualization), SDS-PAGE (one-
or two-dimensional for protein profiling), Western Blotting (for protein identity matching),
ELISA (for quantitative particle concentration measurement), total protein assessment,
total endotoxin assessment, total DNA assessment, glycoprotein analysis and/or N- or
C-terminal protein sequencing (for exposed, essential protein identity matching), mass
spectrometry (for protein identity matching), capillary zone electrophoresis (for enhanced
particle or protein size/molecular weight measurement), size exclusion chromatography
HPLC, dynamic light scattering (DLS) (for size and ζ-potential measurements), and surface
plasmon resonance (SPR) (for equilibrium or sorption kinetics of product or impurities).
This rather extensive wishlist stresses the challenges and complexity underlying purification
of these complex biopharmaceuticals.
1.3.2 The special case of adsorptive chromatography
Chromatography has been for a number of decades the most widely used unit operation
in biotechnological downstream processing (Nfor et al., 2009; Gottschalk, 2008). It offers
tremendous opportunities as far as resolution power/selectivity, throughput and scalability
15
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are concerned. Due to the increasing costs of chromatography within a given DSP, a great
deal of effort is still being devoted to this separation process, especially in the area of
complex biopharmaceuticals as viral vectors or vaccines.
We limit our more technical discussion in this review to the rational advances put for-
ward in the field of adsorptive chromatography, in particular, to IEX chromatography.
Unlike the rather expensive affinity chromatography processes with good recovery yields
based on immobilized metal affinity (Jiang et al., 2004; Ye et al., 2004), heparin or others
(Chen et al., 2009; Wu et al., 2007; Opitz et al., 2007), IEX processes are generally much
more affordable at large scales and offer a broad spectrum of stationary phases for the
capture of virus particles. IEX chromatography is based on the charge of the biological
particles instead of on the existence of very specific ligands on the stationary phase; the
latter may leach from the matrix thus contaminating the product and often require very
harsh elution conditions (that may degrade the product). Although there is now consider-
able literature reporting on the successful implementation of IEX chromatography for the
purification of virus particles, there is still room for improvement and opportunities to take
advantage of while using this IEX chromatography for biopharmaceutical purification.
As pointed out in the previous sections, IEX processes can be operated in positive or
negative mode. In bind-and-elute mode, a large amount of process-related and/or product-
related impurities are removed in the flowthrough, while most of the product from the bulk
is retained adsorbed over the matrix surface functionalized with a given IEX ligand. The
inverse procedure—retention of impurities in the matrix while the product freely flows
through and is collected polished—is also feasible because either the buffer can be adjusted
at a given pH or a ligand of opposite charge can be used.
Recently, the interest on the implementation of other types of chromatographic matri-
ces based on porous membrane layers or monoliths has risen. These porous matrices are
particularly suited for very large particles, as viral vectors or VLPs, due to some key rea-
sons confirmed by a number of studies. First, the specific surface areas (per unit volume)
of porous matrices with pore sizes of 0.8 µm (MustangTM membrane adsorbers from Pall),
3 µm (SartobindTM membrane adsorbers from Sartorius-Stedim Biotech) or > 1 µm (Jung-
bauer and Hahn, 2008) (CIMTM monoliths from BIA Separations, Ljubljana, Slovenia) are
significantly larger than those of resin beads used in packed-bed chromatography, whose
pores go up to 10-20 nm for conventional resins or 400 nm for perfusive resins (Trilisky and
Lenhoff, 2009). Virus particles, ranging from 20 nm to 300 nm, are hindered from binding
onto the internal surface area of the resin, resulting in sub-optimal usage of such matrices.
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Second, due to the porous nature of these matrices, diffusional mass transfer resistances
are reduced to a minimum. Indeed, they allow the use of fairly high linear velocities pro-
moting convective transport. For the case of binding of large particles that have rather
small diffusion coefficients, as compared to smaller biologicals as proteins, these matrices
clearly present an advantage over packed-bed chromatography. Third, and as a corollary
of the latter, these matrices permit very high process throughputs. Due to the very low
pressure drops, higher flow rates can be used for loading and eluting the material using a
given stepwise or linear gradient.
A very pertinent study has analyzed the influence of the pore size distribution of mono-
lith, perfusive and conventional resin matrices (Trilisky and Lenhoff, 2009). Although high
adsorption capacities are obtained for porous matrices, entrapment of the virus particles
should be considered and the linear flow rates used should be also optimized in order to
reduce this phenomenon; indeed, loading the virus bulk at a high flow rate and eluting at
a lower flow rate should improve product recovery (Trilisky and Lenhoff, 2009).
Moreover, most of these porous matrices can now be purchased as disposable units
representing a leap in processing flexibility, eliminating cleaning and sterilization as well
as their validation costs. Other matrices harboring extenders, as tentacle resins, have been
used with good results most likely because they improve the accessibility of their binding
sites to the large virus particles (Rodrigues et al., 2007a). Yet, it is anticipated that packed-
bed chromatography can also be of great interest if flowthrough mode is implemented for
polishing purposes, removing low molecular weight biological impurities; however, to our
knowledge, the implementation of such strategy has not yet been reported in the literature.
Optimization of IEX processes
For the optimization of IEX processes, ionic strength and pH of the buffer/medium con-
taining the complex mixture bulk are critical parameters that should be taken into special
consideration early in the development design (Pujar and Zydney, 1998; Schaldach et al.,
2006; Vicente et al., 2008). These conditions modulate the IEX mechanisms defining the
adsorption and desorption of the product and some of the impurities. To address these
issues, our team has initiated efforts towards a more knowledgeable approach to distinguish
the underlying fundamentals for complex biopharmaceuticals. Rotavirus-like particles have
been purified with better yields by anion-exchange membrane chromatography (Vicente
et al., 2008). The process has been modeled with reasonable accuracy, for the prediction of
the VLP peaks eluted at given conditions using the steric mass-action model proposed by
17
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Brooks and Cramer (1992). This widely used theoretical framework for IEX of smaller and
simpler model biologicals appears to be equally applicable to the more complex particles.
If good estimations of the characteristic charge, equilibrium constants and steric factors
are available, the process can be modeled with significant predictive power. However, in
that preliminary study, the contribution of the impurities (with unknown properties for
most of them) were not included in the multicomponent model. This is a major drawback
when implementing a model that fully predicts the behavior of all the components of an
animal cell-derived bioreaction bulk containing a given virus particle.
It is thus desirable to create a methodology that allows for a better understanding on the
complexity of these virus bulks. This can be done by analyzing the major components of the
bulk, including the impurities that in most cases represent the major mass fraction of the
bulk. Such study has been performed using recombinant baculoviruses as a model system.
The product—the integral virus particle—was compared to major process-related impuri-
ties (e.g., protein, DNA) and major product-derived impurities (damaged virus particles,
eg., deprived of viral envelope or external glycoprotein harbored in the virus envelope) in
terms of adsorption capacities to an IEX surface (Vicente et al., 2010b). For that purpose,
surface plasmon resonance (SPR) was used as a pseudo-chromatography tool for biological
adsorption and desorption on an IEX surface (Vicente et al., 2010c). SPR conveniently
results in a scaled-down analytical tool for predicting adsorption isotherms at varied ionic
strengths. The same type of data typically requires a set of adsorption experiments on
a lab-scale chromatographic matrix resulting in quite expensive optimization routines as
these biologicals are costly. SPR thus offers the possibility to add more rationale in the
typical DoE type of approach at reduced costs given the small volumes required for testing
(Fig. 1.2).
Table 1.1 summarizes relevant scientific reports using rational tools to optimize IEX
processes for viral vectors or VLPs. Trilisky and Lenhoff (2007) produced a pioneering re-
port on a more rational selection of suitable ionic strength and pH conditions for optimizing
adsorption of adenoviruses. Dynamic light scattering and batch uptake were implemented
as tools for determining the ζ-potential of the adenovirus, detecting its point of zero charge
and for devising recommendations for pH and ionic strength of the buffer. Batch uptake
tests have also been part of other studies for ligand screening (Rodrigues et al., 2006; Vi-
cente et al., 2009a). However, SPR as an analytical chromatographic tool, can be used
as a cost-effective alternative for batch uptake resin/ligand selection or HTS (Roper and
Nakra, 2006; Kokpinar et al., 2006; Roper, 2007; Vicente et al., 2010b). Indeed, scaled-
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down models are being considered relevant options for early stage process development for
other more advanced processes, as mAbs (Coffman et al., 2008; Rege et al., 2006; Wensel
et al., 2008).
Following this lead, DLS has also been used as a main analytical support for the design
of a deterministic model capable of discriminating the contribution of the different virus
components of baculoviruses to the overall electrostatic particle potential (Vicente et al.,
2010d). Such tool provides fundamental knowledge on the crucial role of the external
glycoprotein of these virus particles, while predicting the optimal pH and ionic strength
ranges for improved adsorption of integral virus particles with enhanced selectivity to other
product-derived impurities. Studies on retroviruses and other viruses have been performed
with DLS (Schaldach et al., 2006; Rodrigues et al., 2008).
These studies, yet scarce in the literature, provide strategies for selecting/improving the
conditions and materials/technologies available for optimizing the IEX process. The final
goal would be to separate with high yield a product in a sharp and clean peak, decreasing
to acceptable values the impurity contents. The future, utopian perhaps, is reaching a
purely in silico process optimization as defended by Nfor et al. (2009); however, for these
more complex biologicals, the challenges are still too large. Bringing together relevant
and much more advanced work with simpler biologicals should constitute a good starting
point. It has been shown that it is possible to predict the IEX chromatographic behavior
of proteins directly from their crystal structure (Ladiwala et al., 2005). Furthermore, the
examination of the binding orientation of the protein adsorbates (Dismer et al., 2008;
Dismer and Hubbuch, 2007) provides a molecular-based approach for designing the ideal
matrix support with the ideal ligand spacing and density (Dismer and Hubbuch, 2010).
1.4 Outlook
Rational optimization of downstream processes for complex biopharmaceuticals, as viral
vectors or VLPs, is still in its infancy. It is clear that a more knowledgeable approach
shall highly reduce the “meandering” of the optimization path. With the strict demands
in product purity, safety, potency and quality, QbD shall be key in the manufacturing of
these biologicals. Rational tools, overviewed here into more detail for IEX process, will
be crucial for a more sustained process design and development. These case studies add
obvious gains in terms of product characterization and process understanding, which is
transforming the way state-of-the-art and scalable DSP processes are being designed. The
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trend is clear, needed and thus will keep evolving.
1.5 Scope of the thesis
Viral vectors and virus-like particles are examples of biological products holding a remark-
able potential in various clinical applications for gene therapy or vaccination. Enveloped
viruses are amongst the most complex biopharmaceuticals where basic knowledge to more
rationally address their production issues is still lacking. Moreover, the implementation
of robust and scalable downstream processes for these biopharmaceuticals is still in its in-
fancy. In fact, very little is known about the fundamental issues underlying the purification
processes of such viruses. This thesis aimed at improving the state-of-the-art purification
processes for these viral particles by means of developing and using fundamental-based
approaches for a more rational and efficient process development. We took the path high-
lighted in Fig. 1.2 as our rationale.
A virus-like particle from Rotavirus (RLP) system (presented In Chapter 2) provided a
model system where the introduced anion-exchange membrane chromatography step could
be modeled using mathematical tools. For the first time, a steric mass action (SMA)
model for the prediction of the elution profile of purified RLP pulses using membrane
chromatography was implemented with reasonable accuracy.
A leap forward was taken towards an enveloped virus system—our target object of study
of this thesis—in Part II. Increasing the particle complexity by adding an envelope on top
of a much larger viral vector (required to be infective), the VLP-derived knowledge proved
extremely useful to tackle more efficiently the issues in the purification of this virus model—
virus quality (because of the presence of damaged virus particles due, e.g., to the added
lability of the envelope), potency (concentration is often not enough for many applications)
and purity (contaminating HCP and/or HC DNA may still be too high depending on the
dose required).
For that purpose, our SPR (Chapters 4 and 5) and DLS (Chapter 6) tools, used as scale-
down methodologies to address the anion exchange membrane chromatographic step of the
established cGMP-compliant DSP (Chapter 3) were able to generate a better understanding
of the relevant undergoing phenomena. As a final outcome membrane adsorber prototypes
could be evaluated quicker yielding enhanced process performance and providing a proof
of concept where rational design and development can overcome some of the biological and
technological issues in the downstream processing of complex biopharmaceuticals.
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Part I
Stepping into complexity:
downstream processing of a VLP

Chapter 2
ANION-EXCHANGE MEMBRANE
CHROMATOGRAPHY FOR
PURIFICATION OF ROTAVIRUS-LIKE
PARTICLES
Adapted from:
Vicente T, Sousa MQ, Peixoto C, Mota JPB, Alves PM, Carrondo MJT. Anion exchange
membrane chromatography for purification of rotavirus-like particles. J Membr Sci 2008;
311:270–283.

DOWNSTREAM PROCESSING DEVELOPMENT OF ENVELOPED VIRUSES FOR CLINICAL APPLICATIONS
Abstract
Anion-exchange chromatography is one of the separation processes of choice for the re-
covery/purification of proteins and complex bio-structures as viruses or virus-like particles
(VLPs), e.g., rotavirus-like particles (RLPs) representing a potential biopharmaceutical,
where a safer vaccine technology is endeavored. Purification strategies of complex biopar-
ticles are as yet rather empirical. The breakthrough pursued hereby was to gain theoretical
and predictive knowledge on the anion-exchange membrane chromatography processing of
this type of products. Currently, the use of membrane chromatography is expanding due
to its scalability, robustness and disposable nature, allowing high fluxes, rapid processing,
little buffer consumption and a validation-free environment. A novel matrix, SartobindTM
D membrane adsorber from Sartorius, was used and thoroughly studied for the adsorption
of VLPs. Screening studies showed the sensitive effect of the ionic strength and the pH
of the equilibration buffer on product final recovery. Steric mass action (SMA) model for-
mulation was implemented for the prediction of the elution profile of purified RLP pulses.
Experimental data fitting gave good model validation therefore yielding insights on the fun-
damental understanding of the ion-exchange separation mechanism of virus-like particles
and, potentially, for other similar structures. Anion-exchange membrane chromatography
was finally used in a larger scale downstream process, confirming that rotavirus VLPs can
be reproductively purified to clinical grade at 46% global recovery yield, concomitant with
nearly 100% removal of host bulk DNA and approximately 98% of host cell proteins.
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2.1 Introduction
Given existing and potential applications in vaccines and gene therapy, complex biological
structures as VLPs justify the efforts that bioengineers invest in bioprocess development
so as to boost productivities while enabling cost-effective solutions.
Viruses or virus-like particles aimed as biopharmaceuticals are examples of complex
high-added value biologicals where in-depth studies clarifying the downstream purification
steps are scarce. The variability and complex composition of the bulks produced in animal
cell bioreactors include, besides the desired product, mixtures containing host cell pro-
teins, DNA, adventitious agents and/or other contaminant particles. These components
greatly contribute for the complexity of the systems, complicating the understanding and
integration of the purification steps.
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The purification section of a biological process assumes up to 80% of the total costs of the
process (Lightfoot and Moscariello, 2004); downstream processing (DSP) is still recurrently
a bottleneck greatly limiting final productivities (Aldridge, 2006). Process optimization
strategies are thus critical; beyond empirical/systematic know-how, predictive knowledge
of the process mechanisms establishing appropriate objective functions can become a major
driver in directly targeting both final product yield and purity improvements.
RLPs constitute an interesting example of a vaccine candidate for the worldwide bur-
den of early infant Rotavirus diarrhea (Glass et al., 2005). This specific virus-like particle
is an assembly of the Rotavirus protein building blocks, VP2 and VP6, and an outer gly-
coprotein layer, VP7, essential for the immunization response (Bertolotti-Ciarlet et al.,
2003). Avoiding the viral components responsible for infection (e.g., DNA or other pro-
teins) these particles represent a potential advantage over attenuated-live or deactivated
viral vaccines (Nguyen et al., 2003). Self-assembled RLPs are classically produced by the
Baculovirus Expression Vector System / Insect Cell (BEVS/IC) bioreaction and purified
using ultracentrifugation methods (Crawford et al., 1994), impracticable for large scale
biomanufacturing. Strategies involving ultrafiltration and chromatography DSP schemes
are currently the best choices for RLPs. The use of hollow fiber cross-flow filtration fol-
lowed by packed-bed size exclusion chromatography has been demonstrated by our team
with improved overall yields (37% overall product recovery) compared to the traditional
ultracentrifugation processes (Peixoto et al., 2007). The present study extends this effort to
adsorptive chromatography using a weak anion exchange membrane matrix commercially
available from Sartorius Stedim Biotech, SartobindTM D, a diethylamine anion exchanger
(DEAE) matrix. For instance, weak anion exchanger matrices have been used with good
results for purification of retroviruses (Rodrigues et al., 2006). Additionally, adsorption
onto DEAE matrices seems to be in agreement with the theoretical net negative charge of
the RLPs at neutral pHs (see characteristics in Table 2.1).
Disposable membrane adsorbers have already been used in purification schemes of
viruses (Karger et al., 1998; Specht et al., 2004) as well as employed efficaciously in clear-
ance steps of viral particles (Zhou et al., 2006). Adsorptive membranes have the advantage
over traditional resin-bed chromatography of decreasing diffusional effects to a minimum.
Convection is the prevailing mass transfer phenomenon throughout the membrane matrix
allowing a much easier and faster solute approach onto the ligand sites available. Ad-
sorption is consequently favored under these conditions (Teeters et al., 2002; Lightfoot
and Moscariello, 2004). High adsorptive uptake efficiencies, particularly for very large
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Table 2.1: Properties of Rotavirus-like particles (RLP) building block proteins and the full parti-
cle.
Material
Molecular mass
(kDa)
Theoretical
isoelectric
pointa (-)
Theoretical
number in
assembled
particle
Layer
Typical
form in
solution
Observations
VP2 102.7 5.63 60 dimersb
Assembled 60
dimer VP2
particlesb
Insoluble in
aqueous
solutionsb
VP6 44.9 5.48 260 trimersc
Soluble
glycoproteinc
Outer
glycoprotein
prone to
“peel off” in
the absence
of calcium
catione
VP7 37.2 4.74 780 monomersc
Trimers,
tubes, or
spheres of
VP6d
Ionic
strength /
pH
dependent
formsd
Assembled
RLP
76362 ∼5–6 ∼75–85 nmd
acomputed via ExPASy URL (http://www.expasy.org); bLabbe et al. (1991); cPrasad et al. (1988);
dLepault et al. (2001); eRuiz et al. (1996)
biomolecules (e.g., virus particles) with small diffusivities, are the main features of these
units (Teeters et al., 2002). Additionally, the possibility of having rather small bed height-
to-diameter ratios facilitates high fluid velocities and consequently high fluxes, therefore
reducing process time, a major advantage when dealing with a product prone to disas-
sembly, including the “peel-off” of the glycoprotein layer (Peixoto et al., 2007). Up-scaling
of membrane processes tends to be straightforward, since increasing both cross sectional
areas and bed heights without compromising binding efficiency or performance is feasible
using a membrane-like matrix (Teeters et al., 2002).
Ion-exchange process theories can be used to describe and model the mechanisms in-
volved in the anion-exchange membrane chromatography process. Plate models as de-
veloped by Yamamoto and colleagues (Yamamoto et al., 1983; Yamamoto, 1995) or Rate
models can be taken as a basis (Shene et al., 2006). Given its conceptual simplicity and
robust formalism, the Steric Mass Action (SMA) description tool was chosen to be im-
plemented and adapted to the RLP system (Brooks and Cramer, 1992; Shi et al., 2005;
Jakobsson et al., 2005). By establishing proper material differential balance equations and
boundary conditions, the characterization of the elution behavior of the multicomponents
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of a certain mixture becomes feasible (Brooks and Cramer, 1992). This formalism has
been successfully applied for describing the dynamics of the ion-exchange mechanism while
yielding process development and optimization strategies for antibody purification (Iyer
et al., 1999) and should be applicable to complex biopharmaceuticals.
Briefly, in this model it is assumed that the sorption phenomena taking place in an ion-
exchange chromatographic process are explained by the exchange reactions between the
free proteins or particles in solution in equilibrium with a certain number of ions adsorbed
onto the ligands covering the matrix surface (Brooks and Cramer, 1992; Gallant et al.,
1996). Herein, the focus is at the simulation of the elution curves of the different species
present in the RLP system describing the sorption processes using a membrane adsorber
matrix.
This work aimed at the evaluation of the Sartobind D matrix provided by Sartorius
Stedim Biotech. A screening of operational conditions provided experimental input for the
modeling of the anion-exchange membrane chromatography using the SMA model. Finally,
an integration of the membrane adsorber process in the whole DSP route was achieved,
effectively increasing overall recovery yields over the state of the art strategy recently
reported (Peixoto et al., 2007). Modeling of RLPs was thus possible within a membrane
adsorber technology, representing a rational tool for further process optimization on this
and, probably, other viral(-like) systems. Moreover, a successful application of anion-
exchange membrane chromatography for RLPs was demonstrated hereby enlarging the
significance of this technology for the purification of these complex biopharmaceuticals.
2.2 Materials and methods
2.2.1 RLP production
RLPs were produced with a Spodoptera frugiperda Sf-9 cell line obtained from the European
Collection of Cell Cultures (ECACC #89070101, United Kingdom) using the baculovirus
expression vector system (BEVS). The three baculoviruses, containing rotaviral vp2, vp6
and vp7 genes were kindly provided by Dr. Didier Poncet from Centre National de la
Recherche Scientifique (Institut National Recherche Agronomique (INRA), Gif-sur-Yvette,
France). The cells were routinely cultured in shake flasks and propagated in spinner flasks
(125 mL working volume). These cultures were used as inoculum for a 10 L working
volume Wavebag bioreactor (Wave Europe, Cork, Ireland) using GibcoTM Sf-900 II SFM
medium (Invitrogen, Paisley, United Kingdom); cells were co-infected with a multiplicity of
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infection of 2–5 pfu/cell for each type of the three baculoviruses at a cell concentration at
infection of 3.0×106 cells/mL. At the time of infection and every 48 h afterwards, the culture
was supplemented with protease inhibitors (1 µg/mL leupeptin and 1.6 µg/mL aprotinin
(Sigma-Aldrich, München, Germany)); the bioreaction broth was harvested at 120 h post-
infection. Cell concentration and viability were assessed using a Schärfe System CASYTM
1 TTC system (Innovatis, Reutlingen, Germany) and confirmed, whenever necessary, by
haemocytometer (Brand, Wertheim, Germany) with cell viability evaluated by 0.4 % trypan
blue exclusion dye (Merck, Darmstadt, Germany) in phosphate-buffered saline (PBS).
2.2.2 RLP standard purification protocol
Bioreactor bulk fractions were harvested and kept at -20◦C and the standard purification
strategy adopted the methodology established in-house (Peixoto et al., 2007). Briefly, cell
lysis and lipid removal from the bulk were done by incubation with 1% (v/v) TritonTM
X-100 (Sigma-Aldrich) for 30 min at 37◦C. Samples were withdrawn before and after each
step for assessment of RLPs recoveries by Western Blot and SDS-PAGE. The clarification
was carried out using a SartopureTM PP2 depth filter cartridge with nominal 3 µm pores
(Sartorius Stedim Biotech, Göttingen, Germany) through a peristaltic pump (Watson-
Marlow, Wilmington, USA) at a rotation rate of up to 450 mL/min (6.4 mm tubing
bore diameter, 1.6 mm tubing wall thickness) controlling possible overpressure (initial and
maximum/final backpressures were approximately 1 and 2 bar). The clarified bulk was
concentrated afterwards in a cross-flow ultrafiltration/diafiltration QuixStandTM Bench-
top System using a hollow fiber cartridge with a lumen diameter of 1 mm, a nominal
molecular weight cut-off (MWCO) of 750 kDa, a membrane area of 0.042 m2 and a flow-
path length of 30 cm (UFP-750-E-4MA, all GE Healthcare, Uppsala, Sweden). Prior to
use, the membrane was flushed with deionized water and equilibrated with GibcoTM D-
PBS (Invitrogen). The apparatus’ reservoir was loaded with up to 1.7 L of pre-clarified cell
lysate; transmembranar pressure (TMP) was set within the range of 5-10 psi which resulted
in a permeate flow rate range of 5-20 mL/min. When the volumetric concentration factor
reached 2-5, the retentate was diluted five times with D-PBS and further concentrated to
50 mL. The degree of washout of permeable components should be up to 10-20 % (see
mass balance results in Table 5). Samples of the final retentate and permeate were taken
to assess process yield.
The clarified and concentrated RLPs were then purified using size exclusion chromatog-
raphy with a XK26/60 column (2.6 cm diameter, 60 cm bed height) packed in house with
38
DOWNSTREAM PROCESSING DEVELOPMENT OF ENVELOPED VIRUSES FOR CLINICAL APPLICATIONS
SephacrylTM S-500 coupled to an ÄKTAexplorerTM 100 liquid chromatography system
(all GE Healthcare) equipped with UV (three simultaneous wavelength measurements)
and conductivity/pH monitors. System operation and data gathering/analysis was done
using the UNICORNTM 5.0 software (GE Healthcare). The column was loaded with 5
% of the column volume and the elution was carried out with a flow rate of 2 mL/min
(22.6 cm/h) at room temperature with D-PBS as running buffer. A final concentration
step was performed by ultracentrifugation at 100000 g for 60 min at 4◦C. The RLPs pel-
lets were typically re-suspended in 1 mL of D-PBS. Hereafter, this processing route will be
referred to as the “standard purification protocol”.
2.2.3 Analyticals
To assess the RLP content and the relative concentration of the different proteins (VP2,
VP6 and VP7), samples collected during the purification process were loaded onto Nu-
PAGETM Novex 4-12 % Bis-Tris pre-cast polyacrilamide gels (Invitrogen) using stan-
dard running conditions (Laemmli, 1970). Protein visual detection was performed using
SilverXpressTM Silver Staining kit (Invitrogen).
Protein transfer onto nitrocellulose membrane was done with a semi-dry transfer unit
(GE Healthcare); immunochemical detection for the three recombinant Rotavirus proteins,
VP2, VP6 and VP7 was carried out using a polyclonal anti Rotavirus serum produced in
rabbit, provided by Dr. Annie Charpilienne (CNRS INRA, France) followed by incubation
with an alkaline phosphatase conjugated anti-rabbit IgG antibody (Sigma-Aldrich) and
developed using 1-stepTM NBT/BCIP (Pierce, Rockford, United States of America).
SDS-PAGE (for protein purity assessment) andWestern Blot (for RLP yield estimation)
band profiles were analyzed by ImageJ software using an available add-in designed for gel
band densitometry quantification and normalization.
Total protein content of samples was determined using the BCA protein assay kit (96-
well plate protocol) from Pierce (Rockford, USA).
The quantification of DNA content throughout processing was undertaken using the
PicoGreenTM dsDNA Assay kit (Invitrogen) using 96-well plates according to the manu-
facturer’s instructions.
Total baculovirus particles used for the BEVS/IC were quantified by real time quanti-
tative PCR (q-PCR) following the methodology described before (Vieira et al., 2005).
RLP’s integrity and morphology (shape, size) was assessed by electron microscopy.
Briefly, 3 µL of sample was adsorbed onto a formvar coated 400-mesh copper grid (Electron
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Microscopy Sciences, Hatfield, USA) for 60 s. The grid was then soaked in 1 % uranyl
acetate for 30 s and dried in air at room temperature. The purified samples were examined
in a JEM 200 Ex electron microscope (JEOL, Sollentuna, Sweden).
2.2.4 Anion-exchange membrane adsorber studies
Sartobind D MA 75 membrane adsorber provided from Sartorius Stedim Biotech (see
Table 2.2 for details), was connected to the ÄKTA system as if dealing with a packed-bed
column by means of proper luer connections allowing to monitor online the adsorption and
elution processes.
Table 2.2: Manufacturer parameters and operational standards for Sartobind D MA 75 anion
exchange membrane adsorber.
Characteristic Value
Membrane material Reinforced stabilized cellulose
Functional group R-CH2-N-(C2H5)2
Adsorption area (cm2) 75
Diameter (cm) 2.5
Sectional area (cm2) 4.91
Number of layers 15
Bed height (mm) 4
Equivalent bed volume (mL) 2.06
Adsorption area / equivalent volume ratio (cm2/mL) 36.4
Manufacturer’s typical fluxa (mL/(min.cm2)) 80
Minimum static binding capacityb (mg/unit) 45
Specific minimum static binding capacityb (mg/cm2) 0.6
anominal measurement at 1 bar operating pressure; bconsidering bovine serum albumin as reference
protein
Preliminary membrane testing
A preliminary experiment with a clarified sample of RLPs (presenting a high load of im-
purities at this point) was performed in order to check for the potential applicability of
this specific ion-exchange adsorption matrix as a capture/concentration step. The mem-
brane was equilibrated with D PBS and elution was achieved using a linear salt gradient
up to 1 M NaCl in 4 “colum” volumes (CVs). The pool of the flowthrough and fractions
of detected elution peaks were obtained by the fraction collector and further analyzed via
SDS-PAGE and immunoblot testing.
Systematic evaluation of the anion exchange process
Samples of RLPs obtained by the standard purification method were used to perform a
scouting study for the ionic strength and pH of the equilibration/binding buffer.
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For each chromatographic evaluation run, 50 µL of a concentrated and purified RLP
feedstock (∼800 µg/mL) was diluted 10-fold in the desired buffer. For a pH range of 6.7-
7.9 a 0.1 M Tris buffer supplemented with 3-mM CaCl2 and 1.5 mM MgCl2 (all Merck,
Darmstadt, Germany) was used. Buffers at desired pHs and ionic strengths were prepared
using the automated buffer preparation feature of the ÄKTA system operated with the
UNICORN software. Essentially, it takes advantage of the two pumps connected to two
stream selectors (one per pump) allowing four inlet streams. The four feeding solutions
mixed by the system in appropriate proportions were: 0.1 M Tris buffer mentioned above,
0.1 M HCl, Ultra-pure water and 2 M NaCl. An automated method for the operation of the
standard membrane chromatographic process was implemented. In brief, the flow rate was
set to 2 mL/min (24 L/(h.cm2)); equilibration of the membrane was set to 5 CVs; linear
gradient elution (up to 1.5 M NaCl) was performed assuming a specified slope; membrane
cleaning at 1.5 M NaCl and final re-equilibration with binding buffer were set to a total
volume of 5 CVs for both steps. Automated scouting runs were then performed for the
variation of a specific parameter. Conductivities of different equilibration buffers ranging
from 2.5 to 7.1 mS/cm were tested as well as the pH within the range from 6.7 to 7.9
(fixing a selected ionic strength at 5.4 mS/cm). Additionally, varied linear gradient slopes
were employed: 1.5, 3, 6, 9 and 12 CVs. All chromatographic runs were performed at room
temperature.
2.2.5 Modeling and theoretical considerations
In the present study the SMA approach was used for the prediction of the exchange behav-
ior of RLPs in anion-exchange chromatography. The SMA formalism implies the definition
of three major parameters, the characteristic charge, νi, the steric factor, σi, and the equi-
librium constant, Ki, that characterize the adsorption process as a stoichiometric exchange
reaction of each solute with a certain number of adsorbed counterions (Brooks and Cramer,
1992):
ci + νiq0 ! qi + νic0 i = 1, ..., Nc, (2.1)
where ci and qi denote the solute concentration in the mobile phase and in the stationary
phase, respectively, c0 represents the salt concentration in the mobile phase, and q0 is
the concentration of bound salt available for exchange. The corresponding equilibrium
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constant, Ki, is written as:
Ki =
qi
ci
(
c0
q0
)νi
i = 1, ..., Nc. (2.2)
Each solute may sterically obstruct to some extent some salt counterions on the adsorptive
surface; the concentration of the “blocked” salt counterions is given by:
q∗0 =
Nc∑
i=1
σiqi i = 1, ..., Nc. (2.3)
The condition of electroneutrality requires that
Λ = q0 +
Nc∑
i=1
(νi + σi)qi, (2.4)
where Λ is the maximum ionic capacity of the membrane. Equations 7.4 and 7.6 constitute
a system of nonlinear equations describing the multicomponent equilibrium. The dynamics
of the membrane adsorber, which is assumed to behave as a chromatographic column (with
geometric parameters listed in Table 2.2), is described by an equilibrium dispersed plug-
flow model (Guiochon et al., 1994). The differential material balance for the component i
can be written as
∂ci
∂θ
+
1− &
&
∂qi
∂θ
=
1
Pe
∂2ci
∂x2
− ∂ci
∂x
(0 < x < 1), (2.5)
with he usual boundary conditions
ci − 1
Pe
∂ci
∂x
= cini for x = 0,
∂ci
∂x
= 0 for x = 1, (2.6)
where & is the void fraction, x = z/L is the dimensionless axial position (z is the axial
position within the L height of the membrane), θ = t/τ is the dimensionless temporal
coordinate (τ = L/u is the reference time with u the interstitial linear velocity), Pe is
the Péclet number for axial dispersion, and cini is the inlet concentration. The membrane
adsorber is initially solute-free and equilibrated with salt concentration, c00, the initial
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conditions for the membrane adsorber can be written as
c0(0, x) = c
0
0, q0(0, x) = Λ
ci(0, x) = 0, qi(0, x) = 0, i = 1, ..., Nc. (2.7)
For a linear-gradient elution the following conditions apply:
c0(θ, 0) =
 c
0
0, θ < θF
c00 +G(θ − θF ), θ " θF
ci(θ, 0) =
 c
F
i , θ < θF
0, θ " θF
(2.8)
where θF is the dimensionless length of the feed pulse, cFi is the feed concentration, and G
is the gradient slope.
The equations are implemented and numerically solved using gPROMS (Process Sys-
tems Enterprise, London, United Kingdom), a software package for the modeling and
simulation of lumped and distributed-parameter process models with combined discrete
and continuous characteristics. The spatial derivatives are discretized using third-order
orthogonal collocation on finite elements with a sufficiently fine resolution to provide a
grid-independent solution.
Some model parameters are fixed by the experimental setup, while others can be
determined via simulation and curve-fitting using the built-in estimation capabilities of
gPROMS. The characteristic charge, νi, the equilibrium constant, Ki, and the steric fac-
tor, σi are unknown parameters. These parameters should be invariant from experiment to
experiment, as they define the characteristic behavior of a certain solute in the SMA model
framework. In a system with good mass-transfer characteristics operated at reasonable flow
rates (as with membrane adsorbers), the Péclet numbers become fairly high (unless an ex-
tremely low throughput is employed). In this case, dispersion should not be significantly
altered within the velocity window used (there is a physical limitation for the flow). One
should keep in mind, however, that for large values of this parameter, its estimation in
the present work is subjected to a large statistical uncertainty due to the mentioned low
sensitivity of dispersion (and consequent chromatogram shape) as a function of the Péclet
number variation.
Under diluted conditions with respect to particle concentration (ΣNci=1ci → 0), as is the
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case in this study, the adsorption isotherms reduce to the linear or Henry’s law form:
q0 → Λ, qi → Ki
(
Λ
c0
)νi
ci i = 1, ..., Nc. (2.9)
Thus, the steric factor becomes redundant, but the partition coefficient retains the strongly
nonlinear dependence upon salt concentration. For the case of linear gradient chromatog-
raphy, the retention time, θ∗, of an infinitely diluted peak can be predicted using the linear
solvent theory (Gallant et al., 1996):
θ∗ = 1 +
[
γiG+ (c00)
νi+1
]1/(νi+1) − c00
G
, γi = (νi + 1)
1− &
&
KiΛ
νi (2.10)
By fitting Eq. 7.12 to the retention times of several chromatographic runs with different
gradient slopes, G, and different initial salt concentrations, c00 estimations of Ki and νi can
be obtained.
Additional effects might also become important for the refinement of the estimated
fittings. Initial concentrations for each solute can be prominent; although these values
are imposed by the chosen pulse, they refer to very small amounts, so that the inherent
errors on the pipetting, dilution and injection onto the membrane could reflect variations
on the amount of RLPs that were in fact loaded and further detected in the eluted peaks.
Moreover, if we close the material balances, ie, the integral of the modeled outlet concen-
tration (summing both RLP species) have to meet the sum of the experimental peak areas
calculated; then, cF1 and cF2 become mutually dependent by means of:∫ ∞
0
(couttot )simulationdt = (c
F
1 + c
F
2 )simulation ×∆tinjection =
∫ ∞
0
(couttot )experimentaldt (2.11)
An additional effect that is recurrently observed is the tailing of the peaks. This effect
arises normally when the column is overloaded and operated in the nonlinear region of
the adsorption equilibrium, which is not the case here as the RLPs are very diluted, or
when there is a back-mixing effect generated by dead volumes in the system. The latter
effect was taken into consideration by lumping all mixing effects onto a single mixing cell
placed downstream of the membrane adsorber. Assuming a perfectly mixed cell, the solute
balance material can be written as:
d(cmixi )
dθ
=
τF
Vmix
(ci(θ, 1)− cmixtot ) (2.12)
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where Vmix is the volume of the mixing cell, F is the flow rate, ci(θ, 1) is the individual
RLP concentration at the outlet of the membrane, and cmixtot = cmix1 + cmix2 denotes the
concentration measured by the UV monitor placed downstream of the membrane. This
equation lumps the overall tailing effects interfering in the system. Indeed, by using the
buffer preparation feature of the UNICORN software coupled to the ÄKTA system, au-
tomated mixing occurs with the four different inlet solutions and the injected samples
which, in turn, impacts the overall elution behavior and consequently the peaks’ shape.
In addition, the dead volume present in the membrane adsorber may also have an active
contribution to the tailing effect.
2.2.6 Revisiting downstream purification of RLPs
The anion-exchange membrane chromatography process was integrated into the down-
stream scheme by imposing some alterations on the standard purification protocol.
The buffer selected for assaying the Sartobind unit in a larger scale was Tris buffer used
in the characterization studies with a conductivity of about 6 mS/cm and a pH fixed to
7.3 (these were the conditions that maximized product uptake).
The hollow fiber ultrafiltration process duration was reduced by restricting the con-
centration step to approximately 2-fold. The retentate hereby collected was divided in
equal parts for further processing in the membrane adsorber in quadruplicate (to provide
reproducibility assessment). Ultrafiltered bulk was then submitted to the anion-exchange
process defining the following operational conditions: flow rate was set to 10 mL/min
(122 mL/(h.cm2)) except for elution, at 8 mL/min (98 mL/(h.cm2)) due to operational
pressure limitations; amounts of 250 mL were injected into the membrane followed by
a washing step with equilibration buffer with 8 CVs; the linear gradient slope was pro-
grammed to 20 CVs followed by membrane cleaning with maximum salt concentration
and re-equilibration with the starting buffer, both during 5 CVs. This capture and con-
centration step resulted in apparent low purity of the withdrawn fractions. Hence, the
purification scheme had to proceed to a desalting step with a standard HiPrepTM 26/10
Desalting column (GE Healthcare), exchanging to the Tris buffer used before, allowing
further processing. The pool of captured/concentrated particles was then polished by gel
filtration as mentioned in the standard purification protocol. The pool of particles obtained
at this stage is nearly 1.5-fold diluted (comparing to the previous step) and a final con-
centration step was carried out with a second anion-exchange membrane chromatography
using the same operational method already described.
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Samples were collected throughout the experiments for SDS-PAGE, Western Blot, total
protein, DNA assay and host baculovirus q-PCR assessments.
2.2.7 Viral spiking study
To validate the process concerning the regulations imposed for a clinical grade product, a
spiking study was designed to assess the possible binding of baculoviruses to this matrix.
Consecutively diluted samples of 2.8×109 total particles (TP)/mL of a monocistronic
baculovirus stock with the vp2 gene were injected in the membrane adsorber in a series
of runs and eluted under the same conditions. The decimal logarithmic reduction in total
viral particles was assessed.
2.3 Results and discussion
The ultimate goal of a biotechnological process delivering a highly valuable end product is to
maximize the overall process productivity while meeting the necessary purity requirements.
Taking into consideration the process strategy presented in the literature mainly consisting
of an ultradiafiltration followed by size exclusion chromatography (Peixoto et al., 2007), an
attempt was made here to further improve recoveries while increasing the understanding
of the underlying principles of the unit operations.
The results presented in this article can be sorted out as follows: i) the Sartobind D
MA 75 membrane chromatography matrix from Sartorius was utilized and its performance
studied in detail to detect its flaws and optimize the throughput; ii) the elution behavior
was simulated based in SMA modeling approach used for proteins for improved process
understanding and design; finally, iii) this step was integrated into the whole processing
scheme to evaluate whether incorporation of the anion-exchange membrane chromatogra-
phy improved the process.
2.3.1 Identification of a potential capture/concentration step
Samples of a pre-clarified bulk were injected in order to test the membrane for possible ad-
sorption of RLPs; as depicted in Fig. 3.1, the chromatograms suggest adsorption of RLPs:
the eluate peaks, which were collected as a single fraction, demonstrated the presence of
RLPs as measured by Western blotting (see Fig. 3.1B). The molecular weights of the VP
proteins resulting from this analysis differ from the values shown in Table 2.1. This is, how-
ever, rather common for pre-stained markers which do not always provide realistic marker
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weights (see Invitrogen marker application notes). RLPs were furthermore not detected in
the flowthrough pool, even with a reasonable contaminant load mainly composed of host
cell proteins, DNA or baculoviruses (bulk). These encouraging results mandated a further
evaluation of this chromatographic matrix.
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Figure 2.1: Chromatograms demonstrating the binding uptake of RLPs present in a clarified
sample: the matrix was equilibrated with D-PBS, then a 5 mL sample was loaded and eluted in 4
column volumes (CVs) with a linear gradient of up to 1 M NaCl; The pool of the two fractions
delimited in A with arrows was injected in the membrane (post washing in high salt concentrations
and re-equilibration with D-PBS) and chromatogram B was generated; the pool of peaks in B was
analyzed by Western blot, a), and by SDS-PAGE stained with silver, b); Lane MM: BenchMarkTM
Pre-Stained Protein Ladder, Invitrogen and correspondent weights in kDa.
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2.3.2 Evaluation of Sartobind D with purified RLPs
Adsorption isotherms or breakthrough curves determinations are typical procedures when
a more in-depth study in chromatography is proposed. However, these procedures were
avoided due to strong limitations on product availability, since manufacturing of perfectly
assembled RLPs is complex and costly. Moreover, claimed dynamic binding capacities for
this membrane adsorber are reasonably high (Table 2.2). Thus, an experimental setting
was planned where a low amount of RLP would be necessary. As such, looking for the
best conditions for operation of the selected membrane adsorber, a series of experiments
were performed, injecting strict pulses of a purified RLP stock. The following operational
variables, ionic strength and pH, were evaluated. It was observed in this set of chromato-
graphic runs that the flowthrough pools did not present quantifiable amounts of RLPs as
analyzed by Western blot (data not shown). Nonetheless, residual amounts of RLPs in
these fractions shall demonstrate different peak areas reflecting different product uptake
efficiencies in the following studies.
Effect of salt concentration
Buffering of injected RLP samples in a set of solutions differing on salt concentration was
shown to affect the binding efficiency of the product onto the matrix. To address this issue,
narrow variations on salt concentration in the chosen buffer were screened; the aim was to
observe whether or not the equilibration step of the membrane and subsequent dilution of
the sample in the same buffer upon injection/loading would be influenced by such subtle
changes. The same linear salt gradients were applied starting from the imposed salt con-
centration present in the system. Even for a low amount of product expected to adsorb,
a maximum for the binding capacity was attained, directly related to the detected peak
areas (Fig. 3.2). This maximum for the RLPs peak areas was obtained when using a salt
concentration of approximately 50 mM corresponding to ∼5.3 mS/cm. In agreement with
the previous experiment (Fig. 3.1), two peaks were also observed. This may be due to
the presence of either an excess of unassembled RLP proteins or even RLPs with slight
different net density charges. The external protein VP7, presenting a theoretical isoelectric
point lower than the remaining viral particle proteins, can have a stronger adsorption to
the matrix as, in principle, more intense negative charge densities occur. This hypothesis
was not confirmed as no differences could be measured in VP7 amounts for both peaks
by any of the tests used: immunoblot, SDS-PAGE, electron microscopy or analytical size
exclusion analyses (data not shown). No clear differences were detected in the analytical
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Figure 2.2: Effect of the binding/equilibration buffer conductivity on the elution profile of RLPs.
All five chromatograms were obtained by following a scouting method implemented in UNICORN
coupled to the ÄKTA system where equilibration buffer conductivity was allowed to change to the
indicated values; same RLP feedstock was used and the remaining operating variables and gradient
elution parameters were kept fixed (detailed in Materials and methods section).
Superdex 200 chromatograms as well as on Sephacryl S-500 runs; these were very simi-
lar to the ones normally obtained when using the classical DSP strategy (Peixoto et al.,
2007). On the other hand, besides the presence of two distinct populations, the same
RLP may have two modes of binding onto the studied matrix therefore yielding two dis-
tinct adsorption binding strengths. If, for instance, two preferential (but physicochemically
slightly different) points of contact on the RLP surface become available for establishing
electrostatic interactions with the DEAE ligands on the surface of the matrix, then, two
different adsorption/desorption equilibria may occur. Due to the non-elucidation of the
nature of the two peaks shown here (and throughout this work (see Figs. 3.2, 3.3, 3.4, 3.5,
3.6 and 2.9), the end product was defined in this manuscript as the pool of the two peaks.
pH scouting
Another critical variable in ion-exchange processes is the pH of the buffer solution used in
the binding mode. The net charge density of proteins is a function of the proton concen-
tration in solution (Voet and Voet, 1990). Thus, as was acknowledged above the impact
on the peak areas by tight variations on ionic strength, a pH scouting was done in order to
observe whether or not such variable could have a similar influence. As expected (Fig. 3.3),
increasing pH until a certain level resulted in higher peak areas. This is in agreement with
the theory for a single protein: the farther the pH is from the pI of the RLP the higher
the global ionic surface charge is. Therefore, higher electrostatic forces should favor an
improved approach/adsorption of the RLPs to the membrane adsorber. However, a de-
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Figure 2.3: Effect of binding/equilibration buffer pH on the elution profile of RLPs. All five
chromatograms were obtained by following a scouting method implemented in UNICORN coupled
to the ÄKTA system where the pH of equilibration buffer was set to vary from run to run; same
RLP feedstock was used and the remaining operating variables and gradient elution parameters
were kept fixed (detailed in Materials and methods section).
crease in the peak areas was observed when increasing the pH to values higher than 7.6.
As unexpectedly seen above, when lowering conductivity resulted in decreased capacity, by
increasing the charge density (pH>7.6) the binding capacity decreased. A possible expla-
nation could be that in a more alkaline environment (stronger particle negative charge) or
in lower conductivities (weaker solvated particle), the first RLPs being injected may assume
stronger electrostatic binding which in turn sterically hinder other incoming RLPs result-
ing in a non-ideal arrangement in the matrix surface, consequently diminishing capacity.
This phenomenon has been observed both with monoclonal antibodies (Harinarayan et al.,
2006) and antibody fragments (Ljunglof et al., 2007).
2.3.3 Spiking studies
By spiking the RLP samples with a known contaminant in reasonable amounts one could
assess the outcome and distinguish the peaks detected in our chromatography system. In
a set of chromatographic runs, a series of samples were spiked with monocistronic bac-
uloviruses used in the bioreaction in different total viral particle titers; assessment for
possible viral uptake onto the matrix was carried out by quantitative-PCR. Fig. 3.4 shows
an example of such an experiment where the slower linear gradient was used. Additionally,
a negative control where only RLPs were present was run to allow chromatogram com-
parison. These results suggest that adsorptive materials other than RLPs had bound to
the matrix. It is worthwhile referring that the baculovirus stock used here was a clarified
supernatant stock containing likely host cell proteins and/or other contaminants that may
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Figure 2.4: Anion-exchange membrane chromatography curve obtained in a baculovirus spiking
run: a co-injection of ∼40 µg of purified RLP and 109 TP/mL of a stock of baculovirus (“220 nm
Abs (RLP + baculovirus)”) was injected and further eluted in a gradient with a slope of 12 CVs
using 1 M NaCl. A control run maintaining only the RLP content of the co-injection run was used
to serve as control (“220 nm Abs (RLP only)”).
absorb at 220 nm. Possible adsorption of baculoviruses could somehow present an issue as
it contaminates the desired clinical grade preparation of the RLPs. On the other hand, this
observation opens a landscape for processing of such baculoviruses for use in, for example,
gene therapy (Kukkonen et al., 2003). As assessed by q-PCR, baculoviruses corresponded
to the highest retention times, as can be observed in Fig. 3.4. Thus one could foresee the
need for a gel filtration polishing step to assure baculovirus clearance from RLPs.
2.3.4 Modeling of anion-exchange process
The dynamic concentrations of the different species for the anion-exchange membrane chro-
matography process are the numerical solutions of the set of Eqs. 7.7, therefore conversion
of the collected absorbance data during the experiments (220 or 280 nm UV absorbances)
into concentration units are required allowing the comparison between experimental and
modeled data. Assuming perfectly assembled RLP particles (Lepault et al., 2001) (molec-
ular weight of 76362 kDa), extinction coefficients of approximately 5.6×10−9 mmol/mAU
(220 nm) and 4.0×10−8 mmol/mAU mmol/mAU (280 nm) are roughly estimated based
on tests done with a known concentration of RLP pure stock.
In order to use the established SMA model, chromatographic runs at different gradient
slopes were performed to provide experimental data input for model testing and further
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fitting. The gradient velocity is, in fact, one of the most important variables in linear
gradient elution of IEX processes as it can impose a great variation of retention times of
the species present in the mixture impacting, amongst others, resolution.
Model training
In order to assess the suitability of the proposed model in the RLP case study, simulations
were performed in gPROMS using initial guesses for unknown SMA parameters presented
in the literature for other protein solutes (Gallant et al., 1996; Iyer et al., 1999; Pedersen
et al., 2003; Arnau et al., 2006). It is worthwhile noting that this modeling tool could cope
with the set of the multicomponent equations mentioned before within reasonably short
computational times (e.g.: the simulation of an anion-exchange membrane chromatography
linear-gradient experiment took approximately 50 seconds of CPU time on an 3.00 GHz
IntelTM PentiumTM IV machine with 2 Gb of RAM, for a spatial grid of 50 finite elements).
Different chromatograms using a pure RLP stock in diluted conditions were rendered
by the ÄKTA system for runs performed at different gradient slopes allowing estimation
of the two important SMA parameters νi and Ki (see Table 2.3 and Fig. 3.5). Numerical
solutions for the Eq. 7.12 could be obtained using a regular MS ExcelTM solver for the
experiments carried out under the two slowest gradients (see Table 2.3). These values
were thus used for the subsequent model testing. Provided that Ki, νi and remaining
operational conditions listed in Table 2.3 and Table 2.4 were available, simulations could
be conducted. The remaining parameters were proposed initially and further estimated by
curve-fitting: namely, the Péclet number, accounting for the system’s dispersion and the
initial concentration of the RLP species as well as the feed concentrations cF1 and cF2 .
Curve-fitting and parameter estimation
By setting up the above conditions and assumptions, the estimation tool on gPROMS was
run in order to fit the simulated output to the experimental data. Apart from the values
obtained for the SMA parameters (Table 2.4), estimations for the feeding concentrations,
cF1 and cF2 , as well as Péclet number were accomplished (Table 2.3).
As can be seen in Fig. 3.5, very good adjustments were obtained with this approach.
Fine-tuned fits could however be obtained had one performed individual experimental
curve-fitting. Nevertheless, here it was intended to present the broadest result possible that
granted meaningful and predictive knowledge on the description of the elution profiles.
Not only could the estimated SMA parameters deal with the exchange between the
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Table 2.3: Chromatographic runs performed under different linear elution gradients and corre-
sponding experiment-dependent parameters estimated by curve-fitting.
Established Estimated
Run G(mM/min) c00 (mM) c
F
1 + c
F
2 (mM) c
F
1 /c
F
2 (-)
(cF1 +c
F
2 )Run i
(cF1 +c
F
2 )Run 1
(-)
1 113.6 58.6 2.6 0.62 1.0
2 196.7 57.5 3.5 0.67 1.3
3 322.6 57.3 4.2 0.89 1.6
4 394.4 47.4 3.4 0.91 1.3
Table 2.4: Non experiment-dependent parameters assessed within the SMA formalism.
Λ (mM)a 208
&a 0.95*
F (mL/min)a 2.0
Pe (-)b 7882
ν0 (-)b 1.0
ν1 (-)b 7.34
ν2 (-)b 7.29
K0 (-)b 1.0
K1 (-)b 4.26×103
K2 (-)b 2.05×105
Vmix (mL)b 0.33
*value obtained according to V0 determined in a run with a pulse of salt; aestimated using frontal
analysis (Gadam et al., 1993); bcurve-fitting estimated parameters
double component RLPs appearing in the two peaks, but also when estimating proper
feeding concentrations and Péclet numbers even better fits were achieved thus confirming
that the formalism implemented gives strong robustness, even with slight alterations in the
initial ionic strength.
If the information regarding the impact of ionic strength on product uptake during
binding to the matrix (Fig. 3.2 and Fig. 3.3) is integrated, then the slight variations on
the sum of feed RLP concentrations presented in Table 2.3 become reasonable. Neverthe-
less, it should be observed that the model has not assumed residual losses of product in
the flowthrough; in fact, the experimental chromatograms are inconclusive on this issue.
Therefore, the imposed material balance explains the increment on the feeding concentra-
tions (Eq. 2.12). Overall, these results serve as a proof of principle that, indeed, modeling
is possible for this system.
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Figure 2.5: Simulations performed against experimental data of anion-exchange membrane chro-
matography runs of purified RLPs varying the linear gradient slope: A, 12 CV; B, 6 CV; C, 3 CV;
D, 1.5 CV. Details of the experimental chromatographic experiments are shown in the text; simula-
tions and curve-fitting to experimental data-set were done using the gPROMS simulation software;
time zero refers to the injection start.
2.3.5 Scaled-up integration of the anion-exchange membrane chro-
matography
Integrated process
Finding an optimized utilization for a process that simultaneously integrates concentration
and purification steps can be a time- and labor-consuming task since the room for possible
experiments, i.e., selecting operational conditions, is large. Taking into account the results
obtained in the matrix evaluation studies, a sensible integration of the anion-exchange
membrane chromatography step in the standard purification protocol was attempted (see
Fig. 3.8): an ultradiafiltered bulk (obtained by the standard procedure) only nearly 2-fold
concentrated was used after exchanging with the chosen buffer – 0.010 mM Tris buffer
plus 0.050 M NaCl (calcium supplemented) – that was equally divided and used in order
to repeat the process and provide some support to our results. This quite diluted bulk
permitted to significantly accelerate the hollow fiber ultrafiltration process where the per-
meate flux tends to decrease with time due to membrane clogging. In addition, there is
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a gain in both product conservation and processing time as RLPs exposure to high shear
stresses is reduced for a shorter period (the standard procedure step using hollow fiber
could last up to 4 hours, to reach feasible concentration factors considering the subsequent
gel filtration polishing step).
Afterwards, equal retentate quantities where pumped through the membrane adsorber
via the ÄKTA system and subsequently eluted using a linear gradient. Here, the operational
conditions were modified so that they would allow the fastest processing possible. By
increasing the scale, the load flow rate had also to be up-scaled, therefore 10 mL/min was
considered as reasonable. Using this flow rate the membrane capacities were assessed close
to the limit in terms of adsorption kinetics (very low residence times are imposed). In
fact, as can be checked in Table 5, the yield in this step was around 55%; indeed, the
presence of RLPs was detected by immunoblotting in the flowthrough fraction (data not
shown). This problem can be overcome by using different strategies: slowing the flow rates
thus allowing a longer residence time or using a recirculation mode, letting the feed pass
a sufficient number of times over the matrix. It can be of interest to opt for a series of
injection steps if the adsorption to the surface matrix is a limiting step; using highly porous
membrane adsorbers, residence times tend to be quite short (especially if it is intended to
keep the flux or flow rate as high as possible). Worth mentioning in this regard is also that
possible contaminants might adsorb as well and occupy ligand sites therefore counteracting
product uptake and further recovery. Membrane fouling can furthermore become relevant
when very high loads of protein and other contaminants are processed. Future investigation
is needed to further clarify these possible issues.
The elution flow rate was programmed to 8 mL/min using 20 CVs as a linear gradient
slope to allow fair resolutions as well as providing an additional result to confront with the
developed theoretical model.
A stepwise elution mode could be applied here but since it was decided to obtain as
much data as possible as well as comparable with the approach used in the evaluation
studies and modeling a linear salt gradient was used. As can be seen in the chromatogram
depicted in Fig. 3.6, in this step a huge load of contaminants being washed out from the
membrane in the loading mode was observed as expected; furthermore the two eluted
peaks now appear at a higher order of magnitude and with a smaller resolution due in
part to some contaminant binding. Although contaminant binding was not expected, a
less complete ultrafiltration may permit that proteins kept on this bulk, showing similar
charge properties, would also compete for the matrix binding sites.
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Figure 2.6: Chromatograms obtained in two of the four anion-exchange membrane chromatogra-
phy runs carried out for the larger processing scale; only two curves are present, so as to facilitate
reader observation (chromatograms were very highly reproducible); loads of 220 mL with a flow
rate of 10 mL/min were used after which a 2 CVs washing with equilibration buffer and elution
performed for 20 CVs, now using 8 mL/min flow rates.
At this point in the DSP route, the peak fractions containing RLPs obtained during elu-
tion were several times purer but, still in agreement with the discussion above, a reasonable
quantity of host cell proteins could be macroscopically observed by giving a characteristic
color to the solution (present in early step bulks and usually never present, in our experi-
ence, even in concentrated RLP suspensions). This was supported by SDS-PAGE profile
analysis (Fig. 3.7).
At this point, taking into account that this type of products can be very sensitive when
dealt under aggressive conditions, a size exclusion chromatography, serving as a polishing
step was introduced (Peixoto et al., 2007). This step dilutes our product approximately
1.5-fold; therefore, the option was to use anion-exchange membrane chromatography once
again, similarly operated, but this time, mainly acting as a final concentration step. The
outline of the integrated process is depicted in Fig. 3.8; the space between the two dashed
lines in this diagram corresponds to the real volume proportions of the material throughout
each DSP step providing a visual perception of the concentration factors. Yields of around
47% were obtained (Table 2.5) while removing most of the DNA and host-cell protein load
(the final product has about 1.4 µg DNA/mg RLP). The concern underlined before on the
presence of contaminant baculoviruses was avoided by gel filtration as has also been shown
before (Peixoto et al., 2007). The DSP strategy presented here shows an improved overall
yield being faster and more economic than the process described in Peixoto et al. (2007)
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Figure 2.7: Coomassie blue stained SDS-PAGE protein profiles of intermediate DSP steps sam-
ples. Lane MM: BenchMarkł Pre-Stained Protein Ladder, Invitrogen and correspondent weights
in kDa; lane 1: 2 µL of bioreaction bulk sample; lane 2: 2 µL of sample after treatment with
1%Triton X-100; lane 3: 6 µL of sample after 3 µm depth filter clarification; lane 4: 6 µL of
retentate sample after ultra/diafiltration; lane 5: 20 µL of the elution peak fraction of the first
Sartobind D step.
using an expensive and difficult to scale-up ultracentrifugation as the final step. The use of
a membrane adsorber requires lower buffer consumptions for the different steps and uses a
disposable and scalable technology thus avoiding cleaning costs and validation for cGMP
operations.
Table 2.5: Essential values for the assessment of each step and overall outcome.
Process step Puritya (%) Step Yieldb (%) Concentration factorc (-) %DNA removal LRVc (-)
Bioreaction bulk 3.0 - - - 0.0
Cell disruption 2.9 97.6 0.9 37 -
Clarification 5.5 97.0 0.9 856 -
UF/DF 12.5 90.3 1.9 68 -
IEx (capture) 55.0 55.2 29.2 90 1.3
Gel filtration 74.0 99.7 17.5 98 3.5
IEx (concentration) 98.0 97.6 134.6 ∼100 4.5
Overall 98 46 135 ∼100 4.5
aratio SDS-PAGE RLP bands signal/total protein signal; bstep mass yield calculated via BCA total
protein determination adjusted by the corresponding purity degree; cvolume concentration factor
assuming the bulk volume as reference; dlog 10 of total bVP2 baculovirus titer (obtained by qPCR)
reduction assuming the bulk viral titer as reference
Predicted simulation
To validate the attempt to model this complex system, the implementation of the shown
formalism was then tested in a more realistic situation, when this process is used to capture
the product from a complex bulk containing a large load of contaminants. When changing
the operational conditions, i.e., flow rate (binding and elution phases), time schedule of
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Figure 2.8: Flow diagram for the integrated use of anion-exchange membrane chromatography in
the DSP of RLPs.
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the process, elution gradient used, and remaining up-scaled operational parameters, good
simulations are obtained (Fig. 2.9) taking into account the following operations. Again,
some operationally related considerations had to be imposed, such as the feeding concen-
trations which are not known beforehand as well as the ionic maximum capacity, Λ, that
is fixed. Assuming that the RLPs at this capture stage were more concentrated than the
RLP diluted stock used in the evaluation studies, the computed cF1 and cF2 were adjusted
(weighing the concentrations of the RLPs in the evaluation studies and in this capture
step) and the ionic maximum capacity was arbitrarily decreased one quarter, so as to take
into account the contaminant binding that was observed. Within the performed scalabil-
ity testing, where the membrane was led to its limits in terms of material loading, the
capacity was most likely achieved. As seen in Table 2.5, a loss of RLPs is detected in the
flowthrough pool which is probably due to contaminant binding onto the membrane matrix
(see purity in Table 2.5). Indeed, if an unaltered maximum ionic capacity had been used,
the simulation would mispredict the product peaks (Fig. 2.9). The intrinsic ionic maximum
capacity was obviously not physically altered here (at least with an unspoiled membrane).
Effectively, this adjustment was only an artifact to assess whether or not the model could
be applied to a larger scale situation under real contaminant conditions by assuming that
the membrane capacity was in fact fully utilized. Alternatively to this explanation, one
can speculate that in this situation the steric factor may play an important role and that
would generate non-linear SMA isotherms. The applicability of the SMA theory is still
meaningful for the larger scale, as in this case, while it opens new possibilities of investi-
gation in order to elucidate the possible steric effects and contaminant binding studies in
the preparative scale.
Overall, under the mentioned assumptions and approximations, these results provide
evidence on model applicability and validation for larger scale, stressing the relevance of
these calculated SMA parameters.
2.4 Conclusions
An anion-exchange chromatographic process was extensively studied in a membrane ad-
sorber pattern for the purification of RLPs. A process evaluation study using this robust,
scalable and cost-effective DSP step resulted in the determination of a narrow window of
ionic strength and pH conditions where RLP recoveries were maximized. Additionally, an
effort to understand the anion-exchange process mechanism ended up in a model formula-
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Figure 2.9: Simulation versus experimental anion-exchange membrane chromatography elution
curves obtained for one of the performed process runs; time zero refers to the injection start.
tion that accurately described the behavior of the linear gradient step of these particles.
This SMA model utilization was expanded from proteins as earlier presented in the lit-
erature and shown to be able to cope with much larger biological structures as virus-like
particles with an incomparably higher degree of complexity. Moreover and as a proof
of principle, SMA theory not only could be applied to the RLPs purification but also is
suitable for improved understanding of membrane adsorber mechanisms. These results
therefore deliver a starting point for dynamic modeling of separation mechanisms using
non-model protein systems.
In future work, refinements of the model implementation can be carried out by consid-
ering contaminant binding; objective functions may then be more accurately assigned for
both purity and recovery optimization depending on operational set-points.
Having ascertained that the anion-exchange membrane chromatography could be effi-
ciently integrated into the DSP of RLPs, improved recoveries and yields could be effectively
achieved (46% of overall product yield over the 37% previously reported by Peixoto et al.
(2007)) yet meeting clinical-grade product requirements for potential medical applications.
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Nomenclature
Symbols
ci concentration of the component i in the liquid phase (mobile phase) (mM)
c00 initial salt concentration (mM)
cFi feed concentration of the component i (mM)
cini initial concentration of the component i in the liquid phase (mM)
cmixtot sum of solutes’ concentrations on the outlet (mM)
cmixi measured outlet concentration of the component i (mM)
F flow rate (mL/min)
G linear gradient slope (mM/min)
Ki SMA equilibrium constant (-)
L membrane adsorber bed height (cm)
Nc number of total components (-)
qi concentration of the component i in the adsorbed phase (stationary phase) (mM)
q∗0 concentration of salt counterions shielded by the solutes in the adsorbed phase (mM)
t time since the beginning of anion-exchange membrane chromatography injection (min)
v interstitial velocity (cm/min)
V membrane adsorber volume (mL)
Vmix volume of the mixing cell (mL)
x Axial coordinate, x = z/L (-))
Greek letters
& void fraction (-)
Λ maximum ionic capacity of the membrane (mM)
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νi characteristic charge coefficient of the component i (-)
σi steric factor of the component i (-)
τ reference time, τ = v/L (min)
θ temporal coordinate, θ = t/τ (-)
θF dimensionless length of the feed pulse (-)
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DOWNSTREAM PROCESSING DEVELOPMENT OF ENVELOPED VIRUSES FOR CLINICAL APPLICATIONS
Abstract
Recombinant baculoviruses are widely used as vectors for the production of recombinant
proteins in insect cells. More recently, these viral vectors have been gaining increasing at-
tention due to their emerging potential as gene therapy vehicles to mammalian cells. Their
production in stirred bioreactors using insect cells is an established technology; however,
the downstream processing (DSP) of baculoviruses envisaged for clinical applications is still
poorly developed. In the present work, the recovery and purification of recombinant bac-
uloviruses aiming at injectable-grade virus batches for gene therapy trials was studied. A
complete downstream process comprising three steps – depth filtration, ultra/diafiltration
and membrane sorption – was successfully developed. Optimal operational conditions for
each individual step were achieved yielding a scalable downstream processing for recombi-
nant baculoviruses (rBV) as vectors for gene therapy. The processing route designed hereby
presents global recovery yields reaching 40 % (at purities over 98 %) and, most importantly,
relies on technologies easy to transfer to process scales under cGMP guidelines.
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3.1 Introduction
Recombinant baculovirus (rBV) has emerged as a novel vector for in vivo and in vitro gene
delivery (Hu, 2006). Indeed, applications of baculovirus-mediated gene transfer have widely
expanded to drug screening, eukaryotic gene display, cancer therapy and tissue engineering
(Chuang et al., 2007). In addition, rBV envelope can be used for protein/peptide display
rendering rBVs the potential as a vaccine delivery platform (Hu, 2006; Tani et al., 2008).
Current efforts to improve rBVs as gene delivery vehicles for mammalian cells are mo-
tivated by their advantages over existing gene transfer vectors, e.g.: non-pathogenicity to
mammalian hosts; ability to accommodate very large foreign DNA inserts; reliable pro-
duction at high titers using insect cell lines (Palomares et al., 2006; Hu, 2008). However,
the baculovirus distinct properties, in particular surface heterogeneity and non-spherical,
rod-shaped structure, represent major challenges in the development of robust downstream
strategies to produce clinical grade preparations. Moreover, in vivo clinical applications
require high doses of viral vectors to achieve the targeted therapeutic effect and effective
removal of contaminants since these can inhibit transduction efficiency or can initiate host
immune responses leading to unwanted adverse effects. Thus, these challenges on potency
and quality urge for the development of efficient and scalable purification and concentration
methods to optimize the production of rBVs (Hu, 2006).
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The literature is scarce on what concerns the concentration/purification of rBVs as
compared to other viral vectors. Routinely, rBVs are purified and concentrated by a series
of centrifugation and ultracentrifugation steps after harvesting from cell culture (O’Reilly
et al., 1994). However, ultracentrifugation protocols are time- and labor-consuming often
leading to significant loss of infectivity (potency) probably due to irreversible aggregation of
the viral particles; hence, low recovery yields with low reproducibility are typically obtained
(Jorio et al., 2006). A purification strategy combining ultracentrifugation and size exclusion
chromatography has been proposed but the overall recovery yield obtained barely reaches
25% (Transfiguracion et al., 2007). A concentration step based on the electrostatic surface
charge of rBV using cation exchange ligands was also described (Barsoum, 1999; Wu et al.,
2007). Recently, the concentration of biotinylated rBV vectors using magnetic beads was
reported with success (Kaikkonen et al., 2008). Nevertheless, for applications requiring
non-conjugated rBV vectors, there is still no fully scalable downstream processing (DSP)
strategy available.
Animal cell culture derived impurities such as host cell DNA, host cell protein and
endotoxins are major concerns when a clinical application is envisaged (FDA, 2010). The
available purification protocols for rBVs barely address these issues. Viral vectors involved
in a large number of clinical trials, for instance, adenoviruses or retroviruses require a com-
bination of DSP steps (concentration, capture and polishing steps) capable of decreasing
these contaminants to acceptable values (Altaras et al., 2005; Rodrigues et al., 2007; FDA,
2010).
The aim of this study was the development of a simple, robust and cost-effective DSP
strategy for rBV purification. An efficient purification process mostly based on membrane
technology was devised where processing times and validation costs were significantly re-
duced comparing to existing methodologies, thus streamlining the technology transfer to
cGMP operations. The DSP strategy presented herein is divided into three major parts:
(i) clarification by depth filtration, followed by (ii) concentration by cross-flow ultradiafil-
tration, and (iii) purification using anion exchange membrane adsorbers emerging as an
alternative for purification of rBV, with great potential for large scale manufacturing.
71
CHAPTER 3. Purification of an enveloped viral vector for clinical applications using membrane processes
3.2 Materials and methods
3.2.1 Recombinant baculovirus stock propagation
Sf9 insect cells (ECACC #89070101, UK) were routinely grown in GibcoTM Sf-900 II SFM
(serum-free) culture medium (Invitrogen, Paisley, UK) using spinner (stirred at 150 rpm
in a magnetic stirrer) or Erlenmeyer vessels (shaken at 110 rpm in an orbital shaker). Cell
concentration and viability were routinely assessed by haemocytometer (Brand, Wertheim,
Germany) with cell viability evaluated by 0.4 % trypan blue exclusion dye (Merck, Darm-
stadt, Germany) in phosphate-buffered saline.
Infection procedures were done using rBV seed stocks kindly provided by Dr. Kari
Airenne (AIV Institute/UKU, Kuopio, Finland) at multiplicities of infection (MOI) of
approximately 0.1 plaque-forming units (pfu)/cell. Two vectors were used: rBV GF-
Pvp39Nterm (encoding for the baculovirus major structural capsid protein, vp39, con-
taining on its N-terminal a GFP protein reporter (Kukkonen et al., 2003)) referred to as
rBV-GFP, and rBV DsRed2-mCherryvp39Nterm (encoding for vp39 fused with mCherry,
a cherry-red fluorescent protein, plus an additional mammalian expression cassette com-
posed of a strong mammalian cell promoter, CMV, and DsRed2, a red fluorescent protein)
referred to as rBV-cherry-dsred2.
3.2.2 Production of rBV stocks
Stock aliquots of rBV-GFP were produced in Sf9 cells grown in a 25 L working volume
wavebag bioreactor (Wave Europe, Cork, Ireland) using Sf-900 II medium. Sf9 cells were
infected at a viable cell concentration at infection of 1-2×106 cells/mL using an MOI of
0.1 pfu/cell. Cell viability and cell infection were monitored for five days post infection
(Cruz et al., 2000). Quantification of the infected cells during the process was done by
flow cytometry assessing GFP-expressing cell populations using a CyFlowTM Space flow
cytometer system (Partec, Münster, Germany). Data analysis was done using the manu-
facturer acquisition software FloMaxTM (Partec). The rBV production bulk was harvested
when the cell viability reached values of 50 %. Infection bulks were clarified either by cen-
trifugation at 1500 g for 20 minutes or by depth-filtration using 3 and 0.65 µm retention
Sartopure PP2 filter capsules (Sartorius Stedim Biotech, Göttingen, Germany) detailed in
the Downstream Processing methods section. Clarified aliquots were stored at 4 ◦C in the
dark until further use.
rBV-cherry-dsred2 stock aliquots were produced in 2 L Erlenmeyer flasks incubated
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at 27◦C orbital shaker at 110 rpm. Sf9 infections were done for five days post infection
(when the cell viability reached 50 %). Cell infection was monitored using a fluorescence
microscope for the detection of the mCherry signal produced.
3.2.3 Downstream processing
Ultracentrifugation-based purification
rBV standards used as reference for purity and recovery yields were obtained following a
classical ultracentrifugation-based purification protocol using sucrose gradients as described
in the literature (Airenne et al., 2000).
Clarification assays
A clarification scheme was devised based on disposable depth-filter capsules that are easily
integrated downstream of the bioreactor apparatus. Sterile tubing (1/4” inside diameter)
connections were prepared coupling the outlet of the bioreactor to 3 µm retention Sartopure
PP2 filter capsules followed by 0.65 µm retention Sartopure PP2 filter capsules in series.
Virtually, all large cell particulates/aggregates were removed from the rBV containing
supernatant. Filtration flow rates ranging within 3-5 L/h (or a flux of 15-25 L/(m2h))
were achieved by using a peristaltic pump (Watson-Marlow, Wilmington, MA, USA) run
at room temperature. The depth-filters were pre-equilibrated with D-PBS (supplemented
with Ca2+ and Mg2+) (Invitrogen). Samples were collected for analytical purposes before
and after the clarification step.
Concentration/Buffer exchange assays
As an intermediate purification/concentration process, ultrafiltration combined with diafil-
tration using tangential cross-flow filtration was developed. The cross-flow filtration runs
were performed in an automated ÄKTAcrossflow system controlled by the UNICORNTM
software (all GE Healthcare, Uppsala, Sweden). The feed, retentate and permeate side
pressures as well as the retentate and permeate flow rates were digitally controlled by the
equipment software. 200 cm2 HydrosartTM membranes with 100 kDa nominal molecular
weight cut-off (MWCO) (Sartorius Stedim Biotech) were mounted on the holder and con-
nected to the ÄKTA system. Three retentate flow rates were evaluated: 25, 35 and 50
mL/min; at each of these retentate flow rates, a range of transmembrane pressures (TMP)
within 0.25 to 2 bar was screened. Additionally, the impact of DVs (number of buffer vol-
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umes used for medium exchange) in the permeate protein content was assessed collecting
samples throughout the process.
After setting the optimal operational conditions (35 mL/min retentate flow rate and
TMP of 1.2 bar (see Results and Discussion section)), a two-step program was used: (i)
concentration until a desired concentration factor; and, (ii) continuous diafiltration until
a desired diafiltration volume exchanging the spent medium for D-PBS buffer. All ultra-
filtration/diafiltration runs were interspersed with 1 M NaOH cleaning in place sessions,
water washes, water flux tests (where Flux vs. TMP plots are produced to prove membrane
stability and performance for further process runs) and D-PBS system equilibration. All
these protocols were performed using the program templates available in the UNICORN
software package for ÄKTAcrossflow system and modified accordingly. All experiments
were performed at room temperature.
Capture assays
A capture step relying on a bind-elute chromatographic step was chosen as the core of the
rBV purification process. A preliminary screening of potential sorption chromatographic
ligands was performed by simple batch adsorption using equal amounts of resin (5 mL
settled material) and rBV supernatant (5-fold diluted in Tris-base buffer (Merck, Darm-
stadt, Germany) at pH 8.0) to a total of 10 mL. Beakers containing each resin type test
were shaken in an orbital shaker at 200 rpm for a period of 75 minutes. Samples were col-
lected throughout the experiment for rBV quantitation. In parallel, a control experiment
was done using the same amount of 5-fold diluted rBV lacking any resin in suspension.
Resins screened included a weak anion-exchange resin, CaptoTM DEAE (GE Healthcare),
two strong anion exchange resins, CaptoTM ViralQ (GE Healthcare) and UnoSphereTM
Q (Bio-Rad, California, USA), and an affinity-based resin composed of sulfate groups de-
signed for large particles that can also behave as cation-exchanger, CellufineTM Sulfate
(Chisso Corporation, Tokyo, Japan).
The best results were obtained with DEAE (see Results and discussion section); tak-
ing into account the selection of this ligand, a comparison study between two types of
chromatography matrices was performed: an anion-exchange membrane chromatography
matrix using Sartobind D MA 75 (Sartorius Stedim Biotech) units with 75 cm2 effec-
tive membrane area (equivalent to approximately 2 mL of membrane volume) containing
DEAE, and, a packed column-based anion exchange chromatography matrix using Capto
DEAE resin. Both matrices were coupled to an ÄKTAexplorer 100 chromatography sys-
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tem controlled with UNICORN software (all GE Healthcare), equipped with online UV
absorbance cell detector, conductivity meter, pH sensor, and a fraction collector. Both
matrices were equilibrated with D-PBS prior to sample loading with amounts of 100 mL of
previously ultra/diafiltered rBV supernatants. Flow rates varied from 5 mL/min (resin) to
10 mL/min (membrane). After sample loading, D-PBS buffer was allowed to pass through
the matrices to remove unbound/contaminant material. Elution of the viral peaks was
carried out using serial isocratic steps at buffer conductivities of around 48, 73 and 120
mS/cm (using D-PBS containing 1.5 M NaCl as the second mixing buffer).
The dynamic binding capacity of Sartobind D was estimated at 5 mL/min using a
smaller unit, Sartobind D MA 15 (15 cm2 effective membrane area or approximately 0.4
mL equivalent volume), injecting the same rBV material as above and collecting samples
for rBV titration in each fraction. In addition, the impact of residence time was addressed
by testing sample load recirculation at 10 MV/min; samples were collected for detection
of rBV throughout the recirculation loading process.
After purification with the membrane adsorber units, the rBV fraction pools were sub-
mitted to a final desalting step using a standard HiPrepTM 26/10 desalting column (GE
Healthcare). Sterile microfiltration of final material was performed using AcrodiscTM Sy-
ringe Filters with SuporTM PES Membrane (Pall, New York, USA) or Sartorius MinisartTM
NML (Sartorius Stedim Biotech) before storage at 4◦C in the dark. These experiments
were performed at room temperature.
3.2.4 Analyticals
Total rBV particles titration
The number of genome containing particles referred to as total rBV titer (total particles
(TP)) was monitored by real-time PCR (qPCR). Viral DNA was extracted and purified
with the High Pure Viral Nucleic Acid Kit (Roche Diagnostics, Mannheim, Germany).
Purified rBV viral DNA stocks previously quantitated by another validated qPCR method
were used as external standard (Vieira et al., 2005).
The wild-type baculovirus ie-1 gene sequence was used as a template for the ampli-
fication of a chosen amplicon of 150 bp (protocol adapted (Lo and Chao, 2004)). DNA
amplifications were done using the Light Cycler system with Fast Start Master SYBR
Green I kit (Roche Diagnostics). For a 20 µL PCR reaction, 10 µL DNA template and
10 µL of master mix were added to each capillary. The master mix was prepared to obtain
a final concentration of 4 mM MgCl2 and 0.5 µM of each primer in each capillary.
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Selected primers used for the ie-1 gene amplification were: forward, 5’-CCCGTAAC-
GGACCTCGTACTT-3’ and reverse, 5’-TTATCGAGATTTATTTGCATACAACAAG-3’.
The PCR program was set to: DNA denaturation for 10 min at 95 ◦C; standard ampli-
fication using 45 three-step cycles: (i) denaturation-heating at 95 ◦C for 30 second; (ii)
annealing-cooling at 63 ◦C during 5 seconds and; (iii) elongation-heating at 72 ◦C for 6
seconds. Fluorescence data was acquired at the end of the elongation step of each cycle.
Data was analyzed using the LightCycler software (Roche Diagnostics) by means of the ‘fit
points method’ described elsewhere (Rasmussen et al., 1998).
rBV transduction assays
Infective virus titers (IP) were determined either with the traditional end-point dilution as-
say method (O’Reilly et al., 1994) (for rBVs-cherry-dsred2) or with a flow cytometer-based
assay (for rBVs-GFP) as developed by Karkkainen et al. (2009). Briefly, the end-point
method was done with 96-well plates containing 100 µL of cellular suspension at a density
of 0.5×106 cells/mL incubated for 1 hour at 27 ◦C. Dilutions of the virus samples were
performed serially in culture medium, from 1:104 to 1:1011, and 100 µL were used to infect
the seeded Sf9 cells monolayers after removing the medium from the plate wells. Ten repli-
cates for each dilution were performed in the same plate, and two independent plates were
infected for each viral sample. A dilution of 1:102 was used as positive control; culture
medium was used as negative control. Plates were screened after seven days for mCherry
fluorescence detection under an inverted fluorescence microscope. The 50 % tissue-culture
infectious dose (TCID50) and consequent pfu (or number of infective particles) were cal-
culated using the equations described elsewhere (King and Possee, 1992).
In the flow cytometric method, 500 µL of Sf9 cell suspension at 1.5×106 cells/mL, seeded
into 2.2 mL 96-well plates (ABgene Limited, Epsom, UK), were infected with 500 µL of
serial rBV sample dilutions. After incubating the plates at 27 ◦C for approximately 18
h in a shake flask orbital shaker at 420 rpm, cell suspensions were directly submitted to
flow cytometer analysis using a 96-well plate autosampler (Partec) serially feeding each
sample to the flow cytometer for GFP-expressing cell population assessment (Karkkainen
et al., 2009). The maximum GFP-expressing cell population percentage (corresponding to
a non-diluted viral sample) was used as a normalization factor for reliable titer calculation
(Karkkainen et al., 2009).
HepG2 cell line was used as a target cell line for testing of rBV-cherry-dsred2 trans-
duction potency. HepG2 cells were routinely cultured in Modified Eagle’s Medium (MEM)
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supplemented with 10 % fetal bovine serum (FCS) and grown at 37 ◦C in a humidified
atmosphere equilibrated with 5 % CO2. For rBV transduction with samples, HepG2 cells
were seeded in 12-well plates at approximately 50 % confluence; 24 h later the culture
medium was depleted from the wells, and the cells were washed with cold PBS; rBV sam-
ples were either directly added or diluted 1:2 (likewise for all samples) in MEM medium
containing 1% FBS prior to incubation at 37 ◦C (with 5 % CO2) for 3 h. Negative control
wells containing MEM medium deprived of any viral sample were used. The virus dilution
suspensions from each well were then exchanged with MEM (supplemented with 10 % FBS)
after a brief PBS wash. Transduction was monitored for up to 15 days by cell visualization
under an inverted fluorescence microscope coupled with a digital camera.
SDS-PAGE and Western Blot
Protein profiling of samples collected after each of the purification steps were performed
using NuPAGETM Novex 4-12% Bis-Tris pre-cast polyacrilamide gels (Invitrogen, Paisley,
UK) using standard running conditions. Visual detection was carried out using Simply-
BlueTM Safe Stain (Invitrogen).
Protein transfer onto nitrocellulose membrane was done with a semi-dry transfer unit
(GE Healthcare); immunochemical detection of baculovirus main envelope glycoprotein,
gp64, was carried out using a commercially available mouse monoclonal antibody (mAb)
against gp64, AcV5 clone, affinity purified (1:2000 dilution) (eBioscience, San Diego, CA,
USA) followed by incubation with an alkaline phosphatase conjugated anti-mouse IgG
antibody (1:5000 dilution) (Sigma-Aldrich, München, Germany) and developed using 1-
stepTM NBT/BCIP (Pierce, Rockford, USA).
SDS-PAGE and Western Blot band profiles were analyzed by ImageJ software (NIH,
Maryland, USA) using an available add-in designed for gel band densitometry quantifica-
tion and normalization.
Total protein quantification
Total protein content of samples was determined using the BCA protein assay kit (96-well
plate protocol) from Pierce following the manufacturer’s protocol.
dsDNA quantification
The quantification of total dsDNA content in solution throughout processing was per-
formed using the PicoGreen dsDNA Assay kit (Invitrogen) in 96-well plates according to
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the manufacturer’s instructions.
Endotoxin quantification
The endotoxin level in the end products was determined by LAL test using the Limulus
Amebocyte Lysate QCL-1000 kit (Cambrex, Walkerville, MD, USA) following the manu-
facturer’s instructions.
Electron microscopy analysis
rBV integrity and morphology were monitored by transmission electron microscopy. Briefly,
3 µL of sample was adsorbed onto a formvar coated 400-mesh copper grid (Electron Mi-
croscopy Sciences, Hatfield, USA) for 60 s. The grid was then soaked in 1% uranyl acetate
for 30 s and dried in air at room temperature. The purified samples were examined in a
JEM 200 Ex electron microscope (JEOL, Sollentuna, Sweden).
Dynamic light scattering analysis
Hydrodynamic size estimations of sample particles were obtained by dynamic light scat-
tering (DLS) using a Zetasizer Nano-ZS Series ZEN3600 equipped with a 633 nm He-Ne
laser (Malvern, Worcestershire, UK). Viral samples were diluted 25- to 60-fold in D-PBS;
size measurements were performed in semi-micro polystyrene, 10×4 mm, cuvettes. Bovine
serum albumin (BSA) (Merck, Darmstadt, Germany) diluted in D-PBS was used as a con-
trol experiment. The rendered experimental correlation functions from DLS were analyzed
by the CONTIN method to obtain distributions of decay rate profiles which provided distri-
butions of apparent diffusion coefficient and, consequently, of the apparent hydrodynamic
diameter (through the Stokes-Einstein equation). Replicates with over 20 % deviation
were neglected. Before data acquisition, the instrument software automatically optimizes
operational conditions such as signal attenuation, focal distance and number of scans.
3.3 Results and discussion
3.3.1 Clarification and concentration
The clarification of the rBV bulk was performed using two depth filters in series: a 3 µm
pore size followed by 0.65 µm pore size. A recovery of infective particles of 95±5 % was
obtained. This two-stage mode technology allows for the removal of the centrifugation step,
while maintaining the product stream sterile as the filters are autoclavable. Furthermore,
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the filters are easy to use and represent a low up-front capital investment. The typical
sequence used for most of the initial clarification steps in cell line based processes is 0.45
followed by 0.2 µm retention in order to prevent contamination; however, as rBVs are very
large (Blissard and Rohrmann, 1990), larger pore sizes were chosen to reduce eventual viral
coagulation and retention in the filters. Moreover, the selected pore size allowed for a more
effective utilization of the entire depth of the porous filter for rBVs (Roush and Lu, 2008).
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Figure 3.1: Depth filter clarification of rBV: (A) Effect of transmembrane pressure (TMP)
on permeate flux at different retentate flow rates: 25, 35 and 50 mL/min. (B) Relationship
between increasing diafiltration volumes (DVs) and the amount of total protein in the process
sample obtained when using continuous diafiltration along with ultrafiltration step.
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Concentration of rBVs and removal of low molecular weight contaminants was per-
formed using tangential flow filtration (TFF); this is a technique routinely used at large
scale to concentrate and purify viral products Altaras et al. (2005). The best retentate flow
rates and TMP operating conditions were determined aiming at an optimized utilization of
the membrane while reducing membrane fouling and consequent product loss (Fig. 3.1A).
A TMP of 1.2 bar was selected, since for higher values a tendency for stabilization of the
permeate flux occurred for the three different retentate flow rates tested. This stabilization
of the permeate flux occurs most probably due to gel layer formation, which may explain
the decrease in rBV recoveries. Nevertheless, when operated at the TFF optimized condi-
tions, recovery yields of 70±5 % (based on infective rBV titers) were obtained; moreover,
concentration factors of, at least, up to 6 were feasibly achieved. Higher concentration
factors are likely to be accomplished if one could further control the resilient gel layer for-
mation; in fact, this seems to be the most critical issue, as it has been recently reported
that rBVs resist well to other factors such as shear stress (Michalsky et al., 2008).
Table 3.1: Assessment of ultrafiltration/diafiltration step reproducibility using different rBV vec-
tors and different methods for quantification of infective rBV titers.
rBV stock, #Experiment Method used for determination of in-
fectious titer
Recovery yield of
UF/DF step (%)
rBV-GFP, #1 Flow cytometer 70±5
rBV-GFP, #2 TCID50 68±6
rBV-cherry-dsred2, #1 TCID50 65±10
rBV-cherry-dsred2, #2 TCID50 70±4
Since at this point the purity did not meet the quality requirements for use in in
vitro (or in vivo) clinical testing, the product was conditioned for a next downstream
process step, an ion exchange process. The relationship between increasing diafiltration
volumes (DVs) and the amount of total protein removed and recovery yield obtained when
using continuous diafiltration was thus also evaluated (Fig. 3.1B). From these results, it is
possible to conclude that 2 DVs is a good compromise between purity and recovery yield;
after reaching a maximum around 2 DVs, a steep decrease is observed for the recovery
yield for higher DVs accompanying the total protein content decrease (Fig. 3.1B). The
reproducibility of this technique was also investigated with rBVs from different batches for
different applications (Table 3.1). These results indicate that, independently of the batch
or the method used for infective titer determination, the recovery yield obtained was within
the same order of magnitude confirming process robustness. The recovery yields obtained
do not differ much from the recoveries reported in the literature when cation exchange
chromatography or ultracentrifugation steps were used to concentrate the virus (Barsoum,
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1999; Transfiguracion et al., 2007). Moreover, the TFF has several advantages over the
methods previously described in the literature, as it can process larger volumes in shorter
times and can be used as disposable material thus facilitating cGMP operations.
3.3.2 Capture
To remove remaining contaminating proteins and DNA from the concentrated rBV stocks
another purification step was investigated. Four different chromatographic media were
tested (see Material and methods). The ligands selected for this study have been exten-
sively used in protein purification; however, there are no reports in the literature addressing
their applicability to rBV purification. The buffer used in the batch adsorption assay was
Tris-base at pH 8.0 to avoid any pH limitation for virus binding onto the anion-exchange
matrices. Anion-exchange functional ligands are good candidates for virus binding consid-
ering the low pI of the external rBV gp64 glycoprotein (Duisit et al., 1999). Samples were
prepared by diluting 1/5 the baculovirus feedstock (approximately 108 viral particles/mL
(TP/mL)); for each parallel experiment, approximately 2×107 TP/mL was used. The same
viral load was subjected to equal conditions serving as an internal control. The results in-
dicate that Capto DEAE and Capto ViralQ are the best matrices in terms of adsorption
kinetics; from 30 to 50 min Capto DEAE shows slightly faster dynamics than Capto ViralQ
although reaching both the same final plateau (Fig. 3.2). UnoSphere Q shows a lower ca-
pacity comparing to the Capto resins; Cellufine Sulfate does not significantly adsorb rBVs.
Additionally, as it can be seen, rBV stability was not an issue as no significant rBV titer
decrease was observed in the control beaker. As the main objective here was to select a
ligand to proceed with the process development, DEAE seemed to be a reasonable choice.
Membrane chromatography has been applied with success for virus purification (Duffy
et al., 2005; Lajmi et al., 2007); therefore, we investigated the performance of membrane
adsorbers using the same diethylaminoethyl functional group (DEAE). rBV samples previ-
ously clarified by depth filtration and concentrated by TFF were loaded onto Sartobind D
MA 75 for comparison against Capto DEAE resin packed in a column bed (10 mL column
volume). Three elution steps were defined: (i) 48 mS/cm; (ii) 73 mS/cm; (iii) 120 mS/cm.
The chromatogram profiles obtained are shown in Fig. 3.3.
The step elution mode provides a higher concentration factor and allows for the use of
higher flow rates and column loads. Although two well resolved peaks were observed in both
experiments, the Western Blot analysis using a monoclonal antibody anti-gp64 envelope
protein (the major rBV enveloped protein) indicated that both fraction pools contain rBVs
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Figure 3.2: Capture step selection: batch adsorption screening of baculoviral vectors to different
ligands. The control corresponds to supernatant with no chromatographic matrix in suspension.
(data not shown). This can be due to the different interactions taking place between the
heterogeneous viral surface and the matrix. However, in terms of recovery yields and
processing time, the Sartobind D membrane adsorber showed improved performance when
compared to Capto DEAE resin in packed bed; indeed, the recovery yield of total rBV
particles was around 20 % higher using the membrane process.
The loss of rBVs in the flowthrough and wash pools suggested that the residence time
of the rBV feedstock load on the membrane unit could have been too short to allow full
adsorption (data not shown); thus, a recirculation strategy was also evaluated for the
membrane adsorber. An rBV sample was recirculated for 30 min at 10 membrane volumes
per minute (MV/min) and flowthrough samples were withdrawn over time for analysis
by Western Blot (Fig. 3.4). After 6 min of recirculation (roughly corresponding to 2
membrane passages), gp64 was no longer detectable in the flowthrough indicating that
the recirculation mode did not significantly improve the adsorption kinetics of rBV and
consequent recovery yield of baculovirus. One should highlight that a low amount of
material was used as feedstock to remain well below the maximum binding capacity of the
matrix (see below for dynamic binding capacity estimation) in order to assess only the
adsorption dynamics. Alternatively, we decided to reduce the loading flow rate (down to
half of the initial flow rate used) in order to allow the same residence times.
To fully characterize the membrane anion-exchange chromatography matrix, its dy-
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Figure 3.3: Comparison between different matrices support: baculoviral vectors elution profile on
Capto DEAE resin bed (A) and Sartobind D (B) matrices. The sample was previously concentrated
by ultrafiltration and the elution steps were performed setting the elution buffer conductivities
serially at 48, 73 and 120 mS/cm for the two different matrices.
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Figure 3.4: Effect of feed recirculation on recovery of baculoviruses in membrane matrices: West-
ern Blot for detection of gp64 (the major envelope baculovirus glycoprotein) in the flowthrough
samples of Sartobind D loaded at 10 MV/min.
namic binding capacity for rBVs was measured using a sample previously clarified and
concentrated using the methodologies described above; the rBV sample was loaded onto a
Sartobind D MA 15 unit (Fig. 3.5). A flow rate of 5 mL/min was used and viral particles
were analyzed by qPCR. The breakthrough curve demonstrates that the dynamic binding
capacity for rBVs, at these dynamic conditions and at 10 % breakthrough, is approximately
7.7×1010 TP/mL, or per membrane effective area, 8.5×108 TP/cm2; further, up to 70±5
% of the bound virus can be eluted with addition of D-PBS supplemented with 600 mM
NaCl.
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Figure 3.5: Dynamic binding capacity study from breakthrough curve for the capture of baculovirus
from concentrated and diafiltrated supernatant. The sample was loaded onto Sartobind D MA 15
at 5 mL/min. C0 is the initial qPCR titer of rBV and C is the qPCR titer of rBV at sampling
instant.
The purified rBVs samples were also analyzed using SDS-PAGE (Fig. 3.6). The profile
obtained with the membrane strategy (lane 4) is comparable to rBVs purified by sucrose
gradient ultracentrifugation (lane 5) showing even higher purity; several bands disappeared
in the SDS-PAGE pattern when the Sartobind D process was used.
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To assess the eligibility for clinical purposes, DNA levels and endotoxin contents of puri-
fied samples were assessed. Endotoxin levels of end-product samples were below 10 EU/mL,
ie, of sufficient purity, whereas the amount of host cell derived dsDNA was approximately
2 µg/(109 TP). However, this value can be significantly decreased if an additional operation
specifically aimed at reducing DNA is incorporated, eg, by adding a nuclease incubation
step or DNA precipitation (Goerke et al., 2005).
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Figure 3.6: SDS-PAGE analysis of samples obtained from rBV purification using membrane
technology and by classical ultracentrifugation-based purification: (1) molecular weight markers;
(2) baculoviruses clarified with depth-filters; (3) concentrated and diafiltrated sample (4) peak eluted
from Sartobind D (5) rBVs purified with sucrose gradient.
To further characterize the rBV samples obtained after purification with the membrane
adsorber, DLS was used to estimate the hydrodynamic size of the particles; bovine serum
albumin (BSA) and trimers of gp64 (obtained as described elsewhere (Mellado et al., 2008))
were used to serve as comparison entities (internal controls) against rBV particles coming
from sucrose gradient purification and from the proposed purification strategy (Fig. 3.7A).
These results show that rBVs purified using the strategy described are comparable with
the size obtained from the classical sucrose gradient purified rBV sample. A two modal
distribution of sizes can be observed which is most likely due to the rod-shape geometry
of the rBV particles. The extended peak observed to almost 800 nm may also be an
indication of some aggregation as compared to the expected size of the isolated baculovirus
particle of around 300-400 nm in length. Morphological characterization was performed
by transmission electron microscopy. As shown in Fig. 3.7B, the purified rBVs consist of
intact, rod-shaped particles with a size roughly 70 nm × 320 nm, values slightly lower
than the ones obtained with DLS (90-100 nm × 300-400 nm). However, one must recall
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that the size determined by DLS is, in fact, an estimation of a hydrodynamic size, ie, with
rBVs suspended in buffer conditions; as such, this might lead to some particle swelling as
compared to the dried particle observed by transmission electron microscopy.
!
"
Figure 3.7: Characterization of purified rBVs: (A) hydrodynamic size estimations by dynamic
light scattering using D-PBS as dilution buffer, at 25 ◦C; gp64 trimer sample were obtained as
a by-product of the strategy published in-house (Mellado et al., 2008). Plots are obtained from
triplicate runs and subsequent application of Stokes-Einstein equation for size determination. (B)
Transmission electron microscopy photograph from purified rBV sample with the proposed purifi-
cation process (120 k-fold magnification).
Upon achieving high purity with the three membrane purification steps, a desalting
step was introduced after the anion-exchange membrane process, to obtain the rBVs in
the desired salt concentration and pH for storage and/or clinical administration. Finally, a
0.2 µm microfiltration was performed to assure sterility of the final product; the infective
rBV recovery yields were dramatically dependent on the filters used, which might have been
caused by the entrapment of the rod-shaped rBVs particles in the porous membrane. Two
different filters were investigated and the best recoveries, 90±10 %, were obtained for the
filter manufactured with two layers (pre-filter of 0.8 µm + 0.2 µm membrane) (from Pall,
East Hills, NY, USA) as opposed to filters with no pre-filter (data not shown). One can
circumvent this final sterile filtration drawback by designing a fully closed aseptic process,
possible in cGMP operations. However, completely closed processing has its own issues and
all of the tools involved may turn the investment capital higher than regular processing.
Summing up, the indicators of the proposed integrated downstream process are pre-
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Figure 3.8: Transduction assays carried out with rBV-cherry-dsred2 samples: HepG2-expressed
DsRed2 protein signal was detected under a fluorescent microscope 24h post-transduction (left pan-
els); phase contrast micrographs are shown on the right hand side panels; equal volumetric amount
of sample was used in each assay; (A) clarified supernatant sample; (B) concentrated/diafiltrated
baculovirus sample; (C) flowthrough sample from Sartobind D step; and, (D) eluted sample from
Sartobind D step.
87
CHAPTER 3. Purification of an enveloped viral vector for clinical applications using membrane processes
sented in Table 3.2. A final recovery yield of 38±5 % was obtained with a final ratio
between total particles and infective particles (IP) below 20. In order to confirm the gene
delivery functionality of the rBVs throughout the complete downstream process, transduc-
tion assays were carried out using HepG2 as mammalian testing cells. Fig. 8 shows in vitro
fluorescence images of targeted cells 24 hours post-transduction using a low dilution fac-
tor (see Materials and methods) to guarantee unambiguous positive (or negative) DsRed2
expression signal, ie, with at least 100 plaque-forming units (pfu) per target cell in the
positive signal samples. Whereas the flowthrough fractions did not induce any positive sig-
nal, the supernatant and, especially, the concentrated samples after TFF and eluted peak
from Sartobind D showed evidence of bright red fluorescence under green light excitation
demonstrating that the rBVs particles are functional throughout the purification process.
Table 3.2: Evaluation of downstream process steps for baculovirus purification using membrane
technology (depth-filtration, ultra/diafiltration, and membrane chromatography).
Process Step TP/IPa,c µg DNA /
109 TP
Protein
(µg/109 TP)
Endotoxin
(EU/mL)
Recovery yield
of IPb,c (%)
Clarification NA 1980 3983 NA 98±2
Ultrafiltration 53 823 194 NA 70±5
AEX membrane NA 5 66 NA 65±5
Desalting NA NA NA NA 95±3
Sterile filtration /
Final product
18 2 70 <10 90±10
aTP/IP: Ratio between total (TP) and infective (IP) rBVs is an indicator of product quality of the outlet
of the specified step; bBased on the fraction between the total amount of infective rBVs in the outlet
(used for the subsequent process step) and the total amount of infective rBVs in the feed of the specified
step; cTotal amount of rBVs (TP and/or IP) were used for these calculations, ie, by multiplying the
specified titer by the total volumetric amount of material; NA: Not assessed.
3.4 Concluding remarks
This work describes a complete and integrated purification scheme for rBVs mostly based
on disposable membrane technology. An intermediate recovery yield of 70 % was obtained
using TFF and Sartobind D membrane chromatography after optimization of the critical
operating parameters. An overall recovery yield of 40 % while meeting purity require-
ments was achieved. In conclusion, the approach devised here represents a substantial
improvement for the production process of clinical grade rBVs.
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Abstract
Surface plasmon resonance (SPR) spectroscopy is used as a scaled-down, analytical, pseudo-
chromatography tool for analyzing protein binding and elution over an ion-exchange sur-
face under cyclic sorption conditions. A micrometric-scale adsorption surface was pro-
duced by immobilizing a typical ion exchange ligand—diethylaminoethyl (DEAE)—onto
commercially-available planar gold sensor chip surfaces pre-derivatized with a self-assembled
monolayer of 11-mercaptoundecanoic acid with known density. An explicit mathematical
formulation is provided for the deconvolution and interpretation of the SPR sensorgrams.
An adsorption rate model is proposed to describe the SPR sensorgrams for bovine serum
albumin, used here as model protein, when the DEAE surface is subjected to a cyclic series
of binding and elution steps. Overall, we demonstrate that the adsorption rate model is
capable of quantitatively describing BSA binding and elution for protein titers from dilute
conditions up to overloaded conditions and a broad range of salt concentrations.
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4.1 Introduction
Process design and optimization are critical tasks in any pharmaceutical industrial pro-
cess; the time and resources allotted for R&D tasks are relevant issues (Davies et al., 2005;
Pampel et al., 2008). This becomes particularly crucial within the scope of biopharmaceu-
ticals for gene therapy or vaccination, comprising complex structures, such as monoclonal
antibodies, virus-like particles, or viruses. Indeed, these products commonly derive from
highly costly animal cell-based upstream productions. Hence, the optimization of such pro-
cesses becomes mandatory in the interest of cost and time savings. Scaled-down models,
often used in high-throughput technologies, are being considered as viable options for early
stage process development (Coffman et al., 2008; Rege et al., 2006; Wensel et al., 2008),
including downstream processing steps such as ion-exchange chromatography, which is one
of the core purification steps for biopharmaceuticals (Vicente et al., 2008; Rodrigues et al.,
2006; Specht et al., 2004; Yamada et al., 2003; Zydney et al., 2008; Trilisky and Lenhoff,
2007; Kaludov et al., 2002; Vicente et al., 2009). High-throughput robotics operating with
multi-micro-sized matrices are able to generate a considerable amount of data covering the
n-dimensional design space for the selected n-critical process variables (Kelley et al., 2008).
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By using these high-throughput methodologies, the bottleneck seems now to be moving to-
wards data processing and subsequent integration. This drawback opens up the need for
a more focused scaled-down rationale, capable of ultimately yielding better and more se-
lective data for facilitating further optimization choices. In the context of multicomponent
adsorption processes, including ion-exchange chromatography, the understanding of how
the different contaminants interact with the stationary phase provides clues and guidelines
for finding the best strategy for process design and optimization.
Surface plasmon resonance (SPR) is a spectroscopic technique with a wide variety of
applications (established over the last couple of decades) whenever an interaction between
two entities is involved — a ligand, immobilized on a surface, and an analyte, flowing
over that surface (Hoa et al., 2007; Pattnaik, 2005; Rich and Myszka, 2008). Moreover,
SPR permits simpler and faster label-free, real-time interaction analyzes between those two
entities than other analytical technologies (Myszka et al., 1998). By producing interaction
data using highly reduced amounts of material in each run, SPR can play a significant
role in the design of adsorption processes, including ion-exchange chromatography. Such
analytical technology may be used as a cost-effective aid for the early stage systematic
screenings of stationary phases, buffer conditions, and chromatographic steps.
An SPR sensor mainly consists of a surface support with a metal (typically gold) and a
film of fluid flowing over the surface, thus allowing for possible interactions between the gold
surface and the liquid. Commercially available SPR-based sensors can be extremely sensi-
tive; in fact, they can detect, within a fraction of a second, very small refractive index (RI)
changes within the film delimited in the depth of the sensing evanescent electromagnetic
field (Jung et al., 1998). When such a sensor is functionalized with selective ligands for any
given molecule (either chemical or biochemical), then selective (bio)chemical sensors can
be custom-made. A straightforward and self-controlled means to prepare a functionalized
sensor surface from an untreated gold one is to use self-assembled monolayers (SAMs) using
thiolate compounds (Mrksich and Whitesides, 1996). SAMs — particularly those formed
by adsorption of long chain alkanethiols over gold surfaces — are especially suited for
studying interactions between post-functionalized surfaces and proteins or other particles
(Mrksich and Whitesides, 1996). These compounds self-generate well defined, synthetic
surfaces with known molecular and macroscopic properties, thus allowing for consistent
fundamental studies. This is particularly relevant if a SAM is used as a linker to a layer of
covalently coupled functional groups (at known stoichiometry) (Whitesides et al., 2005).
11-mercaptoundecanoic acid (MUA) has been utilized in different applications for the cova-
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lent immobilization of ligands with complex structures, such as viruses (Roper and Nakra,
2006; Kim et al., 2006).
The quantitative interpretation and modeling of SPR rendered data, including cases
where different SAM layers are used, has been addressed in the literature (Myszka et al.,
1998; Jung et al., 1998). However, a detailed analysis for a sensor chip surface functionalized
with a layer of ion-exchange ligands, mimicking the undergoing mechanisms of adsorption
equilibrium and kinetics on a typical adsorbent surface, is still unavailable.
In the present work SPR spectroscopy is used as a scaled-down, analytical tool for an-
alyzing protein binding and elution over an ion-exchange surface under cyclic adsorption
conditions. We review the principles of SPR spectroscopy and establish the required cali-
bration procedures and analytical formulae for converting the SPR signal shift into surface
concentration of adsorbed protein. We propose two different adsorption rate models that
qualitatively describe the general trends observed in the SPR sensorgrams for bovine serum
albumin (BSA) — used here as model protein — when the DEAE surface is subjected to a
cyclic series of binding and elution steps. By carefully analyzing the adsorption/desorption
plateaus we show that it is possible to exclude one of the kinetic models. Furthermore, by
performing SPR experiments at different salt concentrations, the dependency of binding ca-
pacity and rate constants on salt concentration can be established. Overall, we demonstrate
that the resulting adsorption rate model quantitatively describes the SPR sensorgrams for
protein titers from dilute conditions up to overloaded conditions and a broad range of salt
concentrations.
4.2 Materials and methods
4.2.1 Sensor surface preparation
Biacore gold sensor chip surfaces (Biacore/GE Healthcare, Uppsala, Sweden) were mod-
ified according to protocols described in the literature (Mrksich and Whitesides, 1996;
Roper and Nakra, 2006), but with some adjustments. 11-mercaptoundecanoid acid (MUA)
(NanoThinksTM ACID11 solution from Sigma-Aldrich, München, Germany) and 2-diethyl-
aminoethylamine (DEAEA) (99% purity grade from Sigma-Aldrich) were used as thiolate
for SAM preparation and ligand coupling compound, respectively. A Leica AR200 digital
handheld refractometer (Leica Microsystems, Wetzlar, Germany) was used to monitor the
RI changes throughout the MUA-SAM immobilization procedure.
The gold sensor chip surface was first equilibrated with ultra-pure, deionized water, at
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18.2 MΩ·cm. The surface was sanitized with 0.1 M NaOH and 1% TritonTM X-100 (Sigma-
Aldrich) and then re-equilibrated in 10 mM 4-Morpholineethanesulfonic acid (MES) buffer
(Sigma-Aldrich) at pH 5.0. Ethanol was then used to washout the buffer and the surface
was exposed directly to the ACID11 solution (5 mM MUA in ethanol) and left overnight in
a closed compartment inside a laminar flow bench. The freshly formed SAM of MUA was
rinsed with ethanol and re-equilibrated with the 10 mM MES buffer previously used until
the RI stabilized. The sensor chip was then docked into the SPR system — a BiacoreTM
2000 (Biacore/GE Healthcare) — for DEAEA immobilization by amide coupling chemistry.
The same MES solution was used as running buffer for the duration of the immobilization
procedure.
Freshly prepared solutions of 0.4 M 1-ethyl-3-(3-dimethylamino-propyl)carbodiimide
hydrochloride (EDC) and 1.0 M N-hydroxysuccinimide (NHS) (amine coupling kit from
Biacore/GE Healthcare) in water were mixed 1:1 and injected in a pulse of 200 µL at
20 µL/min to activate the terminal carboxyl group for amide bond formation. 1.0 M
DEAEA in MES running buffer was added in serial 100 µL pulses at 20 µL/min until the
SPR signal stabilized. Although there are four flow sensing cells available in the Biacore
sensor chip, only one flow cell was derivatized with DEAEA to allow the comparison of SPR
adsorption data from MUA against MUA-DEAE. All buffers and solutions were prepared
sterile and degassed prior to use.
4.2.2 SPR experiments
The SPR experiments were performed on a Biacore 2000 system at 25◦C. Analytical grade
(> 98% electrophoresis purity) BSA was purchased from Merck KGaA (Darmstadt, Ger-
many). It is well known that commercial BSA samples contain a substantial fraction
(5–20%) of covalent dimmer; the actual amount in our freshly prepared BSA solutions is
estimated to be ca. 6%, from analytical size-exclusion chromatography on a Superdex 200
column. This residual fraction is believed to have only a minor influence on the exper-
imental results. This assumption is supported by the closeness between our estimate of
the thickness of the adsorbed monolayer, obtained from calibration experiments at a high
salt concentration (see discussion below), and the BSA diameter calculated from its molec-
ular weight and mass density; these two lengths are much smaller than the diameter of
the covalent dimmer. All buffers were prepared sterile and degassed prior to use in the
equipment.
The experiments were performed at constant flow rate of running buffer and sample
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injection of 100 µL/min. Each run consisted of the following sequence of steps repeated
over three or four cycles: (i) equilibration of the flow cell with running buffer at a prescribed
NaCl concentration (c0); (ii) injection of 100 µL of BSA solution at given concentration
(c0, cB); and (iii) desorption and equilibration with running buffer (again, at c0). Before
starting a new run, the flow cell was subjected to an aggressive desorption step using 100 µL
of 1.5 M NaCl in 20 mM phosphate buffer at pH 6.8 (c0,ref), and then cleaned/sanitized
with 100 µL of 0.1 M NaOH for complete regeneration of the surface.
DEAE ligands and SAM’s have been shown to be fully resistant to pulses of NaOH (or
HCl) up to 1 M (Knoll et al., 1998). The baseline stability was controlled throughout the
course of each experiment. All sensorgrams were duplicated by repeating each run once
for confirmation of their reproducibility and surface regeneration.
4.3 Supporting theory for SPR data analysis
In order to quantitatively analyze SPR data under adsorption conditions one must first
understand the underlying probing mechanism of the Biacore machine — the medium’s
RI within the sensing evanescent field depth. The RI of an aqueous salt solution (0) with
concentration c0 is
η0 = η˜w + (η˜0 − η˜w)ν0c0, (4.1)
where c0 (M) is the salt concentration, ν0 is the molar volume of the salt ions (M−1), η˜w
is the RI of water, and η˜0 is the RI of the salt ions. Similarly, the RI of the aqueous salt
solution with a given dissolved solute (B) (this can take the form of any analyte, e.g., a
protein), can be expressed as
ηB = η0 + (η˜B − η0)vBcB, (4.2)
where cB (M), vB (M−1) and η˜B are the concentration, specific volume, and RI of the
dissolved solute, respectively.
The Biacore’s signal, R(η), expressed in resonance units (RU), is a function of the
measured RI in the flow cell, η; if η does not vary greatly (i.e., if the shift ∆η is not very
large), then the corresponding change in the Biacore signal, ∆R, will be proportional to
the change in η, that is, ∆R = m∆η (Jung et al., 1998). It is also known that η is not
probed uniformly over the depth of the flow cell height, but proportionally to the intensity
of light at each point. Thus, the effective RI measured by the Biacore system, ηeff , is the
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average of η over the depth of the evanescent electromagnetic field (Jung et al., 1998):
ηeff =
1
dp
∫ ∞
0
η(z)e−z/dp dz, (4.3)
where dp is the effective penetration depth; for the case of the Biacore 2000 machine,
dp ≈ 150 nm.
Let us first consider the case of a uniform adsorbent film of thickness ds, attached to the
metal sensor surface, under conditions where there is no adsorption from the fluid solution
flowing over its surface (this is the case, e.g., when the salt concentration is large enough
to suppress solute binding). The RI of this adsorbent film, ηs, is constant unless there are
external perturbations, such as a temperature change in the flow cell, which is not the case
in the present work. Assuming that ηs is constant, Eq. 4.3 can be rewritten as follows:
ηeff =
ηs
dp
∫ ds
0
e−z/dp dz +
1
dp
∫ ∞
ds
η(z)e−z/dp dz
= ηs(1− e−ds/dp) + 1
dp
∫ ∞
ds
η(z)e−z/dp dz
= ηs(1− φs) + η′eff , (4.4)
where φs = exp(−ds/dp). In the absence of adsorption, η(z) = η for z > ds, where η is the
bulk solution’s RI, and η′eff = ηφs. Therefore, under non-adsorbing conditions, ηeff is given
by
ηeff = ηs + φs(η − ηs). (4.5)
When the salt solution has no dissolved solute (c0 > 0, cB = 0), the effective RI, η0,eff , is
given by Eq. 4.5 with η replaced by η0 defined by Eq. 4.1; the result is
η0,eff = ηs + φs[(η˜0 − η˜w)ν0c0 + η˜w − ηs]. (4.6)
If the baseline (or reference) signal is established for a salt solution with concentration
c0,ref , then the change in the effective RI when the salt concentration is altered to c0 is
(η0 − η0,ref)eff = φs(η˜0 − η˜w)ν0(c0 − c0,ref). (4.7)
The corresponding signal shift in the Biacore system is
∆R = m(η0 − η0,ref)eff = m0(c0 − c0,ref), (4.8)
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where m0 = mφs(η˜0 − η˜w)ν0 is the slope of the linear fitting (with intercept set to zero) of
∆R against (c0 − c0,ref).
When solute is added to the reference salt solution (c0 = c0,ref , cB > 0) and flown over
the sensing surface under non-adsorbing conditions, the effective RI is given by
(ηB,ref)eff = ηs + φs(ηB,ref − ηs), (4.9)
where ηB,ref is defined by Eq. 4.2 with η0 = η0,ref . The corresponding change in the RI is
obtained as follows:
(ηB,ref − η0,ref)eff = φs(η˜B − η0,ref)vBcB
= φs[(η˜B − η˜w)− (η˜0 − η˜w)ν0c0,ref ]vBcB (4.10)
and the shift of the Biacore signal is given by
∆R = m(ηB,ref − η0,ref)eff = (mB −m0vBc0,ref)cB (4.11)
where mB = mφs(η˜B − η˜w)vB. Note that mB −m0vBc0,ref is the slope of a linear fitting
(with intercept set to zero) of ∆R vs. cB. Once m0 and mB are known, we can predict
the shift in the Biacore signal due to the change in the effective RI, (ηB − η0,ref)eff , of
an aqueous buffer with salt concentration c0 and solute concentration cB (assuming that
the baseline was defined for the buffer salt solution with concentration c0,ref) using the
expression
∆R = (mB −m0c0vB)cB +m0(c0 − c0,ref). (4.12)
The more complex case where there is solute adsorption onto the adsorbent sensor
surface film is depicted in Fig. 4.1. The aqueous buffer solution in the bulk has salt
concentration c0 and protein concentration cB; the thickness of the adsorbed layer is dm
and its inter-solute volume is filled with buffer solution assumed to contain the same salt
concentration as that of the bulk. In Fig. 4.1, dm is assumed to be equal to the diameter
of the adsorbed solute molecules, in accordance with the formulation of a single adsorbed
monolayer, though this is not a restriction imposed in our formulation. The effective RI
probed by the Biacore machine, ηm,eff , is
ηm,eff =
ηs
dp
∫ ds
0
e−z/dp dz +
ηm
dp
∫ ds+dm
ds
e−z/dp dz +
ηB
dp
∫ ∞
ds+dm
e−z/dp dz, (4.13)
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Figure 4.1: Schematic of solute monolayer adsorbed onto the film of thickness ds in the Biacore
sensor chip flow cell. The bulk aqueous concentration has salt concentration c0 and solute concen-
tration cB; the isolated (dry) solute’s RI is η˜B; aqueous solution is assumed to fill the gaps between
adsorbed solute molecules, with salt concentration c0 and RI η0; the thickness of the adsorbed
monolayer, dm, is roughly equal to the diameter of the adsorbed solute.
yielding
ηm,eff = ηs + φs(ηm − ηs) + φsφm(ηB − ηm), (4.14)
where φm = exp(−dm/dp). Here, ηm and ηB are the RI’s of the adsorbed monolayer and
of the bulk aqueous solution (c0, cB), respectively.
Considering the adsorption model shown in Fig. 4.1, and assuming that the solute,
when adsorbed, does not change neither its RI nor its specific (or molar) volume, then the
adsorbed monolayer’s RI is
ηm = η0 + (η˜B − η0)vBcm, (4.15)
where cm (M) is the solute concentration in the volume occupied by the adsorbed mono-
layer; cm can be converted into a surface concentration, q (g/dm2), through the simple
formula q = dmcm. If the baseline’s RI is (η0,ref)eff (obtained with a salt solution of con-
centration c0,ref), then the change in the effective RI probed by the Biacore machine will
be
(ηm − η0,ref)eff = φs(ηm − η0,ref) + φsφm(ηB − ηm). (4.16)
Expanding the two right-hand side differences yields
(ηm − η0,ref)eff = φs(η˜B − η0)vB[cm + φm(cB − cm)] + φs(η0 − η0,ref). (4.17)
The corresponding shift in the Biacore signal is
∆R = (mB −m0c0vB)[cm + φm(cB − cm)] +m0(c0 − c0,ref). (4.18)
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Solving for cm gives
cm =
∆R−m0(c0 − c0,ref)
(1− φm)(mB −m0c0vB) −
φm
1− φm cB. (4.19)
Equations 4.18 and 4.19 are the most general ones since they encompass all the cases
discussed above. For example, setting φm = 1 (i.e., dm = 0) eliminates the adsorbed
monolayer; setting cm = cB sets the solute concentration in the adsorbed monolayer equal
to that in the bulk solution and the two phases become optically indistinguishable. In both
cases, Eq. 4.18 correctly reduces to Eq. 4.12.
Equation 4.11 shows that mB can be determined from the slope b of the linear fitting
(with intercept equal to zero) of ∆R against cB, as mB = b+m0vBc0,ref . These calibration
experiments, however, must be carried out under conditions where the solute does not
adsorb; this may be difficult to achieve in practice. When the buffer conditions are such
that a large fraction of the surface is shielded against adsorption, the adsorbed phase will
quickly reach saturation conditions, that is, cm will attain a constant value for moderate
values of cB. Equation 4.18 shows that, in this case, a plot of ∆R against cB still exhibits a
linear relationship for sufficiently large values of cB (i.e., those values of cB for which cm ≈
const.), but with slope equal to φm(mB−m0vBc0,ref) and intercept equal to (1−φm)(mB−
m0vBc0,ref)cm. Under these conditions, an estimate of φm, and of the resulting dm, can
be obtained by noticing that the slope of (η0 − η0,ref)eff against (c0 − c0,ref) yields φs(η˜0 −
η˜w)ν0 = m0/m (cf. Eqs. 4.7 and 4.8) and that the slope of (ηB − η0,ref)eff against cB gives
φs(η˜B − η0,ref)vB = [φm(mB −m0vBc0,ref)]/m (cf. Eqs. 4.10 and 4.11); such measurements
can be performed with a refractometer.
4.4 Adsorption/desorption rate model
In this section we formulate a general adsorption/desorption rate model capable of quanti-
tatively explaining the SPR sensorgrams for the interaction of BSA with the DEAE-SAM
surface under continuous cycling of the solute concentration. As described in §4.2.2, each
SPR experiment consisted of a series of adsorption/desorption cycles, where during the
adsorption step the sensor chip was contacted with buffer solution with given salt and
protein concentrations; after binding, buffer alone was introduced to monitor the desorp-
tion kinetics. This sequence was repeated over three or four cycles. We observed partial
irreversible binding of the protein onto the DEAE-SAM surface (or subject to a very slow
dissociation kinetics which was imperceptible for the duration of the desorption step) and
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Figure 4.2: Kinetic model for reversible/irreversible protein adsorption.
a slight increase of the binding plateau from cycle to cycle, but tending to a constant,
asymptotical value.
Based on these observations, it is assumed that only part of the protein is reversibly
adsorbed, whereas the other part binds irreversibly to the stationary phase. Moreover,
we consider that the irreversible adsorption process is the result of two binding mech-
anisms operating in parallel: one in which irreversible adsorption takes place from the
reversibly adsorbed phase, and another in which irreversible adsorption takes place di-
rectly from the liquid phase. Two possible types of irreversible binding mechanisms are
considered: in mechanism A, irreversible adsorption from the reversibly adsorbed phase is
an autonomous process that is independent of the protein concentration in the liquid phase;
in mechanism B, irreversible adsorption from the reversibly adsorbed phase depends on the
frequency of collisions or interactions between the proteins in the reversibly adsorbed phase
and those contacting liquid solution. The two mechanisms are illustrated in Fig. 4.2.
Let q1 be the concentration of irreversibly bound protein and q2 the protein concentra-
tion in the reversibly adsorbed phase. For mechanism A, the irreversible binding kinetics
can be written as
dq1
dt
= krcB(q˜
∞
1 − q1) + k′rq2, (4.20)
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where kr is the rate constant for irreversible adsorption from the bulk, k′r is the rate constant
for irreversible binding from the reversibly adsorbed phase and q˜∞1 is the apparent capacity
of the stationary phase for irreversible binding; this capacity is apparent because some of
the sites for irreversible binding may be shielded by the presence of reversibly adsorbed
proteins. Hence,
q˜∞1 = q
∞
1 − σ12q2, (4.21)
where σ12 is a steric factor: it gives the number of irreversible binding sites shielded by the
reversibly adsorbed proteins. For mechanism B, the corresponding equation is
dq1
dt
= krcB(q˜
∞
1 − q1) + k′rcBq2. (4.22)
The difference between mechanisms A and B is that for the former the rate of irreversible
adsorption from the reversibly adsorbed phase is proportional to q2 whereas for the latter
it is proportional to cBq2 (cf. Fig. 4.2).
Assuming a Langmuirian kinetic model for reversible adsorption, we can write for mech-
anism A
dq2
dt
= kacB(q˜
∞
2 − q2)− (kd + k′r)q2, (4.23)
where ka and kd are the forward and reverse rate constants for reversible adsorption,
respectively, and q˜∞2 is the apparent capacity of the stationary phase for reversible binding.
Again, the adsorption capacity is apparent because some of the sites for reversible binding
may be shielded by the presence of irreversibly adsorbed proteins:
q˜∞2 = q
∞
2 − σ21q1. (4.24)
For mechanism B the kinetic model is
dq2
dt
= kacB(q˜
∞
2 − q2)− kdq2 − k′rcBq2
= kacB(q˜
∞
2 − q2)− (kd + k′rcB)q2. (4.25)
At equilibrium (which we denote by an overbar):
(
dq1
dt
)
=
(
dq2
dt
)
= 0, (4.26)
which allows us to determine closed-form expressions for the adsorption isotherms, q1(cB)
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and q2(cB).
One way to discriminate between the two types of irreversible binding mechanisms is to
compare the dependencies between q1 and q2 given by Eqs. 4.20 and 4.22. For mechanism A,
we get
q1 = q
∞
1 +
(
k′r
kr
− σ12cB
)
q2
cB
, (4.27)
whereas for mechanism B the expression is
q1 = q
∞
1 +
(
k′r
kr
− σ12
)
q2. (4.28)
Clearly, for mechanism B, q1 varies linearly with q2 with an ordinate and a slope that are
independent of cB.
Let us assume temporarily that the shielding effect can be neglected. In this case,
Eqs. 4.27 and 4.28 simplify to
q1 = q
∞
1 +
(
k′r
kr
)
q2
cB
(mechanism A) (4.29)
q1 = q
∞
1 +
(
k′r
kr
)
q2 (mechanism B). (4.30)
Thus for mechanism A, q1 varies linearly with q2/cB, whereas for mechanism B, q1 varies
linearly with q2; in both cases the ordinate and slope are positive.
The saturation capacities, q∞1 and q∞2 , and hence the total saturation capacity q∞ =
q∞1 +q∞2 , are expected to be modulated by the salt concentration, as is the case for a typical
ion-exchange matrix. The higher the counterion concentration, the lower the binding of
a given solute assuming that no other effects are impacting the overall adsorption process
onto the SPR sensor chip. Thus, an empirical correlation of the form
q∞ = q∞0 e
kc0 or q∞ = q∞0 c
k
0 (4.31)
is adopted here; in Eq. 4.31, q∞0 is the maximum attainable adsorption capacity at residual
ionic strength and k < −1 is an empirical constant. The second expression for q∞ in
Eq. 4.31 is similar to the mathematical formulation used in the steric mass action formalism
for the interpretation of adsorption by ion exchange (Brooks and Cramer, 1992).
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Figure 4.3: (a) Experimental SPR signal shift, ∆R, as a function of salt concentration, c0−c0,ref
(c0,ref = 1.5 M NaCl); (b) experimental SPR signal shift, ∆R, as a function of bulk protein
concentration, cB, under low binding conditions (c0 = c0,ref = 1.5 M NaCl).
4.5 Results and discussion
4.5.1 Calibration of Biacore signal
The Biacore signal was calibrated using various solutions with different salt (c0) and BSA
(cB) concentrations and a baseline defined for a buffer solution with salt concentration
c0,ref = 1.5 M NaCl. First, salt solutions with different c0 values were injected into the
Biacore cell and the corresponding signal shifts measured (Fig. 4.3a). The linear fitting
(with intercept set to zero) of ∆R against (c0 − c0,ref) yielded m0 = mφs(η˜0 − η˜w)ν0 =
9898.1 RU/M with an excellent regression coefficient (r2 = 0.9998); this linearity is in
complete agreement with Eq. 4.8. This calibration accounts for the salt concentration
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Table 4.1: BSA physical properties (Bosma and Wesselingh, 1998).
Molecular Weight 66.7 kDa
Dimensions 4 nm× 4 nm× 14 nm
Radius based on sphere 2.69 nm
Density 1360 g/L
Isoelectric point 4.9
effect without the presence of solute in suspension.
To account for the effect of BSA in solution (c0, cB > 0) a set of BSA concentrations
in buffer with salt concentration c0 = c0,ref = 1.5 M NaCl was used (Fig. 4.3b). This salt
concentration was high enough to reduce BSA adsorption to a residual level, so that the
Biacore signal shifts yielded a straight line when plotted against cB in accordance with
Eq. 4.18 when cm has a constant value. The linear fitting of ∆R vs cB yielded a slope
φm(mB − m0vBc0,ref) = 164.43 RU/(g/L), again with a very good regression coefficient:
r2 = 0.9986 (Fig. 4.3b).
The main physical properties of BSA are listed in Table 4.1 (Bosma and Wesselingh,
1998); from the data, vB = 7.553 × 10−4 L/g, hence m0vBc0,ref = 10.92 RU/(g/L) and
mB = 164.43/φm + 10.92 = 179.79 RU/(g/L). Equation 4.19 can now be applied for
converting the SPR signal (∆R) into concentration values of adsorbed protein, cm (g/L)
and q (g/dm2) = 10−8dmcm, with dm in nm.
In solution, BSA is a prolate ellipse (cigar-shaped) with an axial ratio of about four; if
the assumed BSA radius is calculated from its molecular weight and mass density, then the
thickness of the planar monolayer will be dm = 2×26.9 Å = 53.8 Å (Bosma andWesselingh,
1998). According to our model, dm can be determined from the obtained values of m0 and
mB and RI measurements as follows: plotting (η0 − η0,ref)eff against (c0 − c0,ref) yields the
slope
φs(η˜0 − η˜w)ν0 = m0/m (4.32)
and plotting (ηB − η0,ref)eff against cB yields the slope
φs(η˜B − η0,ref)vB = [φm(mB −m0vBc0,ref)] /m. (4.33)
From these linear plots the calculated value dm is dm,η−based ≈ 5.6 nm, which is closely
comparable to the reference value of 5.38 nm. This supports the applicability of Eqs. 4.18
and 4.19 derived from our theory for SPR data analysis.
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Figure 4.4: Schematic of the nth adsorption/desorption cycle for a Biacore experiment.
4.5.2 Analysis of BSA sensorgrams
The SPR experiments were performed at Biacore’s maximum flow rate (100 µL/min) to
avoid mass transfer limitations. These were, in fact, negligible when compared to the
sorption rates at the tested conditions; a two-compartment, mass transport model coupled
to our kinetic model showed no detectable impact on the apparent adsorption/desorption
rates (see section 4.7).
Figure 4.4 shows the schematic of an adsorption/desorption cycle (say the nth one) for a
Biacore experiment. The durations of the adsorption and desorption steps are τ (n)a and τ (n)d ,
respectively. At the end of the adsorption step the SPR signal is ∆R(n)a and corresponds
to
{
cB, q
(n)
1 , q
(n)
2
}
, i.e., {bulk protein} + {irreversibly adsorbed protein} + {reversibly
adsorbed protein}. When the desorption step begins, the bulk protein is immediately
removed due to the high flow rate used (100 µL/min) compared to the flow chamber
volume (approximately 60 nL) and the conditions in the flow cell change to
{
0, q(n)1 , q
(n)
2
}
;
the SPR signal then decays until it stabilizes at a value∆R(n)d corresponding to
{
0, q(n)1 , 0
}
,
i.e., when only irreversibly adsorbed protein remains in the sensor chamber.
If the step durations, τ (n)a and τ (n)d , are long enough, then the SPR signals, ∆R
(n)
a and
∆R
(n)
d , at the end of the respective steps correspond to steady state conditions in the sensor
chamber (which are denoted by an overbar in our rate model); these are characterized by
an horizontal plateau in the sensorgrams (i.e., the SPR signal becomes constant). This was
found to be the case for most of the runs, particularly for the desorption steps. For those
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cases where the SPR signal had not yet attained a constant value at the end of the step,
the signal was extrapolated to infinite time by fitting the asymptotic part of the signal to
a first-order dynamics,
∆R(t) = α− β exp(−t/τ), (4.34)
where α, β and τ > 0 are fitting parameters; the asymptotic value of ∆R(t) for large values
of time was estimated as the value of the fitted parameter α. Using Eq. 4.18, the value of
∆R
(n)
a was converted into the value of q
(n)
1 + q
(n)
2 and that of ∆R
(n)
d into the value of q
(n)
1 .
From the analysis of the adsorption/desorption plateaus it is possible to make a first
assessment of the adequacy of the two rate models — mechanisms A and B developed in
§4.4 — incorporating different mechanisms for irreversible binding. According to mecha-
nism A, q(n)1 should vary linearly with q
(n)
2 /cB with positive ordinate and slope, whereas for
mechanism B, q(n)1 should change linearly with q
(n)
2 with positive ordinate and slope. As
shown in Fig. 4.5, the experimental results reject mechanism A and support mechanism B.
Therefore, the most suitable kinetic model (mechanism B) can be stated as
dq1
dt
= krcB(q
∞
1 − σ12q2 − q1) + k′rcBq2, (4.35)
dq2
dt
= kacB(q
∞
2 − σ21q1 − q2)− (kd + k′rcB)q2. (4.36)
For this type of kinetic model, the reversible adsorption isotherm (i.e., the equilibrium
dependency of q2 with cB) is
q2 =
(q∞2 − σ21q∞1 )kacB
kd + [k′r + ka + σ21(k′r/kr − σ12)ka]cB
, (4.37)
which is a Langmuir-type isotherm, i.e.,
q2 =
γb2cB
1 + b2cB
, (4.38)
where
b2 =
k′r + ka[1 + σ21(k′r/kr − σ12)]
kd
, γb2 =
ka(q∞2 − σ21q∞1 )
kd
. (4.39)
Figure 4.6 shows plots of 1/q1 and 1/q2 against 1/cB. From the plot of the inverse
of q2 against the inverse of cB it is evident that Eq. 4.37 does apply for the reversible
adsorption isotherm, q2(cB), and that the irreversible component, q1(cB), is the sum of
a Langmuir isotherm model and a constant — derived in our model as q∞1 — in accor-
dance with Eqs. 4.30 and 4.37 (cf. Fig. 4.6). Note that the linear regression coefficients in
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Figure 4.5: Evaluation of the suitability of mechanisms A and B for the description of the
dynamics of the SPR adsorption/desorption cycles: (a) q1 vs q2/cB plot (mechanism A); linear
regression coefficient, r2, is 0.964, 0.975, and 0.983 for c0 = 0.025 M, c0 = 0.30 M, and c0 = 1.5 M,
respectively; note that all slopes are negative in disagreement with Eq. 4.29; (b) q1 vs q2 plot
(mechanism B); r2 is 0.951, 0.995, and 0.999 for c0 = 0.025 M, c0 = 0.30 M, and c0 = 1.5 M,
respectively; note that all slopes are positive in agreement with Eq. 4.30.
Fig. 4.6b are very acceptable, confirming the Langmuir-type adsorption behavior implied
by Eq. 4.38. The inverse plot for q1 shows also a very reasonable correlation; this can be
explained by Eq. 4.28, which expresses the irreversible adsorption component as an irre-
versible adsorption capacity (q∞1 ) plus a Langmuir-type isotherm (q2) scaled by a constant
(k′r/kr − σ12).
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Figure 4.6: Inverse plots of adsorption against bulk concentration: (a) 1/q1 vs 1/cB; linear
regression coefficient, r2, is 0.999, 0.984, and 0.975 for c0 = 0.025 M, c0 = 0.30 M, and c0 = 1.5 M,
respectively; (b) 1/q2 vs 1/cB; r
2 is 0.998, 0.998, and 0.986 for c0 = 0.025 M, c0 = 0.30 M, and
c0 = 1.5 M, respectively.
As shown in both inverse plots of Fig. 4.6, the slope and intercept are functions of the
salt concentration showing evidence of an ion exchange-type mechanism modulated by the
concentration of the salt counterion, Cl−. Although it is not apparent from the inverse
plots, the adsorption equilibrium data extracted from the various SPR sensorgrams span
protein concentrations from dilute conditions, where Henry’s law prevails, up to overloaded
conditions, where the adsorbed monolayer is near completed.
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Let us now analyze the adsorption and desorption rates. During the desorption step,
cB = 0; the equations governing the dynamics for this step (under the assumption of
negligible mass transfer resistance between the bulk and the sensor surface) are:
dq(n)1
dt
= 0, (4.40)
dq(n)2
dt
= −kdq(n)2 . (4.41)
The solution is simply
q(n)1 = q
(n)
1 , q
(n)
2 = q
(n)
2 exp
(
−kdt(n)d
)
. (4.42)
Therefore,
ln q(n)2 = ln q
(n)
2 − kdt(n)d , (4.43)
which shows that the rate constant kd can be estimated from a ln q
(n)
2 -vs-t
(n)
d regression
plot.
From Eq. 4.18 it easy to deduce that
∆R(n)d =
(mB −m0c0vB)(1− φm)
[
q(n)1 + q
(n)
2
]
dm
+m0(c0 − c0,ref). (4.44)
The irreversible component, q(n)1 = q
(n)
1 , is constant during the desorption step, but the
reversible component, q(n)2 , decreases from q
(n)
2 to 0 as t
(n)
d advances from 0 towards large
time (∞). Let ∆R(n)d = limt(n)d →∞∆R
(n)
d ; then
∆R(n)d −∆R
(n)
d = (mB −m0c0vB)(1 − φm)q(n)2 /dm (4.45)
and
ln
[
∆R(n)d −∆R
(n)
d
]
= ln[(mB −m0c0vB)(1− φm)/dm] + ln q(n)2 . (4.46)
Therefore, ln
[
∆R(n)d −∆R
(n)
d
]
and ln q(n)2 both change with time at the same rate; in both
cases the slope of the linear change with t is kd.
Let us assume the case when shielding is negligible, i.e. when σ12 and σ21 both tend
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Table 4.2: Model parameters estimated from three Biacore training experiments with BSA injec-
tions at cB = 2.5 g/L and different salt concentrations, c0.
c0 kd kr k′r ka 106q∞1 106q∞2 σ12 σ21
(M) (s−1) (dm3g−1s−1) (dm3g−1s−1) (dm3g−1s−1) (g dm−2) (g dm−2)
0.025 0.051 0.017 0.0192 0.034 2.79 5.29 ≈ 0 0.023
0.300 0.056 0.017 0.0221 0.020 0.20 4.45 ≈ 0 0.025
1.500 0.128 0.016 0.0031 0.085 0.17 1.13 ≈ 0 0.025
to 0. In this case, Eqs. 4.35 and 4.36 simplify to
dq1
dt
= krcB(q
∞
1 − q1) + k′rcBq2, (4.47)
dq2
dt
= q∞2 kacB − [kd + (ka + k′r)cB]q2. (4.48)
From Eq. 4.30 it is possible to determine q∞1 and k′r/kr. Rearranging Eq. 4.37 gives
1
q2
=
ka + k′r
q∞2 ka
+
kd
q∞2 ka
1
cB
= α+ β
1
cB
. (4.49)
From the linear fitting of q2 vs cB we get q∞2 ka = kd/β and ka + k′r = kdα/β. With this
analysis, values of kd, q∞2 ka and ka + k′r can be estimated; these are the required lumped
parameters to solve Eq. 4.48. As to Eq. 4.47, the values of q∞1 and the ratio k′r/kr are
already known; by curve fitting, kr and k′r parameters can be estimated and all remaining
unknown parameters can easily be calculated.
Once all parameters were estimated using the procedure described above, their values
were refined by taking protein shielding into account. In this case the shielding factors,
σ12 and σ21, were determined by nonlinear curve-fitting using the complete kinetic model.
These fittings were performed using gPROMS, a software package for the modeling and
simulation of lumped and distributed-parameter process models with combined discrete
and continuous characteristics (PSE, 2009). The fittings were applied to sets of sensor-
grams obtained at different salt concentrations. Table 4.2 summarizes the model parame-
ters obtained using the procedure explained above: starting from an estimate of kd using
Eq. 4.46, the simplified model (Eqs. 4.48 and 4.47) was used to determine kr; all parameters
were then introduced in the complete model formulation (Eqs. 4.35 and 4.36) to refine the
parameters and to estimate values for σ12 and σ21.
Figure 4.7 shows the comparison between simulations and experimental data at different
salt concentrations. The results indicate a fairly good agreement between the experimen-
tal curves and our adsorption/desorption rate model with the the estimated parameters
(Table 4.2). The proposed assumption that two distinct adsorption mechanisms occur si-
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Figure 4.7: Model training using three SPR experiments with BSA at cB = 2.5 g/L and different
salt concentrations, c0 = 0.025, 0.30, and 1.5 M: (a) q = q1 + q2 vs t; (b) ∆R vs t. The thick
and thin lines correspond, respectively, to the model predictions and experimental data; increasing
dark tone in gray lines corresponds to decreasing salt concentrations; q is estimated from the
experimental data using Eq. 4.19 and dm = 5.6 nm.
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multaneously, one being reversible and similar to an exchange reaction between the free
protein and a certain number of bound ions, and another, with an extremely low desorption
rate, formally defined as an irreversible mechanism, seems to suit well the experimental
data.
Table 4.2 shows that the total BSA binding capacity of the derivatized surface, q∞1 +q∞2 ,
is ca. 0.81 mg/m2 at 25 mM salt concentration; this value is less than the 5 mg/m2 typically
found for a protein monolayer. It is important to note, however, that the binding capacity
is strongly dependent on the ligand density of the derivatized surface, and our guess is that
the ligand density was low in our MUA-DEAE surfaces. This guess is supported, in part,
by the low values of the binding constants, e.g., b2 = 1.04 L/g at 25 mM NaCl, derived from
the Langmuir adsorption isotherm model (cf. Eqs. 4.38 and 4.39). Another indication of
low ligand density are the small values of the shielding factors, σ12 and σ21, obtained from
the fitting of the kinetic model; small values of σ indicate that the bound BSA molecules
are spread over the derivatized surface with a mean distance between neighboring molecules
large enough for the shielding to have only a mild effect.
Figures 4.5b, 4.6, and 4.7, as well as Table 4.2, show that both the reversible and
irreversible adsorption mechanisms are sensitive functions of the salt concentration. A
speculation for this effect on the irreversible adsorption component is that the degree of
solvation of both the protein and the DEAE ligand sites, which is directly a function
of salt concentration, inhibits the irreversible adsorption mechanism as it does for the
reversible part. Indeed, when the ionic strength or, more precisely, the salt concentration,
are increased, both the reversible and irreversible equilibrium adsorption amounts decrease
exponentially with the salt concentration, c0. Thus, similar trends are observed for the
dependencies of q∞1 and q∞2 with c0: the larger the salt counterion concentration, the
smaller the amount of adsorbed protein, in line with a typical ion-exchange surface using
commercial matrices.
These observations emphasize that the micrometric-scale DEAE surface mimics well an
ion-exchange surface in terms of intrinsic adsorption capacities to different materials, even
though other effects, such as the three-dimensionality of a chromatography matrix or mass
transfer resistances, are not considered. Nevertheless, it is clear that by changing the ligand
type and/or its density, which can be accomplished using different SAM compositions, our
SPR-based method is well suited to small-scale studies of protein adsorption. In fact, a
scale-down factor of over 1200-fold is accomplished using this strategy when compared to
a commercially available Sartobind D MA 15 unit from Sartorius-Stedim Biotech (with
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Figure 4.8: Model validation with cyclic SPR experiments of BSA binding and elution over
micrometric DEAE surface at different injected BSA concentrations, cB = 0.625, 1.25, 2.5, 5, and
10 g/L; (a) c0 = 0.025 M, (b) c0 = 0.30 M, (c) c0 = 1.5 M. The thick and thin lines correspond,
respectively, to the model predictions and experimental data; increasing dark tone in gray lines
corresponds to increasing protein concentration, cB.
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15 cm2 total effective area).
In order to further validate the proposed model, SPR runs with different injected BSA
concentrations were compared against predicted simulation curves; the results are shown
in Fig. 4.8. This data set was used to test the extrapolation capability of the kinetic
model with the parameter values estimated above. Note that the model parameters were
estimated from SPR experiments at fixed cB and varying c0. The results depicted in Fig.
4.8 show that the changes in injected protein concentration are rather well predicted by the
model simulations; additionally, changes in c0 result in lower adsorption and faster kinetics
confirming the expected low or residual adsorption.
4.6 Conclusions
Adsorption equilibrium and kinetics on a derivatized surface, containing an ion-exchange
functional DEAE group, have been measured and analyzed by SPR spectroscopy. BSA
was used as a model protein for system development, implementation and testing. A
complete mathematical description of the SPR sensor mechanism was derived giving rise to
simple algebraic expressions relating the protein concentration in the adsorbed monolayer
with SPR signal shift and protein and salt concentration in the bulk solution. Using
the calibrations performed for salt and free protein in solution, the concentration of the
adsorbed protein monolayer could be directly obtained from the SPR sensorgram data at
different conditions of load and salt concentration.
An adsorption/desorption rate model, incorporating two different adsorption mecha-
nisms, was proposed as a means to explain the SPR sensorgrams. The model is based
on the assumption that only part of the protein adsorbs reversibly, according to a Lang-
muirian kinetic model, whereas the other part binds irreversibly to the DEAE surface; the
kinetics of the latter is proportional to the protein concentrations in the bulk and in the re-
versibly adsorbed phase. The dependency between the estimated reversible and irreversible
adsorbed concentrations in the stationary phase (herein mimicked by the customized chip
surface) allowed us to discriminate between two possible adsorption mechanisms; this anal-
ysis suggests the presence of an adsorption scheme compatible with a first-order kinetics
controlled by the reversibly adsorbed solute and its concentration in the mobile phase.
From the SPR experiments it was possible to determine the adsorption isotherms for dif-
ferent salt conditions and to estimate the parameters of the developed rate model. The
results provided evidence that the DEAE-SAM derivatized surface is a good mimic of an
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ion-exchange surface, as far as intrinsic ion exchange-related interactions are concerned,
without considering transport or exclusion phenomena only present in a chromatographic
matrix.
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4.7 Appendix: Influence of mass transport on measured
binding rate constants
Figure 4.9 shows a schematic of the Biacore’s flow chamber. We assume that laminar flow
is fully developed over the entire length l of the flow cell and neglect any variations along
the z coordinate. Under these assumptions, the velocity field (u, v), which is the solution
for fully developed laminar flow between two parallel flat plates, is
u = 6 u
(y
h
)(
1− y
h
)
, v = 0, (4.50)
where u and v are the velocity components along the x and y coordinates, respectively, and
u is the average velocity; u is related to the volumetric flow rate Q through u = Q/(hw)
(see Fig. 4.9 for the meaning of w and h). Given that h' dp, we can linearize the velocity
field near y = 0; this gives
u(y) ≈ 6u
h
y for y ≈ 0. (4.51)
At a flow rate of 100 µL/min = 100 mm3/min, the average axial velocity of an analyte
molecule in the flow cell is u = 66.7 mm/s; However, the average axial velocity of the
analyte molecules within the fluid film delimited in the depth y ≤ dp of the evanescent
electomagnetic field is reduced to u′ = 0.6 mm/s. Nevertheless, the characteristic residence
time of these molecules in the volume of fluid probed the Biacore sensor is only lc/u′ =
1.6/0.6 = 2.8 seconds (cf. Fig. 4.9).
The effect of mass transfer on the analysis of the SPR signal is usually described by a
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Figure 4.9: Schematic of Biacore’s flow cell.
two-compartment model (Myszka et al., 1998):
dp
dcB
dt
+
(
dq1
dt
+
dq2
dt
)
= km(c
o
B − cB), (4.52)
where km is the transport coefficient describing the diffusional flux of solute from the bulk
of the flow chamber, where its concentration is coB, into the inner compartment, where
its concentration is cB. As a matter of convenience, the inner compartment can be taken
as the layer of fluid delimited in the depth of the evanescent electromagnetic field, whose
volume is lcwcdp (cf. Fig. 4.9).
As discussed by Lok et al. (Lok et al., 1983) and Sjölander and Urbaniczky (Sjölander
and Urbaniczky, 1991), it can be shown that, to a good approximation,
km ≈ 1.282
(
u′D2
dplc
)1/3
, (4.53)
where D is the molecular diffusion coefficient.
Transport effects will not influence the adsorption kinetics if km ' krq∞1 and km '
kaq∞2 ; similarly, the desorption kinetics will not be influenced by mass transfer if kmcoB '
kdq∞2 . For our SPR experiments with BSA, D = 9 × 10−7cm2/s and km = 0.0035 cm/s.
From the data listed in Table 4.2, it is clear that mass transport effects can be safely
neglected in the analysis of the SPR experiments carried out during this work.
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Chapter 5
ANALYSIS OF ADSORPTION OF A
BACULOVIRUS BIOREACTION BULK ON
AN ION-EXCHANGE SURFACE BY
SURFACE PLASMON RESONANCE
Adapted from:
Vicente T, Mota JPB, Peixoto C, Alves PM, Carrondo MJT. Analysis of adsorption of a
baculovirus bioreaction bulk on an ion-exchange surface by surface plasmon resonance. J
Biotechnol 2010; 148:171–181.
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Abstract
The binding and elution of the key components of a bioreaction bulk for production of
recombinant baculoviruses—a promising viral vector for gene therapy and vaccination—on
a model ion-exchange surface have been successfully measured and interpreted by surface
plasmon resonance (SPR) spectroscopy. The micro-scaled, ion-exchange surface was pro-
duced by immobilizing a typical ion-exchange ligand, diethylaminoethyl, onto commercially
available planar gold sensor chip surfaces, which were pre-derivatized with a self-assembled
monolayer of 11-mercaptoundecanoic acid. Each isolated analyte was injected into the
SPR cell at defined operating conditions of salt and solute concentrations to determine
the adsorption equilibrium plateau, and then eluted at the same salt concentration, upon
which a well-defined, residual desorption equilibrium plateau was observed. From the anal-
ysis of the binding and elution curves and equilibrium plateaus for seven key biomolecules,
it is possible to determine the adsorption isotherms over a broad range of equilibrium
conditions for the three main cuts of the baculovirus bioreaction bulk: the product (the
infective baculovirus), the main product-related impurities, and the main process-related
impurities. A model that quantitatively explains the SPR-derived adsorption/desorption
data was successfully developed for this complex biological system.
127
CHAPTER 5. Analysis of adsorption of a baculovirus bioreaction bulk on an ion-exchange surface by surface
plasmon resonance
Contents
5.1 Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 128
5.2 Materials and methods . . . . . . . . . . . . . . . . . . . . . . . . . . 130
5.2.1 Cell culture and baculovirus production . . . . . . . . . . . . 130
5.2.2 Purification of baculoviruses and isolation of product-derived
impurities . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 131
5.2.3 Process derived-impurities . . . . . . . . . . . . . . . . . . . . 132
5.2.4 Sensor surface preparation . . . . . . . . . . . . . . . . . . . . 132
5.2.5 SPR experiments . . . . . . . . . . . . . . . . . . . . . . . . . 133
5.3 SPR data analysis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 134
5.4 Adsorption/desorption rate model . . . . . . . . . . . . . . . . . . . . 136
5.5 Results and discussion . . . . . . . . . . . . . . . . . . . . . . . . . . . 139
5.5.1 Calibration of Biacore signal . . . . . . . . . . . . . . . . . . . 139
5.5.2 Applicability of sorption model to a complex biological system 140
5.5.3 Prediction of total adsorption capacities . . . . . . . . . . . . 147
5.6 Conclusions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 150
5.7 Appendix: Analytical solution of the kinetic model and SPR response
in the absence of mass-transport limitations . . . . . . . . . . . . . . 151
References . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 154
5.1 Introduction
Ion-exchange processes are ubiquitously used in downstream processing of complex bio-
logics for clinical use. The optimization of charge-dependent unit operations relies on the
evaluation of pivotal operating conditions, such as ionic strength and pH of the suspen-
sion buffer. These procedures tend to become exceptionally costly when a high added-value
product is recovered from a complex preparation, such as an animal cell derived bioreaction
bulk. Hence, the optimization of such unit processes becomes mandatory in the interest of
cost and time savings. Scaled-down models, often used in high-throughput technologies,
are being considered as options of choice for early stage process development (Coffman
et al., 2008; Rege et al., 2006; Wensel et al., 2008).
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Recombinant baculoviruses (rBVs) constitute a challenging model system within the
collection of promising complex biopharmaceuticals for clinical therapies. Besides being
used as a robust expression system with insect cell lines (BEVS), the potential of these
viral vectors has evolved to human gene therapy or vaccination due to important (and
alternative) advantages over other more studied vectors such as adeno- or retroviruses
(Kost et al., 2005; Airenne et al., 2009). Since the mid-nineties (Hofmann et al., 1995), it
has been shown that these insect-specific viruses can be genetically modified to transduce
vertebrate cells, by means of a proper mammalian promoter, without replicating themselves
or causing cytotoxic effects. Due to this non-pathogenicity to mammalian cells, the ability
to accommodate very large foreign DNA inserts and the easiness of production at high
viral titers in insect cell cultures, this system presents significant potential and important
advantages over other vectors used in clinical trials (Hu, 2008; Airenne et al., 2009).
The typical insect cell clarified bioreaction bulk comprises a complex mixture of compo-
nents: the desired product—the recombinant baculoviruses, infective/bioactive particles—,
the product-related impurities, which decrease the quality of the product, and the process-
related impurities—DNA, host-cell protein, and/or eventual endotoxin. The understanding
of how these impurities behave in an ion-exchange process provides useful information for
designing and optimizing the chromatographic purification process.
Surface plasmon resonance (SPR) spectroscopy is an extremely sensitive analytical tech-
nique with many applications in fundamental surface science (Hoa et al., 2007; Pattnaik,
2005; Rich and Myszka, 2008). SPR biosensors allow label-free, real-time, quantitative and
qualitative characterization of the specific binding of a mobile analyte to a ligand immo-
bilized on a metal surface (Schuck, 1997). When working with highly expensive biological
materials, such as viral vectors produced in cell culture, SPR can play a supporting role
for the optimization of adsorption-based, downstream purification processes, including ion-
exchange chromatography, by providing quantitative information on the binding kinetics
and equilibria of the various biomolecules of the bioreaction bulk to an immobilized func-
tionalization layer mimicking the adsorbent. Because of the highly reduced sample volume
used in a typical SPR experiment, a critical amount of data on the adsorbed film for a
broad range of analyte loading and salt concentration can be obtained with a small amount
of material.
We have recently applied SPR sensing to the monitoring and quantitative analysis of
protein binding and elution over a micro-scaled, ion-exchange surface under cyclic adsorp-
tion conditions (Vicente et al., 2010). It is the purpose of the present study to employ SPR
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and its mathematical formalism for quantitative interpretation of ion-exchange equilibria
for a much more complex biological system: a recombinant baculovirus bioreaction bulk.
For convenience, we shall split the biological bulk into three cuts or fractions—the
product, the main product-related impurities, and the main process-related impurities—
and identify the key biomolecules governing the chromatographic behavior of each frac-
tion. We will then use SPR sensing to measure the adsorption equilibrium of each isolated
biomolecule over a broad range of solute and salt concentrations. Overall, we shall report
on seven different adsorbates. A kinetic model is proposed to explain the measured SPR
responses for the adsorbed films of the various biomolecules. Our results show that SPR
can be a handy predictive tool by providing fundamental data for the design of down-
stream chromatographic purification processes, and thus very useful in early-stage process
development of complex biopharmaceuticals.
5.2 Materials and methods
5.2.1 Cell culture and baculovirus production
Sf9 insect cells (ECACC #89070101, UK) were routinely grown in GibcoTM Sf-900 II SFM
(serum-free) culture medium (Invitrogen, Paisley, UK) using spinner (stirred at 150 rpm
in a magnetic stirrer) or Erlenmeyer vessels (shaken at 110 rpm in an orbital shaker). Cell
concentration and viability were routinely assessed by haemocytometer (Brand, Wertheim,
Germany) with cell viability evaluated by 0.4% trypan blue exclusion dye (Merck, Darm-
stadt, Germany) in phosphate-buffered saline.
The vector used, rBV-green fluorescent protein (GFP), encodes for the baculovirus ma-
jor structural capsid protein, vp39, containing on its N -terminal a GFP protein reporter
(Kukkonen et al., 2003). Stock aliquots of rBV-GFP were produced in Sf9 cells grown in a
25 liter working volume wavebag bioreactor (Wave Europe, Cork, Ireland) using Sf-900 II
medium. Sf9 cells were infected at a viable cell concentration of 1–2×106 cells/mL, using a
multiplicity of infection (MOI) of 0.1 plaque forming units (PFU)/cell. Cell viability and
cell infection were monitored for five days post infection. Quantification of the infected
cells during the process was done by flow cytometry assessing GFP-expressing cell popula-
tions using a CyFlowTM space-flow cytometer system (Partec, Münster, Germany). Data
analysis was done using the manufacturer’s data acquisition software, FloMaxTM (Partec).
The rBV production bulk was harvested when the cell viability reached values of 50%.
Infection bulks were clarified as described elsewhere (Vicente et al., 2009).
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5.2.2 Purification of baculoviruses and isolation of product-derived
impurities
Infective baculovirus particles, rBVi, which are the target product, were isolated by ultra-
centrifugation based on sucrose density gradients (Airenne et al., 2000), yielding standard
rBVi stocks. Briefly, primary clarification and concentration were accomplished by depth-
filtration and tangential flow filtration using conditions recently described (Vicente et al.,
2009). 3 µm retention Sartopure PP2 filter capsules, followed by 0.65 µm retention Sar-
topure PP2 filter capsules, were operated in series. Tangential flow filtration was run on
an ÄKTAcrossflow system controlled by the UNICORNTM software (all GE Healthcare,
Uppsala, Sweden) with a 200 cm2 HydrosartTM membrane with 100 kDa nominal molecu-
lar weight cut-off (MWCO) (Sartorius Stedim Biotech) at 35 mL/min retentate flow rate
and a transmembrane pressure of 1.2 bar; buffer exchange to D-PBS was accomplished by
continuous diafiltration as described elsewhere (Vicente et al., 2009).
rBVi concentrated stocks were transferred into ultracentrifuge tubes on top of two dis-
crete sucrose density layers: 8 mL of 50% (w/v) and 6 mL of 20% (w/v) sucrose in D-PBS
(bottom); the tubes were centrifuged at 100,000 g and 4◦C for 1 h. The virus bands were
pooled, resuspended into 35 mL of ice-cold D-PBS, transferred into ultracentrifuge tubes
containing 3 mL of 25% (w/v) sucrose in D-PBS, and centrifuged as above. The concen-
trated virus buffer was exchanged to D-PBS using a prepacked HiPrepTM 26/10 desalting
column coupled to an ÄKTAexplorer system (all GE Healthcare, Uppsala, Sweden).
Sterile microfiltration of final material was performed using AcrodiscTM Syringe Filters
with SuporTM PES membrane (Pall, New York, USA) before storage at 4◦C in the dark
(Vicente et al., 2009). Purified rBVi preparations were subjected to enzymatic digestion
using subtilisin (Sigma-Aldrich, Steinheim, Germany) to produce glycoprotein deficient
vectors, rBVgp64− , or lipid removal using TritonTM X-100 (Sigma) to produce envelope
deficient vectors, rBVenv− . Briefly, 0.5 mL of a concentrated subtilisin stock, prepared in
digestion buffer, was added to the purified particles resulting in a final subtilisin concen-
tration of 1 mg/mL. The incubation was done for 2 h at 37◦C, after which 5 µg/mL of
phenylmethanesulphonylfluoride (Sigma) was added to suppress the protease; the material
was stored at 4◦C in the dark until use. Lipid removal of the rBV particles was performed
by addition of a concentrated stock of 20% Triton X-100 to achieve a final concentration
of 0.5% (v/v), followed by incubation of the samples at 37◦C for 30 min. After both incu-
bations, buffer is exchanged to D-PBS using a prepacked HiTrapTM desalting column (GE
Healthcare) coupled to an ÄKTAexplorer system to remove subtilisin or Triton X-100 from
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the resulting baculovirus materials.
The number of genome containing particles was quantified by real-time PCR (qPCR)
following the protocol described elsewhere (Vicente et al., 2009). Infective virus titers (IP)
were determined with a flow cytometer-based assay (for rBVs-GFP) (Vicente et al., 2009;
Karkkainen et al., 2009). To assess the presence of cholesterol in viral samples, AmplexTM
Red cholesterol assay kit (Molecular Probes, Eugene OR, USA) was used and DNA was
measured using the Quant-iTTM PicoGreen DNA assay kit (Molecular Probes).
5.2.3 Process derived-impurities
In this work reference biologicals have been used to study their isolated behaviors in
the ion-exchange-based process. Host-cell dsDNA was obtained from an Sf9 insect cell
culture after DNA extraction using the High Pure PCR template Acid Kit (Roche Di-
agnostics, Mannheim, Germany). Lipopolysaccharide (LPS) is of analytical grade from
Sigma-Aldrich. Bovine serum albumin (BSA) is of analytical grade (> 98% electrophore-
sis purity) purchased from Merck KGaA (Darmstadt, Germany); the amount of covalent
dimer in the freshly prepared BSA solutions is estimated to be ca. 6%, from analytical
size-exclusion chromatography on a Superdex 200 column. All solutes were conditioned in
20 mM phosphate buffer at pH 6.8 with the specified NaCl supplementation.
5.2.4 Sensor surface preparation
Biacore gold sensor chip surfaces (Biacore/GE Healthcare, Uppsala, Sweden) were mod-
ified according to protocols described in the literature (Roper and Nakra, 2006; Vicente
et al., 2010). 11-mercaptoundecanoid acid (MUA) (NanoThinksTM ACID11 solution from
Sigma-Aldrich, München, Germany) and 2-diethylaminoethylamine (DEAEA) (99% pu-
rity grade from Sigma-Aldrich) were used as thiolate for self-assembled monolayer (SAM)
preparation and ligand coupling compound, respectively. The refractive index (RI) was
monitored throughout the MUA-SAM immobilization procedure with a Leica AR200 dig-
ital hand-held refractometer (Leica Microsystems, Wetzlar, Germany). Briefly, the gold
sensor chip surface was first equilibrated with ultra-pure, deionized water at 18.2 MΩ · cm.
The surface was sanitized with 0.1 M NaOH and 1% TritonTM X-100 (Sigma-Aldrich) and
then re-equilibrated in 10 mM 4-Morpholineethanesulfonic acid (MES) (Sigma) buffer at
pH 5.0. Ethanol was then used to washout the buffer and the surface was exposed di-
rectly to the NanoThinks ACID11 solution (5 mM MUA in ethanol) and left overnight
in a closed compartment inside a laminar flow bench. The freshly formed SAM of MUA
132
DOWNSTREAM PROCESSING DEVELOPMENT OF ENVELOPED VIRUSES FOR CLINICAL APPLICATIONS
was rinsed with ethanol and re-equilibrated with the 10 mM MES buffer previously used
until the refractive index stabilized. The sensor chip was then docked in the SPR sys-
tem, a BiacoreTM 2000 (Biacore/GE Healthcare), at this stage for DEAEA immobilization
by amide coupling chemistry. The same MES buffer was used as running buffer for the
duration of the immobilization procedure.
Freshly prepared solutions of 0.4 M 1-ethyl-3-(3-dimethylamino-propyl)carbodiimide
hydrochloride (EDC) and 1.0 M N-hydroxysuccinimide (NHS) (amine coupling kit from
Biacore/GE Healthcare) in water were mixed 1:1 and injected in a pulse of 200 µL at
20 µL/min to activate the terminal carboxyl group for amide bond formation. 1.0 M
DEAEA in MES running buffer was added in serial 100 µL pulses at 20 µL/min until the
SPR signal stabilized. Although there are four flow sensing cells available over the Biacore
sensor chip, only one flow cell was derivatized with DEAE so that SPR sorption data from
MUA could be compared against MUA-DEAE; the background was low as compared to
the MUA-DEAE.
5.2.5 SPR experiments
The SPR experiments were performed on a Biacore 2000 system at 25◦C. Product (rBVi),
product-related impurities (rBVgp64− , rBVenv− , and gp64 glycoprotein) and process-related
impurities (DNA, BSA, and LPS) were diluted to a given concentration (cB) in 20 mM
phosphate buffer at pH 6.8 with the specified NaCl supplementation (c0). All buffers were
prepared sterile and degassed prior to use in the equipment.
The experiments were performed at constant flow rate of running buffer and sample
injection of 100 µL/min. Each run consisted of the following sequence of steps: (i) equili-
bration of the flow cell with running buffer at a given NaCl concentration (c0); (ii) injection
of 100 µL of analyte solution at given concentration (c0, cB); and (iii) desorption and equi-
libration with running buffer (again, at c0). Before starting a new run, the flow cell was
subjected to an aggressive desorption step using 100 µL of 1.5 M NaCl in 20 mM phos-
phate buffer at pH 6.8 (c0,ref), and then cleaned/sanitized with 100 µL of 0.1 M NaOH for
complete regeneration of the surface.
DEAE ligands and SAM’s have been shown to be fully resistant to pulses of NaOH (or
HCl) up to 1 M (Knoll et al., 1998). The baseline stability was controlled throughout the
course of each experiment. All sensorgrams were duplicated by repeating each run once
for confirmation of their reproducibility and surface regeneration.
133
CHAPTER 5. Analysis of adsorption of a baculovirus bioreaction bulk on an ion-exchange surface by surface
plasmon resonance
5.3 SPR data analysis
SPR sensors measure small changes in the refractive index (RI) profile of the sample within
the evanescent field above the sensor surface (Schuck, 1997). The fundamental equation
for interpretation of an SPR sensor’s response to an adsorbed film is (Jung et al., 1998)
R =
m
dp
∫ ∞
0
η(z) e−z/dp dz, (5.1)
where R is the sensor’s signal; η(z), the RI at a distance z from the sensor surface; m,
a proportionality constant; and dp, the effective penetration depth of the evanescent elec-
tromagnetic field; for the case of our Biacore 2000 machine, dp ≈ 150 nm. The maximum
distance from the sensor surface that is effectively probed by the evanescent electromag-
netic field is zmax ≈ 5.3dp, because the truncation of the integral in Eq. (5.1) at that
depth,
1
dp
∫ zmax
0
η(z) e−z/dp dz ≈ 0.995, (5.2)
shows that the cumulative effect of larger distances contributes less than 0.5% to the SPR
signal.
Within the usual range of SPR applications, the sample’s refractive index is, to a good
approximation, the weighted arithmetic mean of the RI’s of its isolated constituents with
weights equal to their volume fractions in the sample (Jung et al., 1998). This is the basis
for converting the SPR signal into a surface concentration.
In a typical ion-exchange experiment, the solute (B) is dissolved into a buffer solution
whose ionic strength is controlled by a dissolved salt (0). By picturing the adsorbed film
as shown in the schematic of Fig. 5.1, it is possible to work out explicit formulae for decon-
voluting the SPR signal into adsorbate concentration, cm, bulk adsorptive concentration,
cB, and salt concentration, c0 (Vicente et al., 2010).
Under general conditions (i.e., measurable solute adsorption), and assuming a constant
pH, the SPR signal shift, ∆R, obtained as response to a typical ion-exchange adsorption
process on the sensor surface is given by (Vicente et al., 2010)
∆R = (mB −m0c0vB) [cm + φm(cB − cm)] +m0(c0 − c0,ref), (5.3)
where m0 and mB are the calibration constants associated with the SPR response to
changes in c0 and cB, respectively; vB, the molar volume of the adsorbed solute; cm, the
solute concentration in the volume of the adsorbed monolayer; φm = exp(−dm/dp) where
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Figure 5.1: Schematic diagram of an adsorbate monolayer over a ligand-functionalized surface
of thickness ds in the Biacore sensor chip flow cell. The thickness of the adsorbed monolayer,
dm, is roughly equal to the diameter of the adsorbed molecules molecules. dp is the effective
penetration depth of the evanescent electromagnetic field; for the case of the Biacore 2000 machine,
dp ≈ 150 nm. The bulk aqueous solution has salt concentration c0 and solute concentration cB; the
isolated (dry) solute’s refractive index is η˜B. Aqueous solution is assumed to fill the gaps between
adsorbed solute molecules, with salt concentration c0 and refractive index η0.
dm is the thickness of the adsorbed monolayer and dp the characteristic penetration depth
of the evanescent electromagnetic field (Fig. 5.1); and c0,ref , the salt concentration in the
buffer solution used to equilibrate the flow cell and to define the baseline of the SPR’s
signal. The adsorbed concentration, cm, can be converted into a surface concentration
through the simple formula q = dmcm.
The constant m0 can be determined from the slope of the linear fitting of ∆R against
c0 for a set of experiments on buffer solutions with different salt concentrations, but no
solute (cB = cm = 0). The constantmB, on the other hand, can be obtained from the slope
of the linear part of the plot of ∆R vs cB for a constant, large value of c0. At high salt
concentrations, most of the ion-exchange sites on the surface are shielded and the available
binding sites are completely saturated for moderately small values of cB. For larger values
of cB, for which cm is constant, Eq. (5.3) shows that ∆R is a linear function of cB with
slope (mB −m0c0vB)φm if the buffer solution is not changed.
Solving Eq. (5.3) for cm gives
cm =
∆R −m0(c0 − c0,ref)
(1 − φm)(mB −m0c0vB) −
φm
1− φm cB. (5.4)
Equations (5.3) and (5.4) can be applied to the complex baculovirus system under study
if the dm values for the different species comprising the bioreaction bulk are measured or
estimated (see Tables 5.1 and 5.2).
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5.4 Adsorption/desorption rate model
In this section an adsorption/desorption rate model that quantitatively explains the SPR
sensorgrams probing the interactions of the studied biomolecules with the DEAE-SAM
surface is proposed. A binding/elution rate model, using BSA as a reference protein, was
validated elsewhere (Vicente et al., 2010); here, we demonstrate that a similar formulation
is equally applicable to the complex biological system of baculoviruses.
Let us first consider a reaction model for the intrinsic adsorption kinetics and assume,
for the moment, that the mass transport by convection and diffusion does not influence
neither the adsorption nor the desorption kinetics. The validity of this assumption will be
discussed in detail later on when the experimental results are presented.
As indicated in a previous section, each SPR experiment consisted of an adsorption/de-
sorption sequence, where the adsorption step consisted of injecting buffer solution with
given salt and solute concentrations through the sensor chip; after binding, buffer alone
with the same salt concentration was injected to monitor the desorption kinetics. Partial
irreversible binding of the biomolecules onto the DEAE-SAM surface was observed (or
subject to an extremely slow desorption rate) because the elution step consistently gave
rise to a well-defined, residual equilibrium plateau whose height decreased with increasing
salt concentration in the buffer.
Given this observation, it is assumed that only part of the solute adsorbs reversibly,
whereas the other part binds irreversibly to the stationary phase. In our previous study
with BSA (Vicente et al., 2010) it was observed that irreversible binding took place from
the bulk solution as well as from the reversibly adsorbed phase; moreover, irreversible
protein adsorption from the reversibly adsorbed phase was seen to be likely dependent on
the frequency of collisions, or interactions, between the proteins in the bulk and those in
the reversibly adsorbed phase. A similar adsorption/desorption mechanism is assumed to
apply here. The mechanism is illustrated in Fig. 5.2.
Let q1 be the concentration of irreversibly bound solute and q2 the solute concentration
in the reversibly adsorbed phase. The rate model for irreversible binding to the DEAE-
SAM surface is
dq1
dt
= krcB(q˜
∞
1 − q1) + k′rcBq2, (5.5)
where kr is the rate constant for irreversible adsorption from the bulk, k′r is the rate constant
for irreversible binding from the reversibly adsorbed phase, and q˜∞1 is the capacity of the
stationary phase for irreversible binding. To make the analysis as general as possible, the
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Table 5.1: Characteristic features of baculovirus and baculovirus-derived impurities.
Species Size Structure Infectivity
rBVi
dm = 120 nm
Lm = 350 nm
Yes; contains gp64 + envelope
+ genome with capsid
rBVgp64−
dm = 100 nm
Lm = 340 nm
No; gp64 peplomers lacking
rBVenv−
dm = 60 nm
Lm = 300 nm
No; envelope lacking
gp64 trimers dm = 15 nm N.A.
Table 5.2: Characteristic features of process-related impurities.
Impurity Structure
BSA protein with diameter dm = 5.4 nm
DNA Linear structure with equivalent diameter dm = 50 nm
LPS Linear structure with equivalent diameter dm = 15 nm
Figure 5.2: Kinetic model for reversible/irreversible adsorption; dm, is roughly equal to the
diameter of the adsorbed solute. ka and kd are the forward and reverse rate constants for reversible
adsorption from the bulk solution, respectively; kr, the rate constant for irreversible adsorption from
the bulk solution; and k′r, the rate constant for irreversible adsorption from the reversibly adsorbed
phase.
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capacity q˜∞1 is assumed to be apparent, because some of the sites for irreversible binding
may be shielded by the presence of reversibly adsorbed solutes. Hence, we write
q˜∞1 = q
∞
1 − σ12q2, (5.6)
where σ12 is a steric factor: it gives the number of irreversible binding sites shielded by the
reversibly adsorbed solutes.
Assuming a Langmuirian kinetic model for reversible adsorption, one obtains
dq2
dt
= kacB(q˜
∞
2 − q2)− kdq2 − k′rcBq2
= kacB(q˜
∞
2 − q2)− (kd + k′rcB)q2, (5.7)
where ka and kd are the forward and reverse rate constants for reversible adsorption,
respectively, and q˜∞2 is the capacity of the stationary phase for reversible binding. Again,
this adsorption capacity is assumed to be apparent, because some of the sites for reversible
binding may be shielded by the presence of irreversibly adsorbed proteins:
q˜∞2 = q
∞
2 − σ21q1. (5.8)
At equilibrium, (
dq1
dt
)
=
(
dq2
dt
)
= 0, (5.9)
which allows closed-form expressions for the adsorption isotherms, q1(cB) and q2(cB), to
be determined.
The functional dependency between q1 and q2 can be derived by applying the equilib-
rium conditions to Eqs. (5.5) and (5.7); the result is
q1 = q
∞
1 +
(
k′r
kr
− σ12
)
q2. (5.10)
If the shielding can be neglected, Eq. (5.10) simplifies to
q1 = q
∞
1 +
(
k′r
kr
)
q2, (5.11)
which shows that, under these simplified conditions, q1 varies linearly with q2 with positive
ordinate and slope.
The adsorption isotherm (i.e., the equilibrium dependency of q2 with cB), for the general
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case where shielding cannot be neglected, is
q2 =
(q∞2 − σ21q∞1 )kacB
kd + [k′r + ka + σ21(k′r/kr − σ12)ka]cB
, (5.12)
which is a Langmuir-type isotherm, i.e.,
q2 =
γb2cB
1 + b2cB
, (5.13)
where
b2 =
k′r + ka[1 + σ21(k′r/kr − σ12)]
kd
, γb2 =
ka(q∞2 − σ21q∞1 )
kd
. (5.14)
For a typical ion-exchange process, the saturation capacities, q∞1 and q∞2 , and hence
the total saturation capacity, q∞ = q∞1 + q∞2 , are modulated by the salt concentration.
The higher the counterion concentration, the lower the binding of a given solute assuming
that no other factors influence the overall adsorption process in the SPR sensor chip. An
empirical correlation of the form
q∞ = q∞0 e
kc0 , (5.15)
is adopted here, where q∞0 is the maximum attainable adsorption capacity at residual ionic
strength and k < 0 is an empirical constant.
5.5 Results and discussion
5.5.1 Calibration of Biacore signal
The Biacore signal was calibrated with various solutions with different salt (c0) and BSA
(cB) concentrations and a baseline defined for a buffer solution with salt concentration
c0,ref = 1.5 M NaCl. Salt solutions with different c0 values were injected into the Biacore
cell and the corresponding signal shifts measured. The linear fitting (with intercept set to
zero) of∆R against (c0−c0,ref) yielded m0 = 9898.1 RU/(g/L) with an excellent regression
coefficient (r2 = 0.9998). This calibration accounts for the salt concentration effect without
the presence of solute in suspension.
To account for the effect of protein in solution (c0, cB > 0) a set of BSA concen-
trations in buffer with salt concentration c0 = c0,ref = 1.5 M NaCl was used. This
salt concentration was high enough to reduce BSA adsorption to a small level, so that
the plot of the Biacore signal shifts against cB yielded a straight line in accordance
with Eq. (5.3) when cm has a constant value (when c0 = c0,ref the adsorbed mono-
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layer is completed for small values of cB because the saturation capacity of the DEAE-
SAM surface is very low at that salt concentration). The linear fitting of ∆R vs cB
yielded a slope φm(mB − m0vBc0,ref) = 164.43 RU/(g/L) with a good regression co-
efficient, r2 = 0.9986; with m0vBc0,ref = 10.92 RU/(g/L), it is possible to determine
mB = 164.43/φm + 10.92 = 179.79 RU/(g/L).
Equation 5.4 can now be applied for converting the SPR signal (∆R) into concentration
values of adsorbed biomolecule, cm (g/L) and q (g/dm2) = 10−8dmcm, with the dm (nm)
estimated for each of the different biomolecules under study (Tables 5.1 and 5.2).
5.5.2 Applicability of sorption model to a complex biological sys-
tem
As a matter of convenience for a future design of the ion-exchange chromatographic process,
a key step of current downstream purification strategy (Vicente et al., 2009), it is best
to split the biological bulk into three cuts, or fractions—(i) the product, (ii) the main
product-related impurities, and (iii) the main process-related impurities—and to define for
each fraction the key components governing its chromatographic behavior.
In the present case, the infective baculovirus (rBVi), which is the integral/functional
particle, is assumed to be the desired product. The baculovirus defective in gp64 glyco-
protein trimers (rBVgp64−) on its envelope (if any) and the envelope defective baculovirus
(rBVenv−), i.e., rBVi without envelope (a “naked” capsid) or with any disrupted version of
it, are considered to be the main product-related impurities; gp64 viral glycoprotein is a
byproduct of the production/degradation of rBVs and can be also included as a product-
related impurity; this protein has been added to the present study in order to compare
it with the rBV particles, either infective (rBVi) or deficient in gp64 (rBVgp64−). BSA is
considered as a host cell protein analogue; LPS and host insect DNA are references for
endotoxin and DNA contaminants, respectively; these are established as the three major
process-related impurities (Vicente et al., 2009).
Each target biomolecule was injected into the Biacore sensor cell, under various condi-
tions of solute and salt concentrations, and the corresponding SPR sensorgrams analyzed
using the analytical and modeling tools described above. The conversion of the experi-
mental SPR sensorgram, ∆R(t), expressed in RU units, into and equivalent sensorgram of
adsorbed concentration, q(t), expressed in g/dm2, was done directly using the aforemen-
tioned calibrations, assuming the following density constants or inverse specific volumes,
1/viB: 1.36 g/mL for BSA and gp64 (Bosma and Wesselingh, 1998), 1.2 g/mL for the
140
DOWNSTREAM PROCESSING DEVELOPMENT OF ENVELOPED VIRUSES FOR CLINICAL APPLICATIONS
recombinant baculovirus particles (Mazzone, 1998), 1.55 g/mL for dsDNA (Sambrook and
Russel, 2001), and 1.4 g/mL for LPS (Ulevitch and Johnston, 1978); the assumed adsorp-
tion layer thicknesses, dm, are those listed in Tables 5.1 and 5.2.
The proposed kinetic model was tested on the baculoviruses, baculovirus-related impu-
rities, and major process-related impurities. Values of q1 and q2 were obtained from the
horizontal plateaus of the adsorption/desorption steps for each of the previously isolated
biological solutes.
Figure 5.3 shows the experimental SPR sensorgrams for one of the studied biomolecules
—the product, rBVi— using the binding/elution procedure; an explanatory nomenclature
is superposed on the topmost sensorgram. The sensorgrams shown in Fig. 5.3 are repre-
sentative of the sensorgrams obtained for the other biomolecules: in all cases, an initial
steep rise is observed, followed by a curved response typical of a pseudo-first-order kinetics,
then a steep fall in the signal upon elution of the sensor cell, and finally a shallow decaying
curve that stabilizes as an horizontal plateau. BSA was seen to desorb slower than the
larger biomolecules. Using Eq. (5.4), the SPR sensorgrams of Fig. 5.3 can be converted
into equivalent surface chromatograms of adsorbed concentration; the latter are shown in
Fig. 5.4.
Before proceeding with the discussion of the results it is important to assess whether
or not our SPR experiments were limited by convective-diffusive mass transport. Previous
studies showed that diffusion through the unstirred fluid film over the sensor surface can
limit the binding kinetics under certain conditions (Glaser, 1993; Hall et al., 1996; Schuck,
1997; Myszka et al., 1997, 1998; Goldstein et al., 1999; Mason et al., 1999). Especially
at low flow rates, large biological particles, like the ones evaluated here, do present dif-
fusion restrictions (Roper and Nakra, 2006); we have observed this effect in exploratory
experiments run at low flow rates.
However, as shown next, for the flow rate used in our SPR runs, 100 µL/min, the
experiments were not limited by mass transport. A two-compartment mass transport
model (Myszka et al., 1998) is usually employed to distinguish intrinsic adsorption rates
from slower diffusive mass transport of the solute across the fluid layer adjacent to the
sensor surface. The model can be written as
hi
dcB
dt
+
(
dq1
dt
+
dq2
dt
)
= km(c
o
B − cB), (5.16)
where km is the transport coefficient describing the effective diffusional flux of solute from
an outer compartment, where its concentration is coB, into an inner compartment adjacent
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Figure 5.3: Experimental sensorgrams of adsorption/desorption runs for different rBVi and salt
concentrations: (a) c0 = 0.023 M, (b) c0 = 0.50 M, and (c) c0 = 1.26 M; the rBVi concentrations in
(108 pfu)/mL are indicated in the middle graphic and are same for all three graphics. The notation
attached to the topmost sensorgram has the following meaning: subscript ’a’, binding/adsorption
step (‘Ads’); subscript ’d’, elution/desorption step (‘Des’); ∆R, SPR signal; overbar, equilibrium
value; (cB, q1, q2) = (bulk solute concentration, irreversibly adsorbed concentration, reversibly ad-
sorbed concentration).
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Figure 5.4: Conversion of the experimental SPR sensorgrams shown in Fig. 5.3, for the rBVi
binding/elution runs, into equivalent surface chromatograms of adsorbed concentration by means
of Eq. (5.4). Salt concentrations: (a) c0 = 0.023 M, (b) c0 = 0.50 M, and (c) c0 = 1.26 M; the
rBVi concentrations in (108 pfu)/mL are indicated in the top graphic and are same for all three
graphics.
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to the sensor surface, where its concentration is cB; hi is the height of the inner compart-
ment and its value is somewhat arbitrary, because it has been shown that, after a brief
initial transient, the binding kinetics are independent of the size of the inner compartment
(Goldstein et al., 1999).
To a good approximation (Lok et al., 1983; Sjölander and Urbaniczky, 1991),
km = 1.282
(
3
2
uD2
hl
)1/3
, (5.17)
where u = Q/(hw) is the average velocity of the fluid in the flow cell; Q, the volumetric
flow rate; h and w, the height and width of the flow cell; l, the length of the sensor surface;
and D, the diffusion coefficient.
The diffusion coefficient for the fastest diffusing molecule of our set, BSA, is DBSA =
9 × 10−7 cm2/s (Schmitz and Lu, 1983), whereas for the largest particles, say rBVi, the
diffusion coefficient is DrBVi ≈ 10−7 cm2/s (Mazzone, 1998); from Eq. (5.17), the mass-
transfer coefficient for the latter case is km ≈ 3 × 10−4 cm/s at 100 µL/min. Transport
effects will not influence the adsorption kinetics if km ' krq∞1 and km ' kaq∞2 ; these two
inequalities are safely verified for our system: km ' krq∞1 ≈ 3 × 10−6 cm/s and km '
kaq∞2 ≈ 7 × 10−6 cm/s, where we majored q∞1 = 2 × 10−7 g/cm2, q∞2 = 2 × 10−7 g/cm2,
ka = 10−2 dm3 · g · s−1 and kr = 10−2 dm3 · g−1 · s−1, the two latter values obtained from
model fitting.
The sensorgrams for rBVi shown in Fig. 5.3, as well as those for the other biomolecules,
can now be interpreted without any worries about mass-transport issues. Although the
primary objective of this work is to report on adsorption equilibrium data, in section 5.7
we provide an analytical solution for the kinetic model and SPR response in the absence
of mass-transport limitations. Here we focus on the shape and equilibrium plateaus of the
SPR sensorgrams.
The initial steep rise in the SPR signal upon start of the adsorption step is the result
of replacing the buffer solution (c0, cB = 0) with the injected sample (c0, cB = coB) over the
sensor surface. The binding kinetics generates the convex curvature in the SPR response;
this part of the sensorgram is described by Eq. (5.3) with cB fixed at coB, cm = (q1+q2)/dm,
and q1 and q2 given by the kinetic model defined by Eqs. (5.5)–(5.8). Under equilibrium
conditions, the SPR signal stabilizes at an upper horizontal plateau, corresponding to
(cB, q1, q2) = (coB, q1, q2), from where q1 + q2 can be determined.
Our SPR experiments with BSA showed that the total BSA binding capacity of the
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derivatized surface is roughly 0.81 mg/m2 at 25 mM salt concentration (Vicente et al.,
2010); this value is less than the 5 mg/m2 typically found for a protein monolayer. Since
the binding capacity is strongly dependent on the ligand density, it appears that the ligand
density was low in our MUA-DEAE surfaces. Under such conditions, bound biomolecules
are expected to spread over the derivatized surface with a mean distance between neigh-
boring molecules large enough for the shielding to have only a mild effect. This is also
supported by the small values of the shielding factors obtained for BSA from the fitting of
the full kinetic model. We have thus assumed in the analysis of our SPR experiments that
the shielding effect can be neglected and that the binding kinetics is given by Eqs. (5.23)
and (5.24) (see section 5.7).
In the elution step, buffer alone is injected into the SPR cell to monitor the desorption
kinetics. The SPR response for this step is given by Eq. (5.3) with cB = 0, cm = (q1 +
q2)/dm, q1 = q1, and q2 governed by Eq. (5.7). The steep fall in the SPR signal upon
start of the elution step is the result of the cooperative effects of replacing the sample
injected in the adsorption step (c0,cB = coB) by buffer alone (c0,cB = 0) and of desorbing
the reversibly bound solute, q2. At the end of the elution step, the horizontal plateau in
the SPR signal is due to the residual solute that is irreversibly bound to the derivatized
surface. This residual horizontal plateau corresponds to (cB, q1, q2) = (0, q1, 0). Thus the
difference between the upper and lower plateaus, (coB, q1, q2) − (0, q1, 0), after the elution
of solute from the bulk solution is taken into account, gives the equilibrium concentration
of the reversibly adsorbed phase, q2.
As expected, for a fixed salt concentration in the buffer the height of the SPR sensor-
grams, expressed in RU units, increases with increasing biomolecule concentration in the
injected sample. On the other hand, the height of the SPR sensorgrams decreases strongly
with increasing salt concentration in the buffer. The impact of salt concentration in the
buffer is directly observed in the equilibrium value of ∆Ra, measured at the end of the ad-
sorption step, and that of ∆Rd, measured after extended elution; these values are denoted
in Fig. 5.3 by an overbar, as do all equilibrium variables in this work.
The dissolved salt in the buffer decreases the heights of the SPR sensorgrams for two
reasons. The first one is the modulation of the ion-exchange interactions between the
adsorbate molecules and the derivatized surface by the salt counter ion, Cl−; this effect
is visible when the sensorgrams are converted into surface chromatograms, such as those
depicted in Fig. 5.4. The second reason is the decrease in the difference between the refrac-
tive index of the biomolecule and that of the buffer solution when the salt concentration is
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increased. This effect can be understood from the schematic of Fig. 5.1 and from Eq. (5.3),
the latter showing that ∆R is proportional to (mB −m0c0vB): increasing c0 will decrease
∆R for the same amount of adsorbed solute. The reason for this is a volume displacement
effect: when a biomolecule adsorbs on the surface it displaces the volume of fluid that it is
going to replace adjacent to the sensor surface; thus, the local refractive index will change
proportionally to η˜B − η0 and not just to η˜B (see Fig. 5.1 for notation).
Upon conversion of RU into concentration units, Fig. 5.5 provides a direct overview of
the effect of the salt concentration on the rBVi’s adsorption isotherm. It can be seen that
both the irreversible and reversible parts of the overall adsorption isotherm are sensitive
functions of the salt concentration; this is in agreement with the typical ion-exchange-type
mechanism occurring in ion-exchange chromatography.
Figure 5.6 provides evidence that the proposed kinetic model is applicable to the biomo-
lecules under study; indeed, the positive slopes and ordinates obtained from the good linear
regressions of q2 vs q1 at all tested ionic strengths corroborate the applicability of Eq. (5.11).
Moreover, the inverse plots of 1/q1 and 1/q2 against 1/cB in Fig. 5.7 show that the good
quality of the linear regressions is in agreement with Eq. (5.12), which expresses q2(cB) as
a Langmuir-type isotherm. Altogether, the results show that our kinetic sorption model
is well suited to quantitatively explain the sensorgrams obtained in the Biacore machine.
Similar trends have been observed for the remaining biological species considered in this
study, including the impurities (data not shown). Thus, it appears that the sorption model
proposed in the present work is sufficiently general for it to be applicable to the complex
biologics of the baculovirus system.
5.5.3 Prediction of total adsorption capacities
The variations of the total adsorption capacities, including both reversible and irreversible
components, with salt concentration show the typical trends observed in an ion-exchange
process, in agreement with what was observed for the BSA protein model (Vicente et al.,
2010). Indeed, the use of empirical fittings of the form given by Eq. (5.15), and shown
in Figs. 5.8 and 5.9, is consistent with an ion-exchange-type mechanism governed by the
salt concentration. One should note, though, that other effects, such as steric hindrance
occurring in a typical chromatographic matrix, are not considered here. Exclusion effects,
perturbing the typical dynamic binding capacity behavior as a function of salt concentra-
tion, have been reported in the literature, especially for large particles, such as virus-like
particles (Vicente et al., 2008) or monoclonal antibodies (Harinarayan et al., 2006).
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Figure 5.5: Adsorption equilibrium of rBVi particles: (a) irreversible component, q1 vs (cB, c0);
and (b) reversible component, q2 vs (cB, c0); cB for infective baculoviruses is calculated assuming
a global particle weight of 1.5 × 10−15 g/pfu (Ilic et al., 2004).
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Figure 5.6: Experimental plot of q1 against q2 (symbols) for rBVi and corresponding fittings of
Eq. 5.15 (lines).
It can be observed that BSA, used here as an analogue of an adsorbing host-cell protein,
endotoxin, and DNA show different binding capacities, which can be directly correlated
with the different retention times obtained in chromatography runs. Retention times are
the most fundamental data required to design a chromatographic process. However, the
adsorption/desorption data obtained here required 1200-fold less material than that em-
ployed in a typical analytical chromatographic experiment. Moreover, Fig. 5.9 gives a
clear indication that the DEAE-SAM surface has a much lower adsorption capacity for the
product-related impurities, either non-enveloped baculoviruses or baculoviruses deficient
in the external gp64 glycoprotein (essential for virus functionality (Monsma et al., 1996)),
than for the desired/complete virus. Such information is valuable for shedding light on
the characterization of the product pools after an ion-exchange chromatography step and
contributing to select the best conditions to improve product quality and potency. For
instance, it can be concluded from Figs. 5.8 and 5.9 that a salt concentration below 0.5 M
would be optimal to obtain improved selectivity in the anion-exchange chromatographic
process.
5.6 Conclusions
Sorption rates onto a micrometric derivatized surface, containing an ion-exchange func-
tional DEAE group, have been measured and analyzed by SPR spectroscopy. A kinetic
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Figure 5.7: Inverse plots for rBVi particles: (a) 1/q1 vs 1/cB; (b) 1/q2 vs 1/cB; cB for infective
baculoviruses is calculated assuming a global particle weight of 1.5× 10−15 g/pfu.
model, incorporating two different adsorption mechanisms, was used to explain the SPR
sensorgrams obtained for a complex biological system of enveloped viral vectors. The model
assumes that a fraction of the biomolecules adsorbs reversibly according to a Langmuirian
kinetic model, whereas the other fraction binds irreversibly to the stationary phase. Using
the SPR experiments it was possible to determine the adsorption isotherms for different
salt concentrations. The results provided evidence that the DEAE-SAM derivatized surface
mimics well an ion-exchange surface, as far as intrinsic ion-exchange-related interactions
are concerned, without considering transport or exclusion phenomena present in a real
chromatographic matrix.
A model enveloped viral system has been studied as an example of a promising viral
vector for clinical therapies – recombinant baculoviruses. The system was conveniently
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discriminated into (i) the desired product (a recombinant baculovirus), (ii) the major
product-related impurities (damaged viral particles, hence non-infective), and (iii) the ma-
jor process-related impurities (protein, DNA, endotoxin). This analysis resulted in the
estimation of the adsorption isotherms of the isolated biomolecules as a function of salt
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concentration. This tool, based on a simple stationary phase model, generates useful pre-
dictions of how the different components interact with a typical ion-exchange matrix used
in a downstream process step. If the adsorption isotherms are known, suitable operating
conditions can be determined through the application of design rules, such as those de-
veloped for simulated moving-bed processes or by computer-aided optimization. We shall
resort to the latter approach for designing the biopurification process. It is worth noticing
that the mechanistic knowledge obtained here for a complex biological system would not
have been granted by other scaled-down approaches, e.g., high-throughput technologies,
in the same time and with similar resources. Once this strategy is set up, it can be used
to rationally enhance early-stage process screenings and increase basic knowledge on an
industrial setting.
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5.7 Appendix: Analytical solution of the kinetic model
and SPR response in the absence of mass-transport
limitations
The initial steep rise in the SPR signal upon start of the adsorption step is the result of
replacing the buffer solution (c0, cB = 0) with the injected sample (c0, cB = coB) over the
sensor surface for z ≤ zmax [see Eq. (5.2)]. From Eqs. (5.3) and (5.16), this steep rise in
the SPR signal can be approximated by
∆R = (mB −m0c0vB)cB, hi dcB
dt
= km(c
o
B − cB), (5.18)
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whose solution for the initial condition cB(0) = 0 is
∆R = (mB −m0c0vB)coB
[
1− exp
(
−km
hi
t
)]
. (5.19)
This equation is valid for the early stages of the adsorption step; in particular, the derivative
of Eq. (5.19) with respect to t for t = 0,
(mB −m0c0vB)coBkm/hi, (5.20)
approximates reasonably well the steep slope of the initial rise in the SPR signal.
The binding kinetics generates the convex curvature in the SPR response; this part of
the sensorgram is described by Eq. (5.3) with cB fixed at coB, cm = (q1+q2)/dm, and q1 and
q2 given by the kinetic model defined by Eqs. (5.5)–(5.8). Under equilibrium conditions,
the SPR signal stabilizes at an upper horizontal plateau corresponding to (cB, q1, q2) =
(coB, q1, q2).
Given that cB ≈ coB during binding because of unrestricted mass transfer, the kinetic
model is governed by two ordinary differential equations amenable to a closed-form, ana-
lytical solution. The solution for the initial conditions q1(0) = q2(0) = 0, in the Laplace
domain, is
Q1(s) =
α1(s+ b2)− α2b1
[(s+ a1)(s+ b2)− a2b1]s , Q2(s) =
α2(s+ a1)− α1a2
[(s+ a1)(s+ b2)− a2b1]s , (5.21)
where Q1(s) and Q2(s) are the Laplace transforms of q1(t) and q2(t), respectively; α1 =
krq∞1 cB, a1 = krcB, b1 = (σ12kr − k′r)cB, α2 = kaq∞2 cB, a2 = σ21kacB, and b2 = kd + (ka +
k′r)cB. The solution can also be written in terms of time constants as
Q1(s) =
K1(τ ′1s+ 1)
[(τ1s+ 1)(τ2s+ 1)− β]s , Q2(s) =
K2(τ ′2s+ 1)
[(τ1s+ 1)(τ2s+ 1)− β]s , (5.22)
where τ1 = 1/a1, τ2 = 1/b2, β = a2b1/a1b2, K1 = (α1b2 − α2b1)/a1b2, τ ′1 = α1/(α1b2 −
α2b1), K2 = (α2a1 − α1a2)/a1b2, and τ ′2 = α2/(α2a1 − α1a2).
The effect of shielding on the binding kinetics is lumped into parameter β. The inversion
of Eq. (5.22) for β = 0 gives
q1(t)
K1
= 1 +
τ ′1 − τ1
τ1 − τ2 e
−t/τ1 +
τ ′1 − τ2
τ2 − τ1 e
−t/τ2, (5.23)
q2(t)
K2
= 1 +
τ ′2 − τ1
τ1 − τ2 e
−t/τ1 +
τ ′2 − τ2
τ2 − τ1 e
−t/τ2. (5.24)
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To assess the influence of β, first note that a2b1 < 0 and so does β, and that b2 > a1.
For nonzero, but small, values of a2b1 the second-order polynomial (s+ a1)(s+ b2)− a2b1
in the denominators of Eq. (5.21) is well approximated by (s + a′1)(s + b′2), where a′1 =
a1−a2b1/(b2−a1) and b′2 = b2+a2b1/(b2−a1). Thus, a1 is increased by & = |a2b1|/(b2−a1),
whereas b2 is decreased by the same value; since the time constants τ1 and τ2 are the
reciprocals of a1 and b2, respectively, then is follows that τ1 is decreased by shielding,
whereas τ2 is increased.
In the elution step, buffer alone is injected into the SPR cell to monitor the desorption
kinetics. The SPR response for this step is given by Eq. (5.3) with cB = 0, cm = (q1 +
q2)/dm, and q1 and q2 defined by
q1 = q1,
dq2
dt
= −kdq2. (5.25)
If the time coordinate is reset to zero at the start of the elution step, the initial condition is
q2(0) = q2. The solution for the reversible component of the adsorbed phase concentration
is thus
q2(t) = q2 exp(−kdt). (5.26)
Nomenclature
Symbols
cB solute concentration in bulk solution
c0 salt concentration in bulk solution
coB solute concentration in outer compartment
R Biacore sensor’s signal
z distance from the sensor surface
c0,ref reference salt concentration
dp penetration depth of the evanescent field
dm thickness of adsorbate monolayer
ds thickness of sensor surface film
cm adsorbate concentration
m correlation coefficient between RI and Biacore’s ∆R signal
m0 slope of linear fitting of ∆R vs (c0 − c0,ref)
mB slope of linear fitting of ∆R vs cB
D diffusion coefficient
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km mass transfer coefficient from bulk to sensor chip surface
hi height of the inner compartment
u average velocity of the fluid in the flow cell, Q/(hw)
h height of the flow cell
w width of the flow cell
l length of the sensor surface
ka reversible adsorption rate constant
kd desorption rate constant
kr rate constant for irreversible adsorption from the bulk solution
k′r rate constant for irreversible adsorption from the reversibly adsorbed phase
q total adsorbed concentration
q1 concentration of irreversibly bound solute
q2 concentration of reversibly bound solute
q∞1 capacity of the derivatized surface for irreversible binding
q∞2 capacity of the derivatized surface for reversible binding
q∞ total capacity of the stationary phase
q˜∞1 apparent capacity of the derivatized surface for irreversible binding
q˜∞2 apparent capacity of the derivatized surface for reversible binding
q1 equilibrium concentration of irreversibly bound solute
q2 equilibrium concentration of reversibly bound solute
Greek letters
ηB refractive index of a salt solution with a dissolved biological solute
η˜B refractive index of the (dry) solute
η0 refractive index buffer solution with salt concentration c0
∆R Biacore signal
η0,ref reference salt solution’s RI (baseline buffer)
φs exponential ratio, exp(−ds/dp)
η˜0 refractive index of the salt ions
vB specific volume of the biological solute
φm exponential ratio, exp(−dm/dp)
σ12 steric factor for shielding of irreversible binding by reversibly bound adsorbates
σ21 steric factor for shielding of reversible binding by irreversibly bound adsorbates
∆Ra sensorgram signal during adsorption
∆Rd sensorgram signal during desorption
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∆Ra equilibrium sensorgram signal upon adsorption
∆Rd equilibrium sensorgram signal upon desorption
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DOWNSTREAM PROCESSING DEVELOPMENT OF ENVELOPED VIRUSES FOR CLINICAL APPLICATIONS
Abstract
Product-related impurities constitute a major burden in the production of recombinant
viral vectors for gene therapy and vaccination; it impairs not only the biological efficacy
of the preparation but the process yield/productivity. Recombinant baculovirus was used
as an enveloped virus model to address this issue. Given that ion-exchange chromatogra-
phy is a process of choice for purification of viral vectors, the analysis of the electrostatic
behavior can be instrumental for the improvement of impurity removal. The main species,
product (infective virus particle) and product-derived impurities (dsDNA-, glycoprotein-,
and envelope-deprived baculovirus particles), were isolated and correspondent ζ-potentials
were analyzed through dynamic light scattering. A model of the virus based on the viral
components critical for biological function is proposed. The contribution of these viral
components to the overall particle electrostatic interaction energy profile (calculated be-
tween the particle and a putative ion-exchange surface) was assessed as a function of ionic
strength and pH. This resulted in a deterministic tool capable of distinguishing the elec-
trostatic properties of the infective virus particle from the major virus-related impurities.
Within an ion-exchange bind-elute process, this knowledge helps narrow the optimization
space in early stage process development for viral vectors by predicting the best selectivity
conditions.
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6.1 Introduction
The application of virus-like particles or recombinant viruses has been gaining momentum
in the fields of vaccination or gene therapy for unmet medical needs (Merten et al., 2005;
Rodrigues et al., 2007; Chuang et al., 2007; Cockrell and Kafri, 2007; Hu, 2008; Airenne
et al., 2009). The growing number of preclinical studies and gene therapy trials require
the purest grade materials in large-scale amounts (:20, 2008). Thus, it is becoming critical
that tightly controlled, scalable and robust production processes become available for these
complex biopharmaceuticals. Recombinant baculoviruses (rBVs) constitute a well estab-
lished technology whose portfolio, in the last couple of decades, includes the production
of many thousands of recombinant proteins using insect cells as host cell producers (Kost
et al., 2005). The approved GSK CervarixTM vaccine against cervical cancer is an example
of these biologics. Over the last decade, with the focus on human gene therapy paving the
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way for innovative alternatives, the versatility of the rBV technology became clear by the
increasing scientific evidence covering rBVs as successful vectors also in mammalian gene
transfer (Kost et al., 2005; Airenne et al., 2009). In the mid-nineties, Hofmann et al. (Hof-
mann et al., 1995) have shown that these arthropod-specific viruses can be engineered to
transiently transduce vertebrate cells by means of a proper mammalian promoter, although
not replicating themselves or causing cytotoxic effects. Due to this non-pathogenicity to
mammalian cells, the ability to accommodate very large foreign DNA sequences and the
reliable production at high titers in insect cell cultures, rBV vectors hold significant ad-
vantages over other, more widely studied vectors (Hu, 2008; Airenne et al., 2009).
Nevertheless, as for other viral vectors or biologicals, bioengineers are currently seeing
the process bottleneck shifting toward the downstream processing steps (Vicente et al.,
2009; Gottschalk, 2008). In the specific case of viral vectors, given the increase in complex-
ity, the workforce costs allocated to the compulsory analyticals and cell culture materials
steeply augment thus resulting in costly process optimization. rBV vectors constitute a
model system for this setting; clearly, a novel purification strategy developed by our lab-
oratory for rBV vectors for clinical use has still room for improvement (Vicente et al.,
2009). Crucial challenges need to be met: the large rod-shaped structure and envelope
surface heterogeneity, the removal of resilient impurities and product derived impurities
should be addressed in order to permit a more rational approach in the process fine-tuning
and, ultimately, enhance yields/productivities of fully functional product.
Ion-exchange purification processes are state-of-the-art choices in purification processes
for biopharmaceuticals (Urabe et al., 2006; Rodrigues et al., 2008; Vicente et al., 2008,
2009; Peixoto et al., 2008); they can be used efficiently to capture either the desired end
product (bind-elute mode) or impurities (flow-through mode). Ionic strength and pH of the
buffer/medium containing the complex mixture bulk are critical parameters one should ob-
serve with special attention (Pujar and Zydney, 1998; Schaldach et al., 2006; Vicente et al.,
2008). Indeed, these conditions dramatically impact the ion-exchange process defining the
binding strength at which the different bulk components undergo adsorption/desorption.
To address these issues a more sound, knowledgeable based approach can be followed in
an attempt to distinguish the underlying fundamental phenomena; hence, avoiding the
need to cover all the possibilities using high-throughput methods used for blind design of
experiments (DoE).
Dynamic light scattering (DLS) analysis can be easily conducted in benchtop machines
with reduced consumable and biological material costs. In addition to the estimation
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of hydrodynamic size and molecular weight of sub-micron particles, DLS can be used to
study the electrokinetic properties of viral particles at chosen operational conditions of ionic
strength and pH (Hiemenz, 1986); in particular, the estimation of the ζ potential provides
a good measure of the electric double layer potential of the particle (Hiemenz, 1986). The
integration of a conceptual model befitting these measurements can be instrumental in
obtaining the conditions for best selectivity.
Following this rationale, DLS was used in this work to study in-depth the electrostatic
features of baculovirus particles (as a model viral vector) and derived impurities. This
resulted in relevant knowledge over the exploitable partitioning points that can be used
for improved recovery of the functional viral vector from the remaining product-related
impurities. This work is outlined into four major steps: (i) adapting a theoretical model
to estimate the electrostatic potential of the relevant components of the viral particle; (ii)
predicting the electrostatic interaction energies between the viral particle and a putative
ion-exchange surface; (iii) validating the modeled predictions with experimental DLS data;
and, (iv) establishing scenarios for best selectivity, hence, impurity removal.
6.1.1 Model of the virus particle and derived impurities
The virus used in this work – Autographa californica multicapsid nucleopolyhedrosis virus
(AcMNPV) – in its budded virus phenotype is a rod-shaped enveloped virus (O’Reilly
et al., 1994; King and Possee, 1992). This virus contains a rod-shaped (bacilliform) capsid
composed of a protein sheath averaging 300 nm in body length and approximately 60 nm
in diameter (Beaton and Filshie, 1976; Fraser, 1986). The capsid is an assembly of stacked
ring subunits spaced 4.5 ± 0.2 nm apart (Beaton and Filshie, 1976), with distinct base
and apex protein structures (Fraser, 1986). Although it is known that vp39 is the major
capsid protein (Braunagel and Summers, 1994), there is still no further information on how
the protein structurally assembles to form the ringlike capsomeres. The capsid encloses
a molecule of dsDNA, typically within 128–140 kbp; electron dense capsids are observed
under negative staining transmission electron microscopy indicating the presence of the
baculovirus condensed genome (Fraser, 1986). These rod-shaped, DNA containing virions
escape from the nucleus of the insect cell forming transient vacuoles that are further lost
upon envelopment with lipid bilayers by budding from the cytoplasmic membrane (Fraser,
1986). Data from transmission electron microscopy and optical diffraction has shown that
the minimum spacing between the envelope and the capsid is approximately 12 nm (Beaton
and Filshie, 1976). The de novo enveloped virus contains an apical region covered with
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Figure 6.1: Schematic representation of the baculovirus particle model used in this study. The
particle can be physically decomposed into three parts: a 135/180 fraction of a sphere at the top, a
cylindrical structure in the middle, and, a semi-sphere at the bottom.
gp64 glycoprotein trimers which differentiates from the cylindrical body and bottom tip
of the baculovirus (see Fig. 6.1) (Fraser, 1986). The postfusion crystal structure of gp64,
mandatory for viral infection (Monsma et al., 1996), has been recently published; it consists
of an elongated 15 × 5.5 nm structure composed of five protein domains per monomer
(Kadlec et al., 2008). Gathering all the above structural data, the complete baculovirus
particle averages approximately 390× 90 nm in body length and diameter (with an apex,
larger “head”, with approximately 120 nm in diameter), respectively. Fig. 6.1 depicts the
baculovirus model used in this work considering the described structural data; four major
components are highlighted: the presence of the baculovirus genome here schematically
represented as a dark (electron dense) rod-shaped capsid; the hollow tube capsid per se;
the envelope surrounding the capsid; and gp64 trimers on the spherical-like apex surface
of the particle.
We thus define in this study four recombinant baculovirus (rBV)-derived species: (i)
infective baculovirus (rBVi), as the integral, functional particle; (ii) empty capsid bac-
ulovirus (rBVe.c.), lacking the viral genome (non-infective); (iii) gp64 defective baculovirus
(rBVgp64−), with a defective amount of gp64 trimers (if any) on its envelope (non-infective);
and (iv) envelope defective baculovirus (rBVenv−), without envelope or with any disrupted
version of it, i.e., a “naked” capsid (a fortiori non-infective). The relevant features and
geometric data for the different model baculovirus-derived species considered in this work
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are collected in Table 6.1.
Table 6.1: Characteristic features of baculovirus and baculovirus-derived impurities considered in
this work.
Species Apex structure
Cylindric and
base
structure
Schematic
illustration Infectivity
Critical
interaction
players
rBVi
135o/180o of a
sphere surface:
R1 = 60 nm
cylinder:
L = 240 nm;
R2 = 45 nm +
half-sphere: R2
Yes; contains
gp64 +
envelope +
genome
containing
capsid
gp64 trimers
+ envelope +
capsid +
viral dsDNA
rBVe.c.
135o/180o of a
sphere surface:
R1 = 60 nm
cylinder:
L = 240 nm;
R2 = 45 nm +
half-sphere: R2
No; viral
genome lacking
gp64 trimers
+ envelope +
capsid
rBVgp64−
135o/180o of a
sphere surface:
R1′ = 50 nma
cylinder:
L = 240 nm;
R2 = 45 nm +
half-sphere: R2
No; gp64
trimers lacking
envelope +
capsid +
viral dsDNA
rBVenv−
half-sphere:
R3 = 30 nm
cylinder:
L = 300 nm;
R3 = 30 nm +
half-sphere: R3
No; envelope
lacking
capsid +
viral dsDNA
aconsidering that approximately 10 nm out of the 15 nm length of the gp64 trimer is exposed off the
envelope (Kadlec et al., 2008)
6.1.2 Interaction energy between the model rBV particle and a
flat plate
A means to understand the interactions governing an ion-exchange process is to obtain
a quantitative estimation of the interaction energies between the different components of
the mixture and the stationary phase. The interaction energy is defined as the Helmholtz
free energy change associated when approaching the two charged surfaces (in this case, the
viral particle and a flat surface) to a specific distance from infinite separation (Schmitz,
1996; Overbeek, 1990). The rBVs (and the remaining rBV-related species defined here
(Table 6.1)) can be considered as colloidal particles, so that one can rely on the Derjaguin-
Landau-Verwey-Overbeek (DLVO) theory to assess the van der Waals (vdW) and electro-
166
DOWNSTREAM PROCESSING DEVELOPMENT OF ENVELOPED VIRUSES FOR CLINICAL APPLICATIONS
static double layer (EDL) interaction energies (Schaldach et al., 2006; Bhattacharjee and
Elimelech, 1997). In fact, due to the non-specificity of the vDW potential energies the EDL
contribution to the ion-exchange interaction energy is targeted here (Yoon and Lenhoff,
1992). The electric double layer interaction contribution is derived from the solution of the
Poisson-Boltzmann equation (Hiemenz and Rajagopalan, 1997).
The surface element integration formalism available in the colloidal interface science
literature (Bhattacharjee and Elimelech, 1997) represents an accurate method for the esti-
mation of the interaction energy between a particle of arbitrary shape and an infinite flat
plate from the corresponding interaction potential per unit area between two hypothetical
infinite plates; in this approach, the differential interaction energy dU of a surface element
dS at a distance h from an infinite flat plate can be expressed through the interaction
energy per unit area between two infinite flat plates Ψ(h) as dU = Ψ(h)n · ezdS, where n
is the unit outward normal to the surface element and ez is the unit normal to the xy plane
(directed along the positive z axis (see Fig. 6.2)), h is the distance of the area element over
the surface of the rBV particle and the infinite plate surface. The integral of the potential
element over the surface of the rBV particle is then obtained by:
U =
∫
x
∫
y
Ψ(h)
n · ez
| n · ez |dxdy. (6.1)
According to the definition of the different rBV particles species (Fig. 6.1, Table 6.1),
this integral can be calculated by the summation of three contributions: (i) the surface
of the apex of the particle; (ii) the cylindrical rod surface whose projected element in
cylindrical coordinates is LRjdθ, L is the length of the cylindrical rod, and θ ∈ [0,pi/2]
(taking into account the symmetry of the cylinder) and j is 2 or 3 (according to Table 6.1);
and, (iii) the semi-sphere surface of the bottom tip of the particle.
Assuming an α angle in the plane xy between the axis of the particle and the normal
to the infinite plate surface as shown in Fig. 6.2, with α = pi/2, for the particle side
facing the plate surface and using the expressions derived by Bhattacharjee and Elimelech
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Figure 6.2: Schematic representation of the recombinant baculovirus particle interacting with an
hypothetical infinite flat plate: the ion-exchange surface is assumed as an infinite plate; for clarity,
the baculovirus particle is simplified as compared to Fig. 6.1.
(Bhattacharjee and Elimelech, 1997), one obtains
U+,v(α = pi/2) = f1 × 2pi
∫ Ri
0
Ψv,apex
[
D1 +Ri −Ri
(
1− r
2
R2i
) 1
2
]
rdr
+ 2× LRj
∫ pi
2
0
Ψv,rod(D2 +Rj −Rj cos θ)dθ
+
1
2
× 2pi
∫ Rj
0
Ψv,base
D2 +Rj −Rj (1− r2
R2j
) 1
2
 rdr. (6.2)
where U+,v is the interaction energy between the side of the rBV particle in study facing the
flat plate and the plate itself, v refers to each of the four different species defined in the first
column of Table 6.1; D1 and D2 are, respectively, the distances of closest approach between
the plate surface and the top sphere surface and the plate surface and the cylindrical or
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base surfaces. For v = rBVi and v = rBVe.c., f1 = 135/180, i = 1 and j = 2 (i and j
being an index of the parameter R in Table 6.1); for v = rBVgp64− , f1 = 135/180, i = 1’
and j = 2; for v = rBVenv− , f1 = 1/2, i = 3 and j = 3. The contribution for the total
interaction energy between the side of the particle opposite to the flat plate and the flat
plate has an analogous form, U−,v, given by
U−,v(α = pi/2) = f1 × 2pi
∫ Ri
0
Ψv,apex
[
D1 +Ri +Ri
(
1− r
2
R2i
) 1
2
]
rdr
+ 2× LRj
∫ pi
2
0
Ψv,rod(D2 +Rj +Rj cos θ)dθ
+
1
2
× 2pi
∫ Rj
0
Ψv,base
D2 +Rj +Rj (1− r2
R2j
) 1
2
 rdr. (6.3)
The resulting interaction energy is Uv(α = pi/2) = U+,v(α = pi/2) − U−,v(α = pi/2).
As the particle contains only one symmetry axis (positioned on the longitudinal axis) one
needs to take into consideration the possible orientations at the instant of interaction. The
three pivotal orientations are: (i) α = 0, when the particle has its apex facing the plate;
(ii) α = pi, for the opposite orientation; and, (iii) α = pi/2, when the particle is parallelly
aligned with the plate. The interaction energy is a function of α according to Eq. 6.1.
Complying with the above motivation and for simplicity, herein we calculate the interaction
energies for the three characteristic α angles, 0, pi/2 and pi, and interpolate for α ∈ [0,pi/2]
and α ∈ [pi/2,pi]. For α = 0, the analogous forms of Eqs. 6.2 and 6.3 become
U+,v(α = 0) = 2pi
∫ Ri
0
Ψv,apex
[
D1 +Ri −Ri
(
1− r
2
R2i
) 1
2
]
rdr (6.4)
and
U−,v(α = 0) = f2 × 2pi
∫ Ri
0
Ψv,apex
[
D1 +Ri +Ri
(
1− r
2
R2i
) 1
2
]
rdr, (6.5)
assuming that only the apex structure has a significant contribution to U , f2 is 1/2 for
rBVi, rBVe.c. and rBVgp64− , and 1 for rBVenv− . The resulting interaction energy is Uv(α =
0) = U+,v(α = 0)− U−,v(α = 0). For α = pi, one obtains
U+,v(α = pi) =
1
2
× 2pi
∫ Rj
0
Ψv,base
D2 +Rj −Rj (1− r2
R2j
) 1
2
 rdr, (6.6)
where Uv(α = pi) = U+,v(α = pi), as only the half-sphere surface of the base structure is
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considered for the interaction contribution in agreement with Eq. 6.1.
To calculate these contributions, expressions for the interaction energy per unit area,
Ψv, between the two surfaces need to be established. An exact expression for the interaction
energy derived from the solution of the linearized Poisson-Boltzmann equation, valid for
small potentials (φ < 25 mV), is given by (Hogg et al., 1966)
Ψv(h) =
&r&0κ
2
(φ2v + φ
2
p)
[
1− coth(κh) + 2φvφp
φ2v + φ2p
cosech(κh)
]
, (6.7)
where &0 is the permittivity of free space, &r is the dielectric constant of the external
medium and κ is the inverse Debye length. Ψv is a function of the distance h between the
two surfaces which is defined according to the schematic presented in Fig. 6.2 and spelt in
terms of r and θ as shown in the arguments of the Ψv functions in Eqs. 6.2 and 6.3; Ψv is
estimated using Eq. 6.7 provided that the surface potentials of the two surfaces experiencing
interaction are assumed constant; φv and φp stand for the specific rBV particle species and
flat plate surface potentials, respectively.
6.1.3 Relationship between interaction energy and chromatogra-
phic retention
In order to compare the chromatographic retention of rBVi particles and their product-
related impurities one can assume that the adsorption of these biological solutes is partly
due to their accumulation in a diffuse layer close to the stationary-phase surface (defined
above as the hypothetical flat plate) (Staahlberg, 1994). A detailed treatment of the
thermodynamic interpretation of the capacity factor (or retention factor), k′, for distance-
dependent interactions has been presented previously in the literature (Staahlberg, 1994;
Okada, 1999, 1998). k′v is defined as
k′v =
tv − t0
t0
, (6.8)
where v is the index corresponding to each of the biological particles studied, tv and t0
are the retention times of the species v and the void peaks, respectively. As derived by
Ståhlberg (Staahlberg, 1994)
k′v =
AS
V0
∫ κ−1
h
[
exp
(
− Uv
RT
)
− 1
]
dx, (6.9)
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where Uv is the free energy associated with transferring the solute v from a point in the
bulk solution assumed here at a boundary distance κ−1, which represents the medium
Debye length, to a distance h separating the two surfaces, AS and V0 are the area and void
volume of a given stationary phase, respectively. κ is calculated using
κ =
(
2× 1000e2NAI
&r&0kT
) 1
2
, (6.10)
where I is the ionic strength (in mol.L−1) of the buffer, e is the elementary charge, NA is
the Avogadro’s number, k is the Boltzmann constant and T is the absolute temperature.
Eq. 6.9 allows to estimate a critical ion-exchange chromatography parameter as a function
of the interaction energy calculated in Eq. 6.1, assuming that the EDL contribution is a
determining factor for the sorption behavior —hence, retention— of the different particles.
Under this hypothesis, the ratio of the capacity factor between any of the impurities (imp.)
and rBVi becomes
k′rBVimp.
k′rBVi
=
∫ κ−1
h
[
exp
(
−UrBVimp.RT
)
− 1
]
dx∫ κ−1
h
[
exp
(
−UrBViRT
)
− 1
]
dx
. (6.11)
Eq. 6.11 is a measure of the selectivity that would be obtained in a bind-elute ion-exchange
process.
6.1.4 EDL potential
Let us now consider the determination of φ of the different rBV species, φv, at defined
buffer conditions (ionic strength and pH). These viruses can be considered colloid-sized
particles, and, therefore, treated as charged particles with geometric characteristics listed
in Table 6.1 immersed in an infinite medium with a characterized inverse Debye length,
κ, surrounding its surface (Schaldach et al., 2004, 2006; Loveland et al., 1996). At small
potentials, the linearized version of the Poisson-Boltzmann equation can be used to predict
φv outside the rBV particle surface (Schaldach et al., 2006):
φv(δ) = Φv
Rk
Rk + δ
exp(−κδ) 1
1 + κRk
, (6.12)
where k is the radius’ index listed in Table 6.1 and δ is the distance from the particle
surface. The average surface potential Φv considering the charges within the particle is
given by:
Φv =
1
N
N∑
m=1
[∑
n
qn
&rmn
exp
(−rmn
λ
)]
, (6.13)
171
CHAPTER 6. Modeling electrostatic interactions of baculovirus vectors for ion-exchange process development
where qn is an elementary charge (amino acid, lipid or DNA), rmn is the distance from
that charge to the surface point, m, λ is the effective screening length due to compensating
ions within the viral particle and N is the total number of m surface points considered for
the calculation. This means that this model takes into account the presence (or absence)
of the charges within the rBV particle. Eq. 6.12 allows for the estimation of the potential
at specific conditions of ionic strength (impacting κ) and pH (impacting Φv). Two key
points are: δ = 0, producing φv included in the definition of Ψv due to the electrostatic
double-layer effect; and, δ = κ−1 producing an estimation of the ζ potential as measured
by DLS.
As stated before (summarized in Table 6.1), critical interaction players can be assigned:
gp64 trimers, envelope, capsid and the viral dsDNA. We thus need to establish expressions
to account for the different qn charges considered for the summation in Eq. 6.13. Concomi-
tantly, n comprises four sets of charges: n1, n2, n3 and n4 corresponding to the number
of elementary charges due to the gp64 trimers, lipidic envelope, capsid protein, and viral
dsDNA molecule, respectively.
gp64 trimers potential
The structure of the gp64 trimers has been recently published (Kadlec et al., 2008). From
the Å-level resolution, Kadlec et al. (Kadlec et al., 2008) defined five main protomer
domains (PDB ID code 3duz); herein we assume domain II and domain IV extended with
10 residues from the connected domain III portion (5 residues) and domain V (5 residues)
(accounting for the 4 charged residues in this close vicinity) as the most exposed polypeptide
sequences to the external medium where the ion-exchange interactions should be governed.
From the polypeptide sequence of the gp64 protein (Combet et al., 2000; Kadlec et al.,
2008), three separate polypeptide sequences can thus be highlighted: 44-60 and 218-271
(we indicate as region I), and 374-418 (we indicate as region II). Table 6.2 contains the
content in charged residues for each of these regions and ionization constants in order to
scrutinize the pH influence.
There is no available study assessing the average number of gp64 trimers per rBV
particle. The mean infected Sf9 cell diameter (18-20 µm) (Palomares et al., 2001; Gotoh
et al., 2008) and the number of trimers per cell has been estimated to be approximately
1.3×106 trimers.cell−1 (Monsma et al., 1996); additionally, from the baculovirus dimensions
described, the fraction of envelope surface holding gp64 trimers is around 0.24. Thus, to
account for this heterogeneity, the gp64 trimers should be localized on the cell membrane
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Table 6.2: Charged amino acid residues in exposed polypeptide sequences of gp64 (Kadlec et al.,
2008) and acid dissociation constants.
Amino
acid
Number charges
per region I
per gp64
monomer
(44-60 +
218-272)
Number charges
per region II per
gp64 monomera
(374-418)
pKab
Glutamate 3 + 2 3 4.5
Aspartate 2 + 5 5 4.5
Arginine 0 + 4 1 13.0
Lysine 2 + 7 2 10.1
aconsidering the residues 414-418 from the domain V we assume being critical due to the number of charged
residues (Asp414, Asp415, Asp416 and Glu418 out of the five); bequilibrium constant estimated for amino
acids embedded in a polypeptide chain (Cantor and Schimmel, 1980)
Figure 6.3: Assignment of charge locations of the selected gp64 regions for the gp64 trimer model
defined in Fig. 6.1 and Table 6.1: the origin 0 is the point over the outer lipid layer surface of the
rBV envelope; it is assumed that approximately 5 nm of the gp64 trimer is buried into the envelope
and that regions I and II have their punctual locations (for simplicity) at 5 and 10 nm from the
envelope.
at condensed regions (1/0.24) before viral budding. Under this assumption the number
of gp64 trimers becomes approximately 96 per rBV particle whose effective area (apex
surface) is 0.024 µm2 out of the total surface area of 0.097 µm2. This number of trimers
is in good agreement with data from other enveloped viruses: e.g. γ-retroviruses contain
approximately 100 trimers per retrovirus particle, a result from a cryo-electron tomography
study (Forster et al., 2005).
With the described physicochemical data, Eq. 6.13 can then be used to quantify the
contribution of gp64 for the average potential Φv.
Viral envelope potential
The baculovirus envelope is derived from the insect cell membrane by budding. An exten-
sive biochemical analysis of the AcMNPV has been performed providing the lipid compo-
sition of the budded baculovirus envelope (Braunagel and Summers, 1994): 62.5±9.2 % in
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acidic lipids (50.2±7.7 % phosphatidylserine (PS) + 12.3±1.4 % phosphatidylinositol (PI))
and 37.5±13.8 % in zwitterionic lipids (5.9±3.9 % lysophosphatidylcholine + 13.2±2.2 %
sphingomyelin + 10.7±1.8 % phosphatidylcholine + 7.6±6.0 % phosphatidylethanolamine).
Nevertheless, there is no additional information regarding the positioning of the acidic lipids
on the lipid bilayer of the baculoviruses. The literature is convergent in that negatively
charged lipids, e.g. PS, are typically located on the inner leaflet of biological lipid bilayers
(plasma membranes (Yeung et al., 2008) and HIV envelopes (Brugger et al., 2006) although
differing in overall composition) and that this lipid orientation is markedly linked with bi-
ological functions such as the interactive role with cytosolic proteins and/or formation of
endosomes or liposomes (Yeung et al., 2008). Moreover, in the case of HIV, consistent ev-
idence holds lipid rafts as precursors of the viral envelope (Brugger et al., 2006); however,
it is still not clear as to how universal this would be (Brugger et al., 2006). Therefore, with
the limited structural information available a simplified approach will use here where the
expected overall negative charge is assumed to be due to the presence of the acidic lipids
spread mostly over the inner lipid leaflet.
The calculation of the electrostatic potential of lipid bilayers has been addressed in the
literature using either the non-linear or linear version of the Poisson-Boltzmann equation
(Arakelian et al., 1993; Peitzsch et al., 1995). Following the purpose of this work and
in line with the rationale above, we will assume that the inner side of the lipid bilayer is
composed exclusively of negatively charged lipids (PS and PI altogether) and the outer side
is composed of 25 % negative lipids and 75 % neutral lipids according to the remaining lipid
composition. The effect of the unknown insect cell-derived membrane proteins and gp64 or
cholesterol are assumed to be negligible to the overall electrostatic potential of the envelope
per se. Furthermore, it has been shown that the potential on the outer lipid leaflet suffers
a weak impact regardless of the potential sensed in the inner leaflet (Peitzsch et al., 1995;
Arakelian et al., 1993); hence, the contribution to Φv in Eq. 6.13 is calculated depending
only on the number of negative charges smeared uniformly over the outer envelope surface.
Viral capsid potential
To account for the viral capsid contribution to the overall potential the same strategy
described in the gp64 trimers section is used to the major capsid protein, vp39. Only in
this case, there is no detailed structural data specifically indicating the exposed amino acid
residues in the vp39 protein; little knowledge is also available on the structural assembly of
the capsid rather than that there is a number of other proteins in a much lower proportion
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(Braunagel and Summers, 1994). As such, we consider the balance of the total number of
charged residues of the vp39 polypeptide and take the resulting charge scattered uniformly
over the surface of the capsid (Asp # + Glu # = 37 and Arg # + Lys # = 35 resulting
in an excess of two negatively charged residues) (Thiem and Miller, 1989).
Viral dsDNA potential
As done by others (Schaldach et al., 2006), the viral dsDNA is assumed in this formalism
as a cylindrical continuum having its negative charge density σDNA (number of base pairs
per cylindrical volume) divided into volume elements dqDNA ≈ σDNA∆V , where ∆V is a
specified finite volume considered for the calculation.
6.2 Materials and methods
6.2.1 Cell culture, rBV stock propagation and production
Sf9 insect cells (ECACC #89070101, UK) were routinely grown in GibcoTM Sf-900 II SFM
(serum-free) culture medium (Invitrogen, Paisley, UK) using spinner (stirred at 150 rpm
in a magnetic stirrer) or Erlenmeyer vessels (shaken at 110 rpm in an orbital shaker)
at 27 ◦C. Cell concentration and viability were routinely assessed by haemocytometer
(Brand, Wertheim, Germany) with cell viability evaluated by 0.4 % trypan blue exclusion
dye (Merck, Darmstadt, Germany) in phosphate-buffered saline.
The vector used, rBV-green fluorescent protein (GFP), encodes for the baculovirus
major structural capsid protein, vp39, containing on its N-terminal a GFP protein reporter
(Kukkonen et al., 2003). Stock aliquots of rBV-GFP were produced in Sf9 cells grown in
a 25 L working volume wavebag bioreactor (Wave Europe, Cork, Ireland) using Sf-900 II
medium. Sf9 cells were infected at a viable cell concentration at infection of 1 − 2 × 106
cells.mL−1 using an MOI of 0.1 pfu.cell−1. Cell viability and cell infection were monitored
for five days post infection. Quantification of the infected cells during the process was done
by flow cytometry assessing GFP-expressing cell populations using a CyFlowTM Space
flow cytometer system (Partec, Münster, Germany). Data analysis was done using the
manufacturer’s acquisition software FlowMaxTM (Partec). The rBV production bulk was
harvested when the cell viability reached values of 50 %. Production bulks were clarified
as described elsewhere (Vicente et al., 2009).
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6.2.2 Purification of rBVi, rBVe.c., rBVgp64− and rBVenv−
Infective baculovirus particles (rBVi), the target product, were purified by ultracentrifu-
gation based on sucrose density gradients (Airenne et al., 2000) yielding standard rBVi
stocks. Briefly, primary clarification and concentration was conducted by depth-filtration
and tangential flow filtration using conditions recently described (Vicente et al., 2009).
3-µm retention Sartopure PP2 filter capsules followed by 0.65-µm retention Sartopure PP2
filter capsules were operated in series. Tangential flow filtration was run on an ÄKTAcross-
flow system controlled by the UNICORNTM software (all GE Healthcare, Uppsala, Sweden)
with a 200 cm2 HydrosartTM membrane with 100 kDa nominal molecular weight cut-off
(MWCO) (Sartorius Stedim Biotech) at 35 mL.min−1 retentate flow rate and a trans-
membrane pressure of 1.2 bar; buffer exchange to D-PBS was conducted by continuous
diafiltration as described elsewhere (Vicente et al., 2009).
rBV concentrated stocks were transferred into ultracentrifuge tubes on top of two dis-
crete sucrose density layers: 8 mL of 50 % (w/v) and 6 mL of 20 % (w/v) sucrose in D-PBS
(bottom) sucrose in D-PBS; the tubes were centrifuged at 100 000 g for 1 h at 4 ◦C. The
virus bands were pooled resuspended into 35 mL of ice-cold D-PBS, transferred into ultra-
centrifuge tubes containing 3 mL of 25 % (w/v) sucrose in D-PBS and centrifuged as above.
The concentrated virus buffer was exchanged to D-PBS using a prepacked HiPrepTM 26/10
desalting column coupled to an ÄKTAexplorer system (all GE Healthcare, Uppsala, Swe-
den). Sterile microfiltration of final material was performed using AcrodiscTM Syringe
Filters with SuporTM PES membrane (Pall, New York, USA) before storage at 4 ◦C in the
dark.
Concerning the CsCl gradient method, a similar protocol was followed (described for
sucrose gradient). Briefly, the first ultracentrifugation was made with two discontinuous
CsCl layers: 8 mL of 34.0 % (w/v) CsCl in D-PBS (1.23 g.mL−1, η = 1.3572) and 6 mL
of 19.3 % (w/v) CsCl in D-PBS (1.11 g.mL−1, η = 1.3455); the second ultracentrifugation
resolved a continuous CsCl self-gradient using 20 mL of 27.7 % (w/v) CsCl in D-PBS
(1.17 g.mL−1, η = 1.3514).
Purified rBVi preparations were subjected to enzymatic digestion using subtilisin (Sigma-
Aldrich, Steinheim, Germany) to produce rBVgp64− or lipid removal using Triton X-100
(Sigma) to produce rBVenv− . Concentrated subtilisin stock was added to the purified par-
ticles in a final subtilisin concentration of 1 mg.mL−1. The incubation was carried out for
2 h at 37 ◦C, after which 5 µg/mL of PMSF (Sigma) was added to suppress the protease;
the material was stored at 4 ◦C in the dark until use. Lipid removal of the rBV particles
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was performed by addition of a concentrated stock of 20 % Triton X-100 to achieve final
concentration of 0.5 % (v/v), followed by incubation of the samples at 37 ◦C for 30 min.
The number of genome containing particles was quantified by real-time PCR (qPCR)
following the protocol in Vicente et al. (Vicente et al., 2009). Viral DNA was extracted
and purified using the High Pure Viral Nucleic Acid Kit (Roche Diagnostics, Mannheim,
Germany) using the manufacturer instructions. Infective virus titers (IP) were determined
with a flow cytometer-based assay (for rBVs-GFP) as developed by Kärkkäinen et al.
(Karkkainen et al., 2009). Briefly, 500 µL of Sf9 cell suspension at 1.5 × 106 cells.mL−1,
seeded into 2.2 mL 96-well plates (ABgene Limited, UK), were infected with 500 µL of
serial rBV sample dilutions. After incubating the plates at 27 ◦C for approximately 18
h in a shake flask orbital shaker at 420 rpm, cell suspensions were directly submitted to
flow cytometer analysis using a 96-well plate autosampler (Partec) serially feeding each
sample to the flow cytometer for GFP-expressing cell population assessment (Karkkainen
et al., 2009). The maximum GFP-expressing cell population percentage (corresponding to
a non-diluted viral sample) was used as a normalization factor for reliable titer calculation
(Mulvania et al., 2004; Karkkainen et al., 2009).
Cholesterol content of the samples was measured using the AmplexTM Red cholesterol
assay kit (Molecular Probes, Eugene OR, USA) and DNA was measured using the Quant-
iTTM DNA assay kit (Molecular Probes).
6.2.3 Dynamic light scattering analysis
Hydrodynamic size estimations of rBV particles were obtained by dynamic light scatter-
ing (DLS) using a Zetasizer Nano-ZS Series ZEN3600 equipped with a 633 nm He-Ne
laser (Malvern, Worcestershire, UK). Viral samples were diluted 25– to 60–fold in D-PBS;
size measurements were performed in polystyrene cuvettes. Bovine serum albumin (BSA)
(Merck) diluted in D-PBS was used as a control experiment. The rendered experimental
correlation functions from DLS were analyzed by the CONTIN method to obtain distri-
butions of decay rate profiles which provided distributions of apparent diffusion coefficient
and, consequently, of the apparent hydrodynamic diameter (through the Stokes-Einstein
equation). Replicates with over 20 % deviation were neglected. Before data acquisition,
the instrument software automatically optimizes operational conditions such as signal at-
tenuation, focal distance and number of scans.
ζ potential profiles at different pH were determined after measuring the electrophoretic
mobility of the viral particles and application of the Smoluchowski approximation of the
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Henry equation (Hiemenz and Rajagopalan, 1997). Electro-osmosis is avoided by applica-
tion of a serial slow field reversal and a fast field reversal (phase analysis) allowing for the
detection of very low electroforetic mobility of the scattering particles. Measurements were
conducted in 10× 10 mm polystyrene cuvettes using a dip cell (Malvern) at 25 ◦C.
6.2.4 Modeling calculations
The estimation of the EDL potential, φ, specific of the different rBV species, φv, at given
ionic strength and pH were calculated using MicrosoftTM Excel (Microsoft, Redmond WA,
USA). To account for the three different sets of m points defined as described in the Intro-
duction section —apex, cylindric and base surface m points—, the summations expressed
in Eq. 6.13 were computed using a macro written in Excel to estimate Φ and further in-
corporated in Eq. 6.12 to calculate φ at a chosen δ. To determine the interaction energy
between the different rBV species and the putative flat plate, the integrals expressed in
Eqs. 6.2-6.6 were computed in MathematicaTM (Wolfram Research, Oxfordshire, UK) using
the φ values obtained and assuming a constant 25 mV potential for φp.
6.3 Results and discussion
6.3.1 EDL potential
As mentioned (see Eq. 6.13), three m points sets were assumed to establish the summation
of the four distinct n charges (the gp64 two regions, n1; the envelope, n2; the capsid n3;
and the DNA, n4): m1, a point over the apex surface; m2, a point over the cylindrical rod
surface; and, m3, a point over the base surface. After fixing these points, the different rmn
lengths were computed using the geometric features illustrated (Fig. 6.1) and characteristic
dimensions (Table 6.1). DLS was used to perform hydrodynamic size measurements of
the different particles studied. These measurements indicated that particle aggregation
did not occur (>600-800 nm) while providing a close agreement between the described
characteristics (Table 6.1) and experimental results: for rBVi, a bimodal distribution was
observed at 110 ± 20 nm × 300 ± 100 nm; for rBVenv− , the first peak of the distribution
was shifted to 70± 20 nm× 300± 100 nm (data not shown). Unfortunately, one does not
have sufficient accuracy with this technique to distinguish rBVi from rBVgp64− or rBVe.c..
For simplicity of calculation, symmetry elements were assigned for the three regions:
a 135/180 circle slice of the apex region (passing through the axis) defining characteristic
ni points within that slice (producing the whole apex surface by a 180o rotation); a line
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of length L on the rod surface for ni points within that region (producing the whole rod
surface by a 360o rotation); and a semi-circle slice of the base region for ni points in the
base surface (producing the whole base surface by a 180o rotation).
To account for the pH impact on the charged amino acid residues or COOH groups of
the negatively charged lipids, the charge ξi of a certain species i was calculated using:
ξi = ξi,0 +
10−(pH-pKa)
1 + 10−(pH-pKa)
(6.14)
where ξi,0 is the charge of the species at pH > pKa.
Fig. 6.4a shows the behavior of the potential Φv calculated at a distance δ = κ−1
providing an estimation of the ζ potential. It is clear that using the amino-acid compo-
sition of the gp64 trimers and vp39 as theoretically proposed in the previous section, the
simulated ζ potential profiles mispredict the order of magnitude and point of zero charge
experimentally obtained by DLS (see Fig. 6.4a). Indeed, by trial-and-error, it was observed
that including in the calculation more arginine and lysine residues in the region I of gp64
belonging to neighboring regions, the fitting considerably improved, particularly at low
pH values. Hence, additional candidate external residues responsible for the interaction
are proposed; the final result is illustrated in Fig. 6.4b showing a reasonable agreement
between this prediction and the overall experimental data obtained. This fine-tuning pro-
cess allowed to use more reliable EDL potential data permitting further interaction energy
analyses.
By examining Fig. 6.4b, the simulated potential curves for rBVi and rBVe.c. overlap
indicating that the contribution of the DNA inside the enveloped particle is negligible
for the overall potential of the particle. As only short-range electric double layer-type
interactions are being addressed, it is expectable that the effect of DNA charges are no
longer effectively sensed at the surface of the particle. Such observation concurs with a
previous report showing that the RNA of a non-enveloped virus (Norwalk virus) is ruled
out by compensating ions with the used ionic strengths due to the thickness of the viral
coat (Schaldach et al., 2006). The data obtained by DLS for rBVe.c. shows a different
behavior compared to the simulated curve especially in what concerns the point of zero
charge, although this may be due to the technical difficulty in obtaining quality data at
values of ζ potential close to zero using this technique.
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Figure 6.4: Comparison between simulated mean particle potential Φv based on the model imple-
mented at a distance δ = κ−1 and experimental ζ potential measurements by DLS at a fixed ionic
strength, I = 25mM: (a) potential calculated using the amino-acid information shown in the Ma-
terials and methods section; (b) potential calculated altering the positive amino-acid composition
of the gp64 region II (see Fig. 6.3) (Arg # = 7 and Lys # = 5) and considering only a fraction
of the constitutive vp39 amino-acids (Asp+Glu # = 8; Arg # = 3; Lys # = 3).
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6.3.2 Interaction energy
Interaction energies were calculated assuming a putative DEAE ion-exchange surface whose
positive constant potential is normalized to 25 mV and adjusted according to the character-
istic titration curve of DEAE as a function of pH. A reference 2 nm distance, h separating
the particle and the surface was assumed in the calculations as done elsewhere (Schaldach
et al., 2006). These simplifications were taken so that one could tackle the electrostatic
behavior of these very complex biologics in a more expedite way. The approximations
and assumptions made upon the formulation of the model recombinant baculovirus par-
ticles studied do bring themselves uncertainty; thus, this simplified model should be still
instructive in pinpointing the best selectivity regions in terms of ion-exchange processing.
The constant potential values were estimated based on the adjusting process shown in
the preceding section, using the conditions set for Fig. 6.4b. The effect of ionic strength,
impacting the Debye length of the particle, is shown in Fig. 6.5 at different orientations.
When the baculovirus particle apex is facing the charged surface, i.e., with α = 0, the free
energy of interaction tends to a negative maximum, indicating that the contribution of the
gp64 glycoprotein trimers is prominent to the overall net negative surface charge; at the
opposite orientation, i.e., with α = pi, only the envelope surface of the tip of the particle
has a significant contribution to the overall interaction energy, which is considerably lower
in absolute terms than that with α = 0. Fig. 6.6 shows a perspective of the influence
of pH and ionic strength on the interaction energy at the three key orientations; one can
observe that at α = pi, the order of magnitude of the interaction energy is strikingly re-
duced in comparison to the other two orientations. Based on this deterministic analysis,
the thermodynamically most favorable positioning of the baculovirus particle undergoing
an electrostatic interaction with a surface of opposite charge is at α = 0. Nonetheless, in a
chromatographic matrix, the three-dimensionality and flux of material inside the stationary
phase may cause a distribution of interaction positions rather than a specific orientation.
Moreover, as shown in Fig. 6.5, the interaction energy is still highly negative at the flat po-
sition (α = pi/2) suggesting a favorable interaction; this can be observed in Figs. 6.6a and b;
the shape of the diagrams is very similar.
To compare the electrokinetic behavior of the desired product, rBVi, and the considered
product-derived impurities, we defined a segregation coefficient, s, as
s =
log10
(
UrBVimp.
UrBVi
)
for U
rBVimp.
UrBVi
> 0
−2 for UrBVimp.
UrBVi
< 0
, (6.15)
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Figure 6.5: rBVi particle – putative DEAE surface interaction energy calculated using the trained
model implemented (see Text) at the following conditions: (a) varying ionic strength and particle
orientation (α angle) at fixed pH=7.4; (b) varying pH and particle orientation (α angle) at fixed
I = 25 mM.
where U rBVimp. is the closest impurity interaction energy to the rBVi interaction energy,
U rBVi . As shown in Eq. 6.15, when the two interaction energies have opposite signals,
for simplicity of representation U rBVimp./U rBVi is computed by 10−2, which means that
the impurity and the desired product are completely segregated based on their interac-
tion energies, i.e., only one of them interacts favorably with the ion-exchange surface.
Figs. 6.7a and b allows to detect the windows of more pronounced interaction differences
therefore predicting the zones of better selectivity as far as a bind-elute anion-exchange
phenomenon is concerned. As seen before, the rBVe.c. impurity has the same interaction
energy based on the model used herein, hence this species is not included in this assessment.
Moreover, this segregation coefficient can be compared to a selectivity based on the
chromatographic retention factors using Eq. 6.11, which relates directly the EDL contri-
bution to adsorption with a hypothetical DEAE ion-exchange bind-elute chromatographic
process. Figs. 6.7c and d show analogous plots to Figs. 6.7a and b, respectively. Both
segregation and selectivity factors calculated seem to follow the same trend, however, the
selectivity factor does not seem to be as sensitive for pH > 6.5. From our experience in
processing these biological particles, this insensitivity is unrealistic which could be due to
the fact that only electrostatics are taken into consideration as shown in the simplifications
considered (see Introduction section); size-exclusion, chromatographic matrix properties
and ligand orientation/density or repulsion effects may play a role as well. At the two
favorable orientations, α = 0 and α = pi/2, when rBVi is expected to bind to the ion-
exchange surface, it can be seen in Fig. 6.7a and b the regions where s→ 0, meaning that
the closest impurity in terms of interaction energy should have the same type of behavior
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Figure 6.6: Ionic strength and pH effect over the rBVi particle – putative DEAE surface inter-
action energy calculated using the trained model implemented (see Text) at fixed (a) α = 0; (b)
α = pi/2; and (c) α = pi particle orientations.
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Figure 6.7: Effect of particle orientation, ionic strength and pH on the logarithm of the ratio
rBVi/closest product-related impurity interaction energy and on the selectivity factor based on
chromatographic retention (see Text): (a) and (c) α = 0; (b) and (d) α = pi/2; rBVe.c. particles
are not considered in this analysis.
in an ion-exchange process, thus compromising the selectivity. This is predicted to occur
for pH within the range of 4.7–6, irrespective of the ionic strength used. The region of pH
within 6.5–9, and I within 0.01–0.05 M seems to be the best working region where s < 0
and k′rBVimp./k
′
rBVi → 0, indicating that the rBVi particles present a higher predicted in-
teraction energy as compared to all the product-derived impurities. Regardless of particle
orientation, regions of complete segregation, s = −2 (opposite signal values) or very low
k′rBVimp./k
′
rBVi , can be detected at pH < 4.5; nevertheless, these conditions are impractical
due to gp64 stability issues at pH values lower than 6 (Monsma et al., 1996). Overall,
this information based on electrokinetic behavior can be used to narrow the experimenta-
tion space on a design of experiments approach for an anion-exchange bind-elute process
optimization task.
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6.4 Concluding remarks
This paper reports on the use of electrokinetic fundamentals as a means to understand/mea-
sure the ion-exchange-type of interactions undergoing between baculovirus vectors (and
baculovirus-derived impurities) and a putative DEAE surface. Using ζ potential measure-
ments through DLS, a structural model for the particles (product and impurities) was
proposed and fine tuned based on the fundamental biological components and calculated
the electrostatic potential and corresponding free interaction energy defined between the
whole virus particle and the charged surface at a chosen distance. In the context of ion-
exchange purification processes for the recovery of infective virus particle from damaged
baculovirus particles, the impact of ionic strength and pH on the overall interaction energy
have been addressed.
This rationale permitted to study the selectivity issue by overlaying the interaction
behavior of the studied species; a segregation coefficient and a chromatography retention-
based selectivity were used to this purpose to predict the best window of operation in a
bind-elute anion-exchange chromatography process. Such information is critical for a more
rational and cost-effective development of the ion-exchange process which is now underway.
Overall, the gp64 trimers covering the head of the baculovirus particles are expected to
be highly determinant to the overall charge of the particle surface while the presence of
dsDNA does not significantly influence the behavior of the enveloped structure. Indeed, the
infective particles are expected to be more negatively charged than their related impurities
within these conditions. This study contributes with guidelines to help decrease the ratio
of total particles to infective particles using an anion-exchange chromatographic step.
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Abstract
The effect of ligand density on anion-exchange membrane chromatography (AEXmc) for
the purification of recombinant baculoviruses (rBVs), potential viral vectors in clinical
applications, is studied by surface plasmon resonance on customized AEX surfaces and
gradient elution experiments on Sartobind D membrane prototypes with different diethy-
lamine ligand densities, complemented by dynamic light scattering analysis for estimation
of the hydrodynamic particle size of the various biologicals. A chromatographic-column
model based on the steric mass action model of ion exchange is employed to analyze the
gradient-elution AEXmc experiments, extrapolate the results to other operating condi-
tions, and provide directions for process improvement. Although counterintuitively, the
experimental evidence provided in this paper shows that the lowering of ligand density is
beneficial for rBV purification by AEXmc in bind-and-elute mode, because it decreases the
residual concentrations of host cell protein, dsDNA, and non-infective rBVs in the eluted
product cut, and increases the overall yield by roughly 20% over current standard values.
Overall, we present a case study on how rational design can streamline downstream process
development.
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7.1 Introduction
The development of scalable processes has been identified as critical for the generation of
recombinant viral vectors for clinical applications (Wu and Ataai, 2000). The increasing
number of pre- and clinical trials urges for larger amounts of highly pure (often challenging,
labile) biological material (Rodrigues et al., 2007; :20, 2009). Still, many downstream
processing teams in the industry and academia frequently resort to ultracentrifugation-
based purification steps to generate their viral stocks; these are typically costly, non-cGMP
amenable and not easily scalable. To circumvent this, ion-exchange (IEX) chromatography,
which is scalable and cGMP compliant, is becoming the process of choice for the recovery
of not only recombinant proteins or vaccines, but also viral vectors (Peixoto et al., 2008;
Vicente et al., 2008, 2009; Opitz et al., 2007; Rodrigues et al., 2006; Okada et al., 2009).
The issue then is to find an efficient means for the optimization of this preferred process.
Charge-dependent unit operations rely on the evaluation of key operating parameters,
such as ionic strength and pH of the suspension buffer. These procedures tend to become
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highly costly when a high added-value product is recovered from a complex preparation,
such as an animal-cell-derived bioreaction bulk. In order to save time and reduce costs,
scaled-down models are often used as economic and convenient tools for early stage process
development (Coffman et al., 2008; Rege et al., 2006; Wensel et al., 2008). For example,
we have recently employed surface plasmon resonance (SPR) as a scaled-down chromato-
graphic tool to measure the adsorption equilibria and kinetics of complex biologicals on a
micrometric surface functionalized with ion-exchange ligands, mimicking an ion-exchange
matrix (Vicente et al., 2010b,a). Additionally, it has been shown that dynamic light scat-
tering (DLS) provides useful information for selecting the correct operating window when
a bind-and-elute chromatographic process is envisaged (Vicente et al., 2010c). To comple-
ment these analytical tools, good modeling tools are also required for a more sound design of
the actual purification process. For instance, the steric mass action model of ion exchange
(Brooks and Cramer, 1992) has been employed in concert with a standard chromatographic-
column model to simulate and predict with reasonable accuracy VLP binding and elution
in anion-exchange membrane chromatography (AEXmc) (Vicente et al., 2008).
Membrane chromatography matrices have important advantages over resin-based ma-
trices (Teeters et al., 2002), e.g.: (i) convection is the prevailing mass transport mechanism
in membrane adsorbers with nearly no diffusion limitation, which improves the chromato-
graphic kinetics and imposes less constraints on the flow rates; (ii) the ligands bound to the
membrane surface are accessible to very large biologicals (e.g., virus particles) with small
diffusivities, which are excluded from the intra-bead pores of a typical resin bead; (iii)
membrane chromatography is easy to scale-up because of the significant level of flexibility
in flow rate selection; (iv) because membrane chromatography capsules are designed for
disposable operation, they are simple to use without the need for cleaning, sterilization
and validation. These advantages led to a number of reported application studies on vac-
cine/viral vector purification by membrane chromatography operated in a bind-and-elute
mode (Vicente et al., 2008, 2009; Wu et al., 2007; Kutner et al., 2009).
The purification of recombinant baculoviruses (rBVs) is a challenging case study; these
viral vectors hold potential in human gene therapy or vaccination due to important (and
alternative) advantages over other more studied vectors as adeno- or retroviruses (Kost
et al., 2005; Airenne et al., 2009). An integrated strategy for rBV purification that is fully
based on scalable and cGMP compatible downstream processing steps has been reported
(Vicente et al., 2009). However, there is still room for improvement especially at the capture
step using AEXmc. It is not difficult to anticipate that a sensible selection of binding
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gel layer
matrix support
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Figure 7.1: Schematic representation of ligand density exclusion effect for large particles within
the gel layer of a cut of Sartobind D membrane adsorber cellulose matrix (Tatárová et al., 2009).
Here, rod-shaped baculovirus particles (120-350 nm) (Vicente et al., 2009) are used as an illustra-
tive example of the inability of a large particle to have to access to the ligand groups within the
depth of the gel layer.
conditions (pH and ionic strength) should result in process performance improvements.
Here we shall demonstrate that scaled-down analytical tools, such as SPR, are useful helpers
in this task.
A recent study shows that an exclusion effect occurs for very large molecules, with over
100 nm, when approaching the ligand sites functionalized within the gel layer covering a
commercially available membrane adsorber matrix backbone (Tatárová et al., 2009). This
effect is illustrated in the schematic of Fig. 7.1. We hypothesize that an excess in ligand
binding sites may be counterproductive for virus purification, because the excess sites will
favor the adsorption of process-derived impurities, such as host cell protein (HCP), host cell
dsDNA, and/or other smaller biologicals, over the virus particles themselves. Therefore,
the use of lower ligand densities than those found in commercially available membrane
units may yield improved purity without sacrificing the capacity of the binding step (for
the virus particle).
In the present work the effect of varying the ligand density on AEXmc using SPR-sensor
surfaces derivatized with diethylaminoethyl cellulose (DEAE) and Sartobind D membrane
prototypes grafted with similar diethylamine functional groups was studied. The hydrody-
namic particle sizes of the various biologicals were determined by dynamic light scattering
analysis. To validate the results, a design of experiments (DoE)-based approach was de-
vised to address the influence of ligand density, loading salt concentration, and elution
gradient length on the rBV purification by AEXmc. The steric mass action (SMA) model
of ion exchange is employed in concert with a chromatographic-column model to predict
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the performances of the capture and elution steps and to provide directions for process
improvement.
We provide evidence that the sensible reduction of ligand density to a level below those
of current commercial chromatographic membranes improves purity and quality of the final
eluted product fraction. In the present case, a rational optimization of the anion-exchange
chromatography step leads to improved yields as high as 85%, which is an improvement of
20% over the currently reported state-of-the-art values of around 65%. This work consti-
tutes a proof of concept on how the leverage of fundamental strategies can be implemented
to streamline downstream process development for complex biologicals.
7.2 Materials and methods
7.2.1 Cell culture and recombinant virus production
Sf9 insect cells (ECACC #89070101, UK) were routinely grown in GibcoTM Sf-900 II SFM
(serum-free) culture medium (Invitrogen, Paisley, UK) using spinner (stirred at 150 rpm
in a magnetic stirrer) or Erlenmeyer vessels (shaken at 110 rpm in an orbital shaker). Cell
concentration and viability were assessed by haemocytometer (Brand, Wertheim, Ger-
many) with cell viability evaluated by 0.4% trypan blue exclusion dye (Merck, Darmstadt,
Germany) in phosphate-buffered saline. The vector used, rBV-green fluorescent protein
(GFP), encodes for the baculovirus major structural capsid protein, vp39, containing on
its N -terminal a GFP protein reporter (Kukkonen et al., 2003). Stock aliquots of rBV-
GFP were produced in Sf9 cells grown in a 25 liter working volume wavebag bioreactor
(Wave Europe, Cork, Ireland) using Sf-900 II medium. Sf9 cells were infected at a vi-
able cell concentration of 1–2×106 cells.mL−1, using a multiplicity of infection (MOI) of
0.1 pfu.cell−1. Cell viability and cell infection were monitored for five days post infec-
tion. Quantification of the infected cells during the process was done by flow cytometry
assessing GFP-expressing cell populations using a CyFlowTM space-flow cytometer sys-
tem (Partec, Münster, Germany). The rBV production bulk was harvested when the cell
viability reached values of 50%.
Replication-defective adenoviruses type 5 (Ad5) were produced in 293 cells (ATCC–
CRL–1573) adapted to suspension and grown in CD293 supplemented with 4 mM of glu-
tamine (all from Invitrogen, Paisley, UK) in a humidified atmosphere of 8% CO2 at 37◦C.
Ad5 production was performed in a 5-L bioreactor (Sartorius, B. Braun, Germany). The
dissolved oxygen and pH were controlled at 80% of air saturation and 7.2, respectively.
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Infections were performed using an MOI of 10 and the Ad5 bulk was harvested at 72 hours
post-infection. Standard Ad5 stocks were purified using CsCl-based ultracentrifugation
density gradient as described elsewhere (Kanegae et al., 1994).
7.2.2 Purification of standard baculovirus stocks
Infective baculovirus particles, the target product, were isolated by ultracentrifugation
based on sucrose density gradients (Airenne et al., 2000). Clarification and concentration
were conducted using depth-filtration and tangential flow filtration described elsewhere
(Vicente et al., 2009). Briefly, 3 µm retention Sartopure PP2 filter capsules, followed
by 0.65 µm retention Sartopure PP2 filter capsules, were operated in series. Tangential
flow filtration was run on an ÄKTAcrossflowTM system controlled by the UNICORNTM
software (all GE Healthcare, Uppsala, Sweden) with a 200 cm2 HydrosartTM membrane
with 100 kDa nominal molecular weight cut-off (MWCO) (Sartorius Stedim Biotech) at
35 mL/min retentate flow rate and a transmembrane pressure of 1.2 bar; buffer exchange
to D-PBS was accomplished by continuous diafiltration. rBV concentrated stocks were
transferred into ultracentrifuge tubes on top of two discrete sucrose density layers: 8 mL of
50% (w/v) and 6 mL of 20% (w/v) sucrose in D-PBS (bottom); the tubes were centrifuged
at 100,000 g and 4◦C for 1 h. The virus bands were pooled, resuspended into 35 mL of ice-
cold D-PBS, transferred into ultracentrifuge tubes containing 3 mL of 25% (w/v) sucrose in
D-PBS, and centrifuged as above. The concentrated virus buffer was exchanged to 10 mM
phosphate buffer pH 7.2 with 10 mM NaCl using a prepacked HiPrepTM 26/10 desalting
column coupled to an ÄKTAexplorer100 system (all GE Healthcare). Sterile microfiltra-
tion of final material was performed using AcrodiscTM Syringe Filters with SuporTM PES
membrane (Pall, New York, USA) before storage at 4◦C in the dark.
7.2.3 Main process-derived impurities
Reference biologicals have been used to study their behavior in binary mixtures with rBV
in the SPR-based studies. DNA was obtained from an Sf9 insect cell culture after DNA
extraction using the High Pure PCR template Acid Kit (Roche Diagnostics, Mannheim,
Germany). Bovine serum albumin (BSA) is of analytical grade (> 98% electrophoresis
purity) purchased from Merck KGaA (Darmstadt, Germany). All solutes were conditioned
in 10 mM phosphate buffer at pH 7.2 with a given NaCl concentration.
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7.2.4 Dynamic light scattering analysis
Hydrodynamic size estimations of sample particles were obtained by dynamic light scat-
tering (DLS) using a Zetasizer Nano-ZS Series ZEN3600 equipped with a 633 nm He-
Ne laser (Malvern, Worcestershire, UK). Viral samples were diluted 25- to 60-fold in D-
PBS; size measurements were performed in polystyrene cuvettes. Bovine serum albumin
(BSA) (Merck, Darmstadt, Germany) diluted in D-PBS was used as a control experiment.
The rendered experimental correlation functions from DLS were analyzed by the CON-
TIN method to obtain distributions of decay rate profiles which provided distributions of
apparent diffusion coefficient and, consequently, of the apparent hydrodynamic diameter
(through the Stokes-Einstein equation). Replicates with over 20% deviation were neglected.
Before data acquisition, the instrument software automatically optimizes operational con-
ditions such as signal attenuation, focal distance and number of scans.
7.2.5 Surface plasmon resonance
Sensor surface preparation
In order to address prospectively the impact of DEAE ligand density on the adsorption
of baculoviruses and major process-related impurities, three different DEAE ligand den-
sity sensor chips were produced: an 11-mercaptoundecanoid acid (MUA)-DEAE sensor
chip, a CM3-DEAE sensor chip, and a CM5-DEAE sensor chip. These sensor chips were
customized as follows.
For MUA-DEAE, DEAE ligands were covalently immobilized to a self-assembled mono-
layer (SAM) previously coupled on a gold sensor chip (Biacore/GE Healthcare, Uppsala,
Sweden) surface according to protocols described in the literature (Roper and Nakra,
2006; Vicente et al., 2010b). MUA (NanoThinksTM ACID11 solution from Sigma-Aldrich,
München, Germany) was used as thiolate for SAM preparation. The refractive index (RI)
was monitored throughout the MUA-SAM immobilization procedure with a Leica AR200
digital hand-held refractometer (Leica Microsystems, Wetzlar, Germany). Briefly, the gold
sensor chip surface was first equilibrated with ultra-pure, deionized water at 18.2 MΩ · cm.
The surface was sanitized with 0.1 M NaOH and 1% TritonTM X-100 (Sigma-Aldrich) and
then re-equilibrated in 10 mM 4-Morpholineethanesulfonic acid (MES) (Sigma) buffer at
pH 5.0. Ethanol was then used to washout the buffer and the surface was exposed directly
to the NanoThinks ACID11 solution (5 mM MUA in ethanol) and left overnight in a closed
compartment inside a laminar flow bench. The freshly formed SAM of MUA was rinsed
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with ethanol and re-equilibrated with the 10 mM MES buffer previously used until the
refractive index stabilized.
For CM3-DEAE and CM5-DEAE, DEAE ligands were covalently immobilized to either
a CM3 sensor chip or a CM5 sensor chip (all Biacore/GE Healthcare), which contains a
dextran extension layer of 30 nm (Kyprianou et al., 2009) or 100 nm (Yu et al., 2004; Wofsy
and Goldstein, 2002), respectively, over the sensor surface with available carboxyl groups
for coupling chemistry.
Each of the three different density sensors –MUA-DEAE, CM3-DEAE and CM5-DEAE–
were docked in the SPR system, a BiacoreTM 2000 (Biacore/GE Healthcare), for 2-diethy-
laminoethylamine (DEAEA) (99% purity grade from Sigma-Aldrich) immobilization using
amide coupling chemistry. MES buffer was used as running buffer for the duration of the
immobilization procedure. Freshly prepared solutions of 0.4 M 1-ethyl-3-(3-dimethylamino-
propyl)carbodiimide hydrochloride (EDC) and 1.0 M N-hydroxysuccinimide (NHS) (amine
coupling kit from Biacore/GE Healthcare) in water were mixed 1:1 and injected in a pulse
of 200 µL at 20 µL/min to activate the terminal carboxyl group for amide bond formation.
1.0 M DEAEA in MES running buffer was added in serial 100 µL pulses at 20 µL/min
until the SPR signal stabilized.
SPR experiments
All SPR experiments were performed on a Biacore 2000 system at 25◦C. Product (rBVs)
and main process-related impurities (dsDNA and model BSA) were diluted to a given con-
centration (cB) in 10 mM phosphate buffer at pH 7.2 with the specified NaCl concentration
(c0). All buffers were prepared sterile and degassed prior to use in the equipment.
The experiments were performed at constant flow rate of running buffer (with a salt
concentration c0,ref) and sample injection of 100 µL/min. Each run consisted of the fol-
lowing sequence of steps: (i) equilibration of the flow cell with running buffer; (ii) injection
of 100 µL of analyte solution or binary mixture of analytes at (c0 = c0,ref , cB); and (iii)
desorption and equilibration with running buffer (c0 = c0,ref ,cB = 0). Before starting a
new cycle, the flow cell was subjected to an aggressive desorption step using 100 µL of
1.5 M NaCl in 10 mM phosphate buffer at pH 7.2, and then cleaned/sanitized with 100 µL
of 0.1 M NaOH for complete sanitization of the surface.
DEAE ligands and SAMs have been shown to be fully resistant to pulses of NaOH (or
HCl) up to 1 M (Knoll et al., 1998). The baseline stability was controlled throughout the
course of each experiment.
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SPR data analysis
q
(c0 ,cB)
dm
ds
h
a
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(c0 ,cB)
ds
h
dm
dl 
b
Figure 7.2: Schematic of rBV adsorption onto a surface film of thickness ds in the Biacore sensor
chip flow cell. (a) represents monolayer adsorption onto MUA-DEAE, i.e., without dextran layer
extension; (b) represents adsorption onto CM3-DEAE or CM5-DEAE, with a dextran layer, dl.
It is assumed that rBVs cannot diffuse into the dextran layer, contrary to what happens freely
for an adsorbing protein model, BSA. The bulk aqueous solution has salt concentration c0 and
rBV concentration cB; h = 0.05 mm is the height of the Biacore flow cell; dm is the thickness of
the adsorbed monolayer, q is the surface concentration of adsorbed rBV, and dp is the effective
penetration depth of the evanescent electromagnetic field; for the case of the Biacore 2000 machine,
dp ≈ 150 nm.
The underlying probing mechanism of the Biacore machine for a MUA-DEAE ion-
exchange surface system has been recently reviewed, and explicit formulae for deconvoluting
SPR data into adsorbate biological concentration, cm, bulk adsorptive concentration, cB,
and salt concentration, c0, have been derived (Vicente et al., 2010b,a).
For solute monolayer adsorption (i.e., on a MUA-DEAE), and assuming a constant
pH, the SPR signal shift, ∆R, obtained as response to a typical ion-exchange adsorption
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Table 7.1: Characteristic features of rBVs and BSA as model protein impurity.
Biological Structure
rBV Rod-shaped virus particle dm = 120− 350 nm
BSA Protein with diameter dm = 5.4 nm
process on the sensor surface is given by (Vicente et al., 2010b,a)
∆R = (mB −m0c0vB) [cm + φm(cB − cm)] +m0(c0 − c0,ref), (7.1)
where m0 and mB are the calibration constants associated with the SPR response to
changes in c0 and cB, respectively; vB, the molar volume of the adsorbed solute; cm, the
solute concentration in the volume of the adsorbed layer; φm = exp(−dm/dp) where dm
is the thickness of the adsorbed layer and dp the characteristic penetration depth of the
evanescent electromagnetic field (Fig. 7.2); and c0,ref , the salt concentration in the buffer
solution used to equilibrate the flow cell and to define the baseline of the SPR’s signal.
The adsorbed concentration, cm, can be converted into a surface concentration through
the trivial formula q = dmcm.
For the general case, when there is a dextran layer of height dl, Eq. 7.1 remains valid,
however, the thickness dm becomes the specific dl for the case of small biomolecules as the
model BSA protein, of the dextran layer (30 nm or 100 nm, for CM3 or CM5 sensor chip,
respectively). For the case of large particles, hindered by the dense dextran layer which
mimics the gel layer present in a membrane adsorber (Tatárová et al., 2009), dm is assumed
to be 120 nm (Table 7.1).
Solving Eq. 7.1 for cm gives
cm =
∆R−m0(c0 − c0,ref)
(1− φm)(mB −m0c0vB) −
φm
1− φm cB. (7.2)
7.2.6 Anion-exchange membrane chromatography
AEXmc experiments
Sartobind D membrane prototypes with different diethylamine ligand densities were man-
ufactured by Sartorius-Stedim Biotech (Göttingen, Germany) (see Table 7.2 for details).
Each prototype was assembled as stack of three layers with 5 cm2/layer mounted in a
membrane disc holder, and then connected to an ÄKTAexplorer100 system coupled with
the UNICORN software. Concentrated virus bulks previously prepared by the method
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Table 7.2: Characteristics of Sartobind D membrane prototypes used in this study.
Charge density (µmol.cm−2) % charge density (%) 10% DBC* (mg.cm−2) Λa (mM)
2.2 36.1 0.32 81
5.0 82.0 0.58 185
6.1 100.0b 0.98 226
aΛ stands for ligand binding capacity; breference ligand density; *stands for dynamic binding capacity of
BSA model protein
described elsewhere (Vicente et al., 2009), using 10 mM phosphate buffer pH 7.2 (optimal
pH for rBV binding (Vicente et al., 2010c)) with a given NaCl concentration (buffer A)
as diafiltration buffer, were subjected to AEXmc experiments. These runs were carried
out using the following systematic procedure: (i) loading of concentrated virus bulk into
the membrane at a flow rate of 5 mL/min; (ii) washing out of weakly- or non-adsorbing
biological solutes from the membrane with 2 MVs of buffer A; (iii) gradient elution with
a specified length (in MVs) by the admixture of buffer A and buffer A containing 1.5 M
NaCl (buffer B).
Between each run, the membrane adsorber was regenerated with buffer B, sanitized
with a pulse of 0.5 M NaOH, and equilibrated with buffer A supplemented with a given
NaCl concentration. Fractions were collected for analysis throughout the course of each
run. The chromatographic runs were performed at room temperature.
The same sort of experiments, but with diluted injections of each biological, were carried
out to estimate the relevant SMA parameters for the IEX interactions of the baculovirus
and main impurities with the membrane ligands, namely Ki and νi (these are discussed
below in section 7.2.6). Pulses of 1× 106 pfu of rBVs obtained from standard purification
procedure and 0.5 mg of BSA and dsDNA were used for these runs.
AEXmc process modeling
In this section a brief description of the implementation of a SMA model for interpreting
the IEX adsorption interactions of the baculovirus system with the membrane ligands is
provided. The SMA model has been widely used for the understanding of ion-exchange
processes (Brooks and Cramer, 1992; Shi et al., 2005; Karlsson et al., 2004). We use
previous work on a virus-like particle system (Vicente et al., 2008) as a basis to address
the AEXmc step for the purification of baculoviruses.
The SMA model defines three parameters—the characteristic charge, νi, the steric fac-
tor, σi, and the equilibrium constant, Ki—that determine the adsorption process as a
stoichiometric exchange reaction of each solute with a certain number of adsorbed counte-
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rions (Brooks and Cramer, 1992):
ci + νiq0 ! qi + νic0 i = 1, ..., Nc, (7.3)
where ci and qi are concentration of the biological i in the mobile and in the stationary
phase, respectively, c0 is the concentration of the salt in the mobile phase and q0 is the
concentration of bound salt available for exchange. The inherent equilibrium constant, Ki,
is
Ki =
qi
ci
(
c0
q0
)νi
i = 1, ..., Nc. (7.4)
Some salt counterions are assumed to be sterically hindered by each biological i on the
adsorptive surface; the concentration of the "blocked" salt counterions, q∗0 , is given by
q∗0 =
Nc∑
i=1
σiqi i = 1, ..., Nc. (7.5)
The condition of electroneutrality requires that
Λ = q0 +
Nc∑
i=1
(νi + σi)qi, (7.6)
where Λ is the capacity of the membrane.
The dynamics of the membrane adsorber, which is assumed to behave as a chromato-
graphic column (with geometric parameters listed in Table 7.2), is described by an equilib-
rium dispersed plug-flow model (Guiochon et al., 1994). The differential material balance
for component i can be written as
∂ci
∂θ
+
1− &
&
∂qi
∂θ
=
1
Pe
∂2ci
∂x2
− ∂ci
∂x
(0 < x < 1), (7.7)
with boundary conditions
ci − 1
Pe
∂ci
∂x
= cini for x = 0,
∂ci
∂x
= 0 for x = 1, (7.8)
where & is the void fraction, x = z/L is the dimensionless axial position in the adsorber
(z is the axial position within the thickness L of the stack of membrane sheets), θ =
t/τ is the dimensionless temporal coordinate (τ = L/u is the reference time with u the
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interstitial linear velocity), Pe is the Péclet number for axial dispersion, and cini is the inlet
concentration. Initially, the membrane adsorber is solute-free and equilibrated with salt
solution with concentration c00; in this case the initial conditions are
c0(0, x) = c
0
0, q0(0, x) = Λ
ci(0, x) = 0, qi(0, x) = 0, i = 1, ..., Nc. (7.9)
For a bind-end-elute experiment, where the desorption is carried out by linear-gradient
elution, the following boundary conditions apply:
c0(θ, 0) =
 c
0
0, θ < θF
c00 +G(θ − θF ), θ " θF
ci(θ, 0) =
 c
F
i , θ < θF
0, θ " θF
(7.10)
where θF is the dimensionless duration of the feed pulse, cFi is the feed concentration,
and G is the gradient slope. The equations are numerically solved using gPROMS (Pro-
cess Systems Enterprise, London, United Kingdom) as described elsewhere (Vicente et al.,
2008). The characteristic charge, νi, the equilibrium constant, Ki, and the steric factor,
σi are unknown parameters. The Péclet number is expected to be high, as we are using a
system with good mass-transfer characteristics operated at reasonable flow rates; therefore,
dispersion should not be significantly altered within the operating velocity window.
Under diluted material concentrations (ΣNci=1ci → 0), the adsorption isotherms are sim-
plified to the linear form of Henry’s law:
q0 → Λ, qi → Ki
(
Λ
c0
)νi
ci i = 1, ..., Nc. (7.11)
The partition coefficient retains the nonlinear dependence on salt concentration but the
steric factor becomes redundant. For the case of linear gradient chromatography, the reten-
tion time, θ∗, of an infinitely diluted peak can be predicted using the following expression
(Gallant et al., 1996):
θ∗ = 1 +
[
γiG+ (c00)
νi+1
]1/(νi+1) − c00
G
, γi = (νi + 1)
1− &
&
KiΛ
νi (7.12)
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Values of Ki and νi can be determined by fitting Eq. 7.12 to the retention times of several
chromatographic runs at different gradient slopes, G, and different initial salt concentra-
tions, c00.
7.2.7 Analyticals
The number of genome containing particles was quantified by real-time PCR (qPCR)
following the protocol described elsewhere (Vicente et al., 2009). Infective virus titers
(IP) were determined with a flow cytometer-based assay (Vicente et al., 2009; Karkkainen
et al., 2009). Protein profiling of samples collected after each of the purification steps
were performed using NuPAGE Novex 4-12% Bis-Tris pre-cast polyacrilamide gels (Invit-
rogen, Paisley, UK) using standard running conditions. Visual detection was carried out
using SimplyBlue Safe Stain (Invitrogen). Protein transfer onto nitrocellulose membrane
was done with a semi-dry transfer unit (GE Healthcare); immunochemical detection of
baculovirus main envelope glycoprotein, gp64, was carried out using a commercially avail-
able mouse monoclonal antibody (mAb) against gp64, AcV5 clone, affinity purified (1:2000
dilution) (eBioscience, San Diego, CA, USA) followed by incubation with an alkaline phos-
phatase conjugated anti-mouse IgG antibody (1:5000 dilution) (Sigma-Aldrich, München,
Germany) and developed using 1-step NBT/BCIP (Pierce, Rockford, USA). SDS-PAGE
and Western Blot band profiles were analyzed by ImageJ software (NIH, USA) using an
available add-in designed for gel band densitometry quantification and normalization. The
quantification of total dsDNA content in solution throughout processing was performed us-
ing the PicoGreen dsDNA Assay kit (Invitrogen, Paisley, UK) in 96-well plates according
to the manufacturer’s instructions. Total protein content of samples was determined using
the BCA protein assay kit (96-well plate protocol) from Pierce following the manufacturer’s
protocol.
7.3 Results and discussion
7.3.1 Impact of ligand density on the adsorption capacity of DEAE-
modified surfaces
The impact of DEAE ligand density on the overall capacities for either rBVs or BSA (the
latter used here as a host-cell protein model) was first studied by surface plasmon resonance
using the previously reported protocol (Vicente et al., 2010b,a), but with three different
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derivatized surfaces rather than just a single one. The three new sensor chips employed
here were customized to expose different ligand densities: a self-assembled monolayer on
a bare gold sensor surface, MUA-DEAE; a 30 nm long dextran layer chip, CM3-DEAE
(Kyprianou et al., 2009); and a 100 nm long dextran layer chip, CM5-DEAE (Yu et al.,
2004; Wofsy and Goldstein, 2002). All three chips were covalently immobilized with DEAE
ligands.
Using this approach we were able to prepare three anion-exchange sensor chip surfaces
with different ligand densities; furthermore, the use of a dextran layer mimics well the
gel layer from a commercially available Sartobind D membrane adsorber (Tatárová et al.,
2009). Analysis of adsorption of rBV and BSA (as a control) was performed on the three
surfaces to assess the impact of DEAE ligand density.
As shown in Fig. 7.3a, the decrease in ligand density has a clearer impact on BSA ad-
sorption than on rBV. Indeed, the BSA overall adsorption capacity dramatically decreases
to approximately 20% of the highest reference ligand density surface. However, for rBV,
a decrease to approximately 60% is obtained, indicating that ligand density is playing a
less important role for equally efficient viral particle adsorption. The maintenance of the
adsorbed rBV concentration at high levels regardless of ligand density is indicative that
these particles (of over 90-120 nm in diameter and 350 nm in length) remain outside the
inner dextran layer ligand sites which are only freely accessible to smaller biomolecules like
BSA. The same type of phenomenon is anticipated to occur in a membrane adsorber with
decreased ligand densities.
In order to support these exploratory experiments, similar tests were performed with
another important viral vector in clinical applications: human adenovirus type 5, a non-
enveloped virus with an equivalent particle diameter of approximately 90-100 nm (Trilisky
and Lenhoff, 2007). Even with a smaller overall size compared to rBV, the maximum
adsorption of these particles is not affected by the decrease in ligand density (Fig. 7.3b).
Thus, reduced ligand densities seem to improve selectivity for virus as less contaminating
protein is being adsorbed under lower ligand densities.
The results obtained from these SPR experiments justified the production of prototypes
Sartobind D membranes with lower ligand densities for testing this hypothesis.
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Figure 7.3: Comparison between adsorption concentration obtained under equal adsorption con-
ditions (same ionic strength) on surfaces with different DEAE ligand densities: respectively, a)
rBV particles, and, b) Ad5 particles compared to BSA total adsorption versus ligand density on
SPR sensor chip; each isolated biological was injected over previously sanitized sensor surfaces at
c0 = 0.010 M at a constant pH=7; ligand fraction = 1 is defined as the highest DEAE density (in
this work, CM5 sensor chip derivatized with DEAE); 100% total adsorbed concentration stands for
the value obtained for CM5 sensor chip derivatized with DEAE; dm =100 nm for Ad5 particles, a
value from hydrodynamic size measurements via DLS; the lines serve as guide.
7.3.2 AEXmc experiments with Sartobind D membrane proto-
types
Impact of ligand density, salt equilibration, and elution gradient length on
process performance
Sartobind D membrane adsorber sheets with different ligand densities were used as mem-
brane prototype layers for studying the impact of ligand density on process performance
(Table 7.2). The prototype units were assembled by stacking 3 layers, with a summed
total area of 15 cm2 equal to total membrane area of the commercially available Sarto-
206
DOWNSTREAM PROCESSING DEVELOPMENT OF ENVELOPED VIRUSES FOR CLINICAL APPLICATIONS
bind D MA15 units from Sartorius-Stedim Biotech. A DoE-type of experimental design
was devised to evaluate the impact of ligand density, salt equilibration of the rBV bulk feed-
stock (by means of adjusting the buffer salt concentration upon the previous diafiltration
process), and linear elution gradient length.
Table 7.3 summarizes the results obtained for the systematic testing of the Sartobind D
membrane prototypes. Four process performance indicators are assessed for the evaluation
of the sets of experiments derived from the permutation of the three operating conditions.
These results refer to the analysis of the peak pools obtained in each of the experiments.
Although some variability is observed, the active, infective rBV yields are highest at the
lowest ligand density. Compared to the current purification strategy based on commercial
Sartobind D membranes (Vicente et al., 2009), an increase of over 20% in infective particles
is achieved with the lowest membrane ligand density tested here. The quality of the rBV
pools are also improved, which should be directly related to the increase of infective titer
obtained, but might also be due to the fact that some of the damaged rBV particles
(product-derived impurities) have either flown through the membrane during the loading
step or, being weakly adsorbed, eluted during the washing step before the actual linear
gradient elution; as a consequence, the TP/IP was decreased from 18 to 5.
With regards to the process-derived impurities, the decrease in ligand density has a
clear impact on the host cell derived dsDNA content; this impurity concentration is lowest
at the lowest ligand density (Table 7.3). The total protein content is also lowest at the
two lower ligand density membranes and lower at higher salt equilibration concentration
(Table 7.3).
Overall, these results show the expected trend: improved product purity and yield as an
outcome of decreased membrane ligand density. This suggests that for this rBV system the
deprivation of some of available ligand sites affects primarily the binding of process-derived
impurities (total protein and dsDNA) and, to a smaller extent, also the product-derived
impurities (damaged rBV particles). The tested range of salt equilibration concentration
does not show a significant impact on the process indicators; however, in some cases (as
for total protein) an increase in the salt concentration confers an increase in purity. The
gradient lengths seemed of no significance here possibly due to the short range chosen, not
sufficient to improve peak resolution. This gradient effect is addressed in more detail in
the following section using the implemented SMA model predicting tool.
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Table 7.4: SMA parameters used for AEXmc process simulation.
&a 0.62
Salt equilibration (mM) 40
Peb 7880
(ν0,K0) (1, 1)
(ν1,K1) (4.3, 6.0× 10)
(ν2,K2) (4.7, 6.7× 103)
(ν3,K3) (4.8, 6.8× 104)
(ν4,K4) (5.1, 8.0× 102)
(ν5,K5) (2.6, 8.0)
(ν6,K6) (1, 0)
aobtained through estimation of membrane void volume; b(Vicente et al., 2008); in this table the indexes
0, 1, 2, 3, 4, 5, and 6 correspond, respectively, to salt, rBV 1st peak, rBV 2nd peak, rBV 3rd peak,
dsDNA, HCP, and non-adsorbing material.
SMA modeling and recommendations
In this section, the implementation of our previously used SMA-based model for AEXmc
process interpretation and prediction (Vicente et al., 2008) is presented. The first step was
to estimate the key model parameters described in the Materials and methods section. Ta-
ble 7.4 summarizes the used parameters for process simulations. The total porosity, &, was
estimated by injecting a salt pulse on the ÄKTA system with and without the membrane
unit mounted; the membrane void volume is obtained by difference. As we have observed
in our experimental chromatograms of rBV preparations the elution of three peaks with
different retention times (or volumes), we assume the whole sum of the three rBV peaks to
be the final product, as all three contain active (infective) viral particles, although not in
the same proportion. The last peak to elute was observed to be somewhat more infective
(data not shown), suggesting that the rBVs eluting earlier may either adsorb at a different
position or may contain an altered envelope (deprived of a fraction of the gp64 glycopro-
teins). This result was confirmed by qPCR (data not shown). The remaining components
constitute the two major process derived impurities, dsDNA and HCP. Simulations of the
chromatograms obtained could then be rendered using the gPROMS software tool.
Figure 7.4 shows the simulations performed after parameter estimation, identification of
the different component peaks and comparison with experimental chromatograms. Overall,
there is a good prediction of the rendered chromatograms agreeing well with the experi-
mental runs. This reinforces the applicability of the SMA model to this viral vector system,
similarly to what was observed before for a VLP system (Vicente et al., 2008).
One can now hypothesize that the lowest membrane prototype ligand density tested
in this work, 2.2 µmol.cm−2, does not significantly limit the adsorption of rBV particles,
because their large size (> 100 nm) prevents them from having access to the ligands within
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the depth of the hydrogel layer (Tatárová et al., 2009). If this were the case, one can assume
that when the total adsorption capacity, Λ, is increased, only the smaller biomolecules—
HCP and host cell dsDNA—should experience an increase in total adsorption and thereby
an increase in the released peak intensity upon elution using the linear salt gradient. This
can be confirmed with the SMA formalism implemented in this work: using the described
model and membrane characteristics, simulations can be performed for the different Λ
values corresponding to the prototype membranes used.
Figure 7.4 compares the experimental and simulated chromatograms of the AEXmc
process at different Λ values. From the simulated chromatograms it is possible to estimate
when the rBVs are expected to elute (see Figs. 7.4b, d and f). Additionally, the peaks of
the process-derived impurities are seen to be partially co-eluting with the rBVs. This is in
agreement with the fact that HCP and dsDNA are still present in the viral peaks samples
obtained (Table 7.3).
If Λ is varied, the simulated chromatograms still predict well the retention volume
of the different material peaks. However, if the amount of HCP and dsDNA that was
obtained in the flowthrough and peak pools and the peak concentration of the rBVs are
taken into account, one concludes that the decrease in ligand density results mostly in the
decrease of the process-derived impurities peaks. In fact, the AEXmc simulations show
good agreement with the results shown in Table 7.3.
These results provide evidence that the model is capable of explaining the possible
accessibility issue of large particles to the available ligand sites. It is worth noting, however,
that the simulations assume that the large particles are not hindered by the overloading of
the other process-derived impurities. Such effect has to be studied in more detail to assess
how much of the ligands are effectively available at the exposed hydrogel layer over the
membrane cellulosic backbone.
Looking at the elution profiles obtained with the chosen linear salt gradients (typical
lengths used in preparative ion-exchange chromatography), it is clear that the process
resolution is unsatisfactory. Resolution of eluted peaks can be increased either by extending
the linear salt gradient length or by increasing the amount of stationary phase.
Figure 7.5b shows an extension of the linear salt gradient predicted by the SMA model.
Comparing this figure with the original chromatogram in Fig. 7.5a, it is seen that in
Fig. 7.5b there is a better separation of the eluted peaks; however, they also elute more
dispersedly. Moreover, a too extended linear salt gradient can be an unacceptable option as
it reduces the benefits of using membrane adsorbers: buffer consumption is dramatically
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Figure 7.4: Effect of ligand density, i.e., total adsorption capacity, Λ, on AEXmc elution peaks
and comparison with simulated chromatograms. Experimental runs: Λ = 81 mM (a), 185 mM (c),
226 mM (e); the corresponding simulated chromatograms are, respectively, (b), (d), and (f), in
which “simulated chromatogram” stands for the sum of all component curves. The flow rate in all
experiments is 5 mL/min.
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Figure 7.5: AEXmc process resolution improvement assessment via SMA model simulations
using the membrane with lowest ligand density, Λ=81 mM: a) represents the original AEXmc
process; b) and c) show, respectively, the elution profile prediction when increasing the gradient
length 5-fold (flow rate is maintained at 5 mL.min−1), and, when increasing 10-fold the membrane
bed height with concomitant 10-fold load scale-up (flow rate is maintained at 5 mL.min−1 except
at the membrane loading step, increased to 50 mL.min−1).
increased and productivity may be decreased by too extended duration of the AEXmc
process. Alternatively, resolution can be improved by using a membrane matrix with a
taller stack of membrane layers (increased amount of stationary phase); for instance, if the
height of the membrane is increased 10-fold while maintaining the membrane unit diameter,
even if scaling-up the load by 10-fold, the resolution is enhanced as observed in Fig. 7.5c
in comparison to the original membrane in Fig. 7.5a.
7.4 Conclusions
This paper evaluated the ligand density effect on an anion-exchange membrane chromatog-
raphy process for the purification of recombinant baculoviruses, potential biopharmaceu-
ticals in clinical applications. A previously implemented scale-down strategy based on
surface-plasmon resonance to address DEAE ligand density was used. Exploratory results
combined with previous knowledge indicating inaccessibility of large particles to some of
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the ligand sites in the hydrogel layer covering the cellulose backbone of the membrane ma-
trix led to the development of membrane prototypes with different ligand densities. Both
SPR-derived and membrane chromatography-derived results suggest that lower ligand den-
sity is beneficial for rBV particle purification, increasing the overall yields by over 20%,
improving the removal of process-derived impurities and increasing product quality as mea-
sured by the decreased TP/IP ratio. A theoretical model based on the steric mass action
formalism, served as a useful predicting tool to determine how conditions can be altered
to further improve process resolution/selectivity ultimately enhancing final product purity
and recovery yield. A patent has been filed to support the use of these knowledge-based
strategies to improve membrane design and faster process optimization.
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8.1 Discussion
Innovative advanced therapies are emerging; gene therapy and novel vaccines are becoming
increasingly relevant for the treatment of prominent human diseases. Complex biopharma-
ceuticals, like the VLPs from Rotavirus and baculovirus vectors studied in this dissertation,
are examples of relevant biologicals holding a number of advantages and with very encour-
aging results in pre-clinical trials. However, as for any pharmaceutical product, efficient,
scalable, cost-effective manufacturing processes capable of generating material to support
clinical trials are required. This currently constitutes a great challenge in an investigational
new drug (IND) product lifecycle.
Although very important advances have taken place in the last decade, the development
of economic and highly efficient downstream processes is still quite incipient. The work
presented in this thesis aimed at building sound tools for a more rational understanding of
the downstream processing of enveloped viruses, in particular baculoviruses.
The focus has been directed to one of the most relevant purification steps: ion-exchange
(IEX) chromatography. Due to its very appealing advantages, which include scalability,
robustness, cost-effectiveness, and high resolution power, we have attempted to better
understand the physicochemical phenomena involved in the product-matrix interaction in
order to more efficiently design the chromatographic processes.
8.1.1 Improved tools for process design
Understanding the ion-exchange chromatography step
The work carried out during this thesis gave rise to:
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(i) A mathematical model of IEX membrane cromatography based on a thermodynamic
formulation of the multicomponent adsorption equilibrium, which uses the steric mass
action (SMA) model for predicting the IEX process (Chapters 2 and 7, Vicente et al.
(2008, 2010a));
(ii) A scale-down analytical tool based on surface plasmon resonance (SPR), which works
as a planar micrometric chromatographic adsorber, for measuring adsorption equi-
librium and kinetics, supported by the required theory and modeling tools that ex-
plain in detail the binding and elution mechanisms (Chapters 4 and 5, Vicente et al.
(2010b,c));
(iii) A theoretical analysis, supported on dynamic light scattering (DLS) experiments, of
the impact of the electrostatics of the different viral components and their implication
on the overall electrokinetic potential of the infective virus (Chapter 6, Vicente et al.
(2010d)); the combination of these fundamental tools created a good knowledge basis
to study a complex bioproduct—an enveloped virus, the baculovirus—and allowed
to improve a critical purification step—IEX chromatography.
The IEX chromatography step, implemented under the configuration of a membrane
adsorber, could be simulated appropriately using the developed models. Successfully pre-
dicting the product peak elution using this model allowed to estimate the relevant process
parameters. Furthermore, knowledge from the SPR- and DLS-based experiments was em-
ployed in the early-stages of process development for identifying an optimum range of
operating conditions, namely ionic strength and pH, for process optimization at-scale. In
Chapter 7, useful recommendations for process and matrix improvement could be made by
performing chromatographic simulations; the effects of flow rate, elution gradient velocity,
and feedstock loads were studied in order to determine possible matrix alterations yielding
better resolution. Overall, the following outcomes were achieved:
• Baculovirus characterization with regards to infectivity, i.e., infective versus non-
infective baculovirus particles; the impact of envelope and glycoprotein on IEX ad-
sorption and elution was studied in Chapters 5 and 6;
• Baculovirus binding orientation: non-spherical nature and heterogeneity of the rod-
shaped baculovirus particles dictated a distribution of the thermodynamically most
favored interaction orientations (Chapter 6);
• Baculovirus versus process-related impurities: a comparison based on adsorption
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isotherms of the isolated components could be obtained (Chapter 5).
This type of in silico tools facilitate bridging of efforts from bioseparation scientists and
manufacturers of purification materials. Using these tools, novel prototype matrices can
be designed and evaluated much more rapidly using minute amounts of biological material.
The determination of the adsorption isotherms of the critical players in this system over a
broad range of equilibrium conditions in a scaled-down system permits to setup advanced
process design strategies for this IEX process.
In principle, continuous or semi-continuous, multicolumn processes, like the ones being
developed in the mAb field based on the simulated moving bed (SMB) concept (Müller-
Späth et al., 2008, 2010), can be conveniently and cost-effectively designed with the ana-
lytical techniques proposed in this thesis. Multicolumn or multi-unit processes (where by
‘unit’ we mean any suitable adsorbent matrix) present great advantages over single-column
solvent-gradient batch chromatography, with or without recycle, but are more difficult to
design (Rodrigues et al., 2010) and require knowledge about the adsorption equilibrium of
the competing solutes. This information is the basis for the design or optimization of any
chromatographic process governed by the thermodynamics of adsorption; this is the case of
IEX chromatography. Mass transfer and axial dispersion influence the composition fronts
in the chromatographic matrix, by smearing the concentration profiles, but do not change
their stoichiometric positions when the process is not limited by the adsorption kinetics.
Moreover, convection is known to be the prevailing mass transport mechanism in membrane
adsorbers where there are nearly no diffusion limitations. If the adsorption isotherms are
known, suitable operating conditions can be determined through the application of design
rules, such as those developed for SMB chromatography, or by computer-aided optimiza-
tion (Araújo et al., 2010). We propose the use of scaled-down models of IEX stationary
phases and others, such as those employed in our SPR experiments, for the preliminary de-
sign of the multicolumn solvent-gradient chromatographic processes that are now emerging
for the separation of complex biomixtures.
Fig. 8.1 illustrates the design and optimization of an IEX process: (i) we start by
gathering fundamental data using cost-effective strategies as the ones developed during this
thesis; (ii) this information is then used to design an optimized IEX process operated in
batch mode; (iii) but we can envisage its ultimate use on the design of a more sophisticated
continuous (or semi-continuous) IEX process, granting high productivity, recovery yield,
purity and process consistency.
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Figure 8.1: From batch to continuous IEX process development. The present thesis focused its
attention on the first and part of the second stage.
To do this optimization, targets and constraints need to be clearly defined. The follow-
ing premises can be used in an in silico process optimization routine:
• Constraint one: minimum purification factor – cutting the peaks at a maximum “peak
overlapping”: the process-derived impurities (host cell protein (HCP) and host cell
DNA (HC DNA)) in the final product peak must be below a certain threshold value;
• Constraint two: minimum total particle/infective particle (TP/IP) ratio at final prod-
uct peak due to likely product and product-related “peak overlapping”;
• Constraint three: minimum concentration factor – linear flow velocity or flow rate in
a per day and per batch volume: an efficient purification step time and productivity
has to be reached.
• Objective one: maximum throughput/productivity – assess how, by changing one
(or more) operating conditions, the process can be run faster yielding the desired
performance indicators;
• Objective two: maximum product titer (potency) – assess how, by changing one
(or more) operating conditions, the process can yield a higher product titer, whilst
preventing product aggregation.
It should be emphasized that the above constraints and objectives are closely inter-
related, which means that the best compromise has to be obtained in order to optimize
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the whole process. These type of interrelations can be assessed by a DoE approach. For
instance, if the concentration factor attained is too high (objective two), the impurities co-
eluting in the product fraction peak might also exceed the acceptable concentration limit:
this may turn out to be critical in the case of HC DNA or HCP (constraint one). Also, if a
too extended linear elution gradient is necessary to permit an acceptable TP/IP (constraint
two), it may result in a very low throughput and probably in a low titer (objectives one
and two). Therefore, such hurdles inherent to this complex biological system may oblige
to add extra rules in order the find the best solution for the optimization problem.
The importance of a good DSP backbone
The overall strategy outlined in Fig. 8.2 summarizes the rationale in this thesis. The first
efforts were based primarily on a pragmatic and preliminary sensible selection of the best
technologies and matrices available in the market. This constitutes the essence of the work
presented in Chapter 3, where an industrially relevant DSP strategy is proposed (Vicente
et al., 2009a). From that point on, process development could be performed in a much
more solid way. Such an integrated view of the process optimization was successful in
improving the overall DSP, capable of delivering the final material within the required QC
specifications.
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Figure 8.2: Schematic representation of the rationale used in the thesis for improved process
design and optimization.
As shown in Chapters 2 and 3, gathering the best empirical/heuristics information
about the current state-of-the-art technologies for the purification of complex biophar-
maceuticals was shown to be critical. The use of membrane processes for early clarifica-
tion/recovery and concentration/purification, studied in Chapters 2 and 3, indicates how
disposable processes can be implemented with very good yields and throughputs. Even
though centrifugation is still the gold standard in industry for cell debris removal, the type
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of flexibility these new technologies bring in terms of upfront investment and cGMP ease
of operation is highly attractive (Peixoto et al., 2008; Gottschalk, 2008; Vicente et al.,
2009a,b). Especially when a complex biological tends to be highly labile, the higher the
throughput that can be obtained using mild conditions the better. Depth-filtration and
tangential flow filtration (TFF) both have been shown to be best for this enveloped virus
system (Vicente et al., 2009a) but also for non-enveloped viruses (Peixoto et al., 2008),
outperforming other alternatives at the upfront clarification and concentration stages.
Moreover, these technologies are now available from various disposable equipment man-
ufacturers saving validation labor and costs. As emphasized in the introduction chapter,
it is anticipated that monoliths will be added to these “new” generation matrices, together
with membrane adsorbers, for the purification of large biopharmaceuticals as viral particles
(Jungbauer and Hahn, 2008; Trilisky and Lenhoff, 2009).
8.1.2 The leverage of fundamental knowledge in process develop-
ment
Chapter 7 provides a proof of concept where the usage of the proposed scaled-down ap-
proaches streamlined a DoE-type of approach (Vicente et al., 2010a). The suitable pH and
ionic strength of the equilibration buffer could be determined from the modeling tool based
on ζ-potential (Vicente et al., 2010d) and the information gathered during preliminary SPR
data modeled as an IEX chromatography tool (Vicente et al., 2010b). Ligand density, a
major parameter in any chromatographic matrix, was assessed by expedite means: counter-
intuitively, too high ligand density seems not to be conducive to improved capture of virus
particles as it mainly contributes to increasing impurity binding and thus contamination
of the product peaks. Therefore, lower than maximum ligand densities improved recovery
yields whilst also increasing product quality (by decreasing TP/IP) and decreasing the
content in process-related impurities (HCP and HC DNA).
However, there is still much more to be known in terms of accessibility of these large
biological particles to the ligand sites placed within the hydrogel of the membrane adsorber
(Tatárová et al., 2009). Only smaller (and simpler) biomolecules as proteins seem to have
full access to the ligand sites. It is perhaps due to this fact that, using our SMA model
implementation (in Chapters 2 and 7, Vicente et al. (2008, 2010a)), the characteristic
charges, νi, found for the viral particles studied, where quite comparable to the values found
for protein molecules (Ladiwala et al., 2005). Most likely, only a very small fraction of the
viral particle surface is effectively participating in the interaction with the ion-exchange
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matrix; further research in this topic is thus needed to assess whether the capacity of these
porous matrices to bind these biological particles can still be increased.
8.1.3 Putting targets into perspective: did we do the job?
A clear identification of the goals of the purification design must be set from the very
beginning. For instance, the level of HC DNA must be below 10 ng/dose. As shown in
Chapter 2, the purified RLP product contained a final dsDNA concentration in the range
of 2-20 ng/dose, assuming that the VLP dosage may be up to 10-20 µg, although doses as
low as 1 µg are possible, as seen for an influenza VLP (Galarza et al., 2005). As for protein
impurities it is still challenging to find highly accurate methods to clearly identify VLP-
derived protein from the host cell-derived protein; immunoblotting and ELISA combined
with SDS-PAGE provides an indication, but the accuracy is still low. Nonetheless, it could
be observed that the employed DSP resulted in HCP purity over 98% (Vicente et al., 2008).
Similarly, for the baculovirus system, very good reduction of both impurities resulted in
over 98% of final product purity (Vicente et al., 2009a). However, as discussed in Chapter
3, the amount of impurities depends on the dose required to attain a certain biological
response. In special cases, where the final formulation and/or application requires very
high doses (Airenne et al., 2009), virus titers above 1010 pfu/mL may be needed, requiring
larger concentration factors than usual in DSP. This may prove challenging as aggregation
might start to be an issue decreasing the potency of the final, purified vectors (Barsoum,
1999). At the same time, the other impurities, non-infective viral particles, HCP and HC
DNA may also get co-concentrated. Although engineering improvement is still feasible,
efforts directed towards enhanced molecular biology for these products are also needed:
e.g., one of the issues to overcome in the case of baculovirus, often requiring too high
virus titers for efficient gene transfer, is to create virus surface modifications evading the
complement system upon virus transduction (Airenne et al., 2009). Thus, extra hurdles
still lie ahead for which the tools developed herein may facilitate progress.
8.2 Conclusions and perspectives
Rational optimization of downstream processes for complex biopharmaceuticals, as virus
particles or VLPs, is in its infancy, this thesis contributing to such efforts. It could be
shown that knowledgeable approaches improve optimization reducing its time and costs.
A step towards a concept that is now familiar in the biopharmaceutical industry—Quality
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by Design (QbD)—has been taken, improving early stage screening strategies based on
DoE and/or HTS.
Studies focusing on the orientation and placement of the specific binding sites of proteins
have been published recently (Dismer and Hubbuch, 2010; Dismer et al., 2008; Dismer and
Hubbuch, 2007); combining such molecular-based knowledge with the thermodynamic data
obtained using the electrokinetic model presented in Chapter 6 (Vicente et al., 2010d) and a
refined three-dimensional structure resolution of the hydrogel layer present in a membrane
adsorber matrix could push rational design forward.
Furthermore, the SPR-based tools open up new perspectives of possible investigation,
for example, modified sensor chips harboring the desired ligand chemistry produced by
chromatographic manufacturers themselves. Such sensor chips will be able to mimic much
more closely a real-world chromatographic matrix, including mass transfer issues in a three-
dimensional environment, allowing to focus into the adsorption and desorption of the dif-
ferent components of these complex systems. The SPR-based methodology developed in
this thesis was intended, as a first step, to make a broad comparison, providing a means
to evaluate how, by changing critical operating conditions, the best resolution and yield
could be obtained. This was more important at a preliminary stage than calculating very
accurately the adsorption of each component, either the product (the virus particle) or the
impurities present in the bulk. A next step performing multi-component analysis using
enhanced sensor chips shall provide a closer picture of the actual IEX process. Evaluating
simultaneously the binding of the virus particles and HCP (or other impurities) may pro-
vide further insights regarding the impact of ligand density and/or ligand approachability.
We expect that monoliths, showing excellent results for large particle purification, shall
also greatly benefit from these studies; indeed, these matrices use very similar principles
to membranes but allowing enhanced resolution.
The ultimate objective for the future would be to be able to design continuous IEX
processes like the advanced strategies based on simulated moving bed (SMB) being devel-
oped for mAbs. Continuous processes are standard in chemical engineering processes, but
the biopharmaceutical industry is clearly not there yet.
Although this thesis focused on IEX, the same rationale can be used to improve other
interaction-based purification processes, e.g., affinity. It should be emphasized that affinity
chromatography can also become a cost-effective option at the large scale when justified
by outstanding gains in concentration and purity during DSP. This has been the case in
mAb purification using Protein A affinity chromatography. SPR methodologies as the one
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developed in this study can also be easily adapted to help improve such processes.
In conclusion, this dissertation has enlarged the rational toolbox by developing method-
ologies to unravel some of the many issues of complex biopharmaceuticals. As shown herein
for IEX chromatography, working out the underlying mechanisms and understanding the
product has proved to be key for a better control and better design of the process. Likewise,
we anticipate that the type of tools created here shall be extremely helpful to tackle other
biological systems, either enveloped virus or simpler particles as non-enveloped viruses or
VLPs, as well as other chromatographic processes.
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